improv
understand
sever
group
streptococc
ga
diseas
europ
achiev
integr
pictur
infect
strepeuro
project
compris
countri
start
septemb
european
case
definit
sever
invas
ga
diseas
agre
upon
amongst
particip
order
obtain
nationwid
coverag
inform
project
given
infectioncontrol
unit
relev
hospit
microbiolog
laboratori
clinic
questionnair
contain
background
identif
data
possibl
predispos
factor
portal
entri
infect
epidemiolog
risk
factor
sourc
isol
clinic
condit
complic
outcom
use
case
enhanc
surveil
ga
invas
diseas
commenc
januari
twoyear
period
juli
invas
ga
isol
collect
uk
diseas
incid
rate
differ
countri
seem
vari
per
popul
molecular
method
type
clonal
identif
clinic
isol
use
overal
increas
new
invas
type
note
higher
emm
type
thu
report
almost
partner
contrast
type
predomin
sever
year
sweden
exampl
emm
type
account
major
isol
unusu
chang
type
distribut
europ
seriou
concern
high
level
ml
antibiot
resist
countri
franc
itali
frequent
tetracyclin
resist
almost
countri
note
furthermor
pathogen
aspect
sever
ga
diseas
proteolyt
activ
contact
system
select
virul
factor
surfac
protein
superantigen
investig
new
strepeuro
websit
wwwstrepeurolus
construct
updat
regularli
websit
link
relev
websit
contain
intranet
site
access
person
particip
within
project
extranet
site
gener
public
central
databas
sever
ga
case
receiv
clinic
laboratori
inform
local
databas
also
establish
strepeuro
creat
european
network
epidemiolog
analysi
surveil
sever
streptococc
diseas
ten
eu
one
associ
countri
object
strepeuro
eu
fund
programm
design
greatli
enhanc
understand
sever
group
streptococc
ga
infect
present
earli
epidemiolog
find
gather
uk
team
method
enhanc
populationbas
surveil
implement
uk
part
fulfil
strepeuro
object
two
preexist
data
sourc
reconcil
maximis
case
ascertain
routin
nation
surveil
base
local
microbiolog
investig
isol
referr
nation
refer
laboratori
individu
case
followedup
captur
clinic
epidemiolog
inform
preliminari
data
relat
case
diagnos
analys
determin
burden
clinic
present
risk
factor
diseas
microbiolog
characterist
strain
result
total
case
report
laboratori
across
england
wale
overal
incid
per
popul
clear
season
pattern
appar
peak
incid
midmarch
april
observ
incid
male
higher
femal
rr
ci
twelv
percent
case
occur
children
year
nineti
percent
case
bacteraem
septic
arthriti
pneumonia
clinic
manifest
includ
toxic
shocklik
syndrom
necrotis
fasciiti
puerper
sepsi
mening
skin
lesionswound
common
predispos
factor
inject
drug
use
report
case
predisposingrisk
factor
identifi
nineteen
percent
case
report
die
within
day
diagnosi
local
microbiolog
analysi
identifi
ga
isol
erythromycin
resist
type
characteris
strain
use
combin
serolog
sequenc
techniqu
reveal
mtype
common
conclus
enhanc
surveil
sever
ga
infect
begin
yield
inform
valu
target
public
health
initi
estim
diseas
burden
substanti
improv
understand
role
specif
risk
factor
inject
drug
use
comparison
european
countri
understand
data
object
studi
creat
anim
model
aerosol
infect
coxiella
burnetiiphas
nine
mile
strain
determin
pathogen
potenti
organ
mice
expos
infecti
aerosol
inoculum
bacteria
mice
n
inocul
use
aerosolis
devic
min
five
mice
sacrif
day
studi
c
burnetii
detect
perform
light
cycler
nest
pcr
assay
lung
blood
sampl
antibodi
phase
ii
c
burnetii
whole
cell
antigen
determin
sera
immunofluoresc
test
inflammatori
reaction
lung
spleen
sampl
investig
histolog
immunohistolog
analysi
c
burnetii
detect
genom
amplif
blood
mice
sacrif
day
lung
sampl
infect
mice
sacrif
day
develop
antibodi
c
burnetii
phase
ii
antigen
titer
inflammatori
infiltr
seen
lung
mice
sacrif
day
bacteria
detect
immunohistochemistri
macrophag
cell
studi
demonstr
infect
first
result
interstiti
pneumonia
c
burnetii
releas
may
spread
hematogen
organ
conclus
murin
model
aerosolinduc
experiment
q
fever
first
step
studi
acut
q
fever
especi
term
pathogen
carret
g
mihailaamrouch
l
b
chirouz
c
b
j
loubinoux
b
bouvet
b
hospic
civil
de
lyon
de
lyon
sud
franc
b
centr
nation
de
de
streptocoqu
dieu
pari
franc
clinic
data
nosocomi
infect
due
streptococcu
pyogen
voluntarili
report
januari
june
french
nation
refer
center
streptococci
analyz
togeth
microbiolog
trait
strain
period
surveil
invas
infect
enhanc
accord
strepeuro
project
activ
surveil
exerc
region
franc
decemb
februari
nation
health
servic
ie
institut
de
veill
sanitair
direct
de
affair
sanitair
et
social
total
unrel
episod
nosocomi
infect
involv
patient
patient
per
episod
invas
nosocomi
infect
account
total
invas
streptococc
infect
report
period
predispos
factor
mostli
surgic
oper
child
deliveri
postsurg
infect
includ
superfici
deeptissu
infect
softtissu
necrosi
abcess
erysipela
pneumonia
periton
bacteremia
without
toxic
shock
syndrom
death
postpartum
infect
suspect
nosocomi
although
evid
hospit
acquisit
rare
obtain
bacteremia
endometr
periton
occur
earli
vagin
deliveri
caesarian
less
frequent
associ
malign
outcom
differ
emm
type
repres
among
pyogen
isol
three
predomin
emm
type
account
virul
strain
strain
emm
type
mostli
associ
invas
infect
toxic
shock
necrot
fasciiti
death
sole
respons
five
episod
strain
mostli
associ
postsurg
infect
respons
five
episod
mostli
associ
puerper
sepsi
respons
six
episod
addit
one
cluster
six
case
puerper
sepsi
involv
three
differ
emm
type
simultan
result
indic
divers
streptococc
strain
risk
nosocomi
infect
associ
postpartum
surgic
wound
burden
sever
invas
pyogen
diseas
nation
health
author
mandat
workshop
current
process
draft
recommend
guidelin
includ
inter
alia
isol
patient
reinforc
infect
control
practic
case
postpartum
surgic
infect
see
front
matter
mark
increas
soft
tissu
invas
infect
caus
ga
note
also
observ
amongst
children
superfici
ga
infect
alway
promin
children
also
serv
potenti
reservoir
virul
ga
strain
may
turn
transmit
high
risk
adult
caus
invas
diseas
profil
sever
ga
infect
amongst
children
particular
greec
analys
identif
organ
sourc
clinic
predispos
factor
outcom
accord
treatment
regimen
microbiolog
characterist
total
invas
ga
isol
male
femal
children
hospitalis
januari
june
aghia
sophia
p
kyriak
children
hospit
athen
examin
isol
characteris
memm
type
sensit
penicillin
erythromycin
clindamycin
tetracyclin
use
kirbybau
etest
method
identif
streptococc
exotoxin
spe
antimicrobi
resist
gene
mean
age
patient
year
age
rang
month
year
total
patient
present
varicella
infect
admit
hospit
sixth
day
mean
averag
erupt
vesicl
overal
admiss
rang
day
avail
data
children
mean
durat
hospitalis
day
rang
h
day
three
children
admit
icu
one
present
varicella
mening
die
within
first
hour
admiss
total
patient
bacteraemia
nine
varicella
cellul
eight
varicella
clinic
manifest
includ
septic
arthriti
osteomyel
pneumoniaempyema
stss
necrotis
fasciitismyos
mening
brain
abscess
upper
respiratori
abscess
primari
focu
infect
upper
respiratori
tract
children
follow
skin
resist
penicillin
found
howev
ml
b
resist
found
amongst
six
isol
four
belong
phenotyp
two
exhibit
ir
cr
ml
b
resist
resist
gene
profil
correl
antimicrobi
resist
pattern
six
four
strain
resist
intermediari
resist
tetracyclin
respect
amongst
ga
strain
serotyp
belong
bar
one
possess
spe
gene
acknowledg
foustouk
team
p
kyriak
hospit
immunopathogenesi
invas
group
streptococc
ga
infect
involv
complex
interplay
bacteri
virul
factor
host
factor
cytokin
elicit
bacteri
superantigen
suggest
play
central
role
sever
system
clinic
manifest
gramposit
sepsi
analys
vivo
vitro
cytokin
respons
patient
sever
streptococc
toxic
shock
syndrom
andor
necrot
fasciiti
nonsever
toxic
shock
deeptissu
involv
invas
ga
infect
reveal
direct
correl
cytokin
respons
sever
invas
diseas
significantli
elev
frequenc
proinflammatori
cytokin
observ
acut
phase
peripher
blood
mononuclear
cell
sever
case
compar
nonsever
case
analys
tissu
biopsi
patient
ga
tissu
infect
reveal
similar
correl
magnitud
proinflammatori
cytokin
particular
cytokin
sever
infect
differ
vivo
cytokin
respons
acut
phase
could
reproduc
pair
age
sexmatch
sever
nonsever
case
infect
clonal
ga
strain
test
vitro
convalesc
phase
immun
respons
cultur
supernat
infect
isol
find
indic
propens
either
high
low
respond
superantigen
stabl
featur
host
may
contribut
sever
diseas
studi
reveal
specif
hla
class
ii
haplotyp
confer
protect
sever
diseas
wherea
other
increas
risk
sever
diseas
function
analysi
reveal
risk
hla
type
promot
significantli
higher
cytokin
respons
ga
superantigen
protect
one
taken
togeth
studi
show
hla
class
ii
molecul
influenc
magnitud
immun
respons
ga
superantigen
play
pivot
role
determin
outcom
invas
ga
infect
vitro
studi
reveal
synergi
colistin
rifadin
mdr
baumannii
giamarellosbourbouli
et
al
dmid
test
hypothesi
experiment
model
wistar
rat
becam
neutropen
ip
inject
two
dose
mgkg
cyclophosphamid
sepsi
induc
im
inject
right
femor
cfu
one
isol
baumannii
resist
rifadin
imipenem
ciprofloxacin
suscept
colistin
five
hour
induct
sepsi
anim
divid
four
group
follow
control
b
im
administ
mgkg
colistin
left
femor
c
iv
administ
mgkg
rifadin
cathet
insert
right
jugular
vein
administ
agent
four
hour
treatment
anim
sacrif
blood
sampl
punctur
inferior
cava
cultur
segment
liver
lung
spleen
cut
cultur
quantit
cultur
perform
homogen
tissu
consecut
dilut
mean
log
viabl
cell
count
given
tabl
group
blood
cfuml
liver
cfug
lung
cfug
spleen
cfug
conclud
rifadin
intensifi
vivo
bactericid
effect
colistin
seem
despit
indic
antibiogram
colistin
provid
rapid
bacteri
erad
coadministr
rifadin
necessari
infect
mdr
nosocomi
isol
clinic
signific
mrsa
methicillinresist
staphylococcu
aureu
mrsa
replac
suscept
predecessor
across
world
whilst
perceiv
inevit
consequ
antimicrobi
consumpt
acquisit
individu
collect
hospit
import
implic
regard
healthcar
societ
cost
everi
countri
affect
crux
problem
lie
difficulti
manag
colonis
infect
patient
well
organ
propens
surviv
spread
difficulti
creat
oppos
opinion
whether
point
fund
rigor
infect
control
activ
mani
countri
continu
wit
persist
increas
tempt
though
abandon
search
destroy
polici
mrsa
convinc
reason
control
remain
prioriti
manageri
interest
could
direct
toward
financi
consequ
mrsa
sinc
robust
evid
demonstr
costbenefit
hospit
variou
control
initi
also
consid
cost
individu
patient
well
societi
noncalcul
save
obtain
gener
specif
control
interventionsth
former
encompass
estim
reduct
hospit
bedday
overal
cost
hospitalacquir
infect
latter
allud
handwash
programm
screen
antibiot
prescrib
hospit
rise
number
mrsa
patient
experi
increas
financi
burden
influenc
healthcar
polici
overal
societ
cost
indefin
impact
upon
human
health
wellb
escal
without
manageri
polit
commit
introduct
clinic
improv
programm
resourc
must
first
releas
implement
evid
present
clear
control
effort
pay
would
gener
direct
indirect
benefit
individu
patient
societi
whole
object
descript
monocentr
seri
patient
chronic
pulmonari
necrot
aspergillosi
test
recent
radiolog
classif
method
retrospect
analysi
medic
record
special
focu
evolut
radiolog
aspect
result
six
patient
neg
search
aspergillu
posit
serolog
intratissulari
rod
seen
three
patient
go
surgeri
first
line
treatment
consist
itraconazol
patient
amphotericin
b
voriconazol
primari
failur
rate
followup
month
respondor
relaps
relaps
among
patient
normal
serolog
end
treatment
patient
easili
classifi
use
den
recent
subclassif
nine
chronic
cavitari
form
two
chronic
fibros
form
four
subacut
invas
form
ambigu
fibrosingform
frequent
role
aspergillu
gener
fibrosi
uncertain
simplifi
den
classif
subacut
chronic
pulmonari
aspergillosi
allow
easi
classif
patient
subacut
form
system
immunodepress
usual
one
excav
fibrosi
search
aspergillu
usual
posit
tissular
invas
seen
locoregion
extens
possibl
relaps
unusu
surgeri
interest
radic
treatment
chronic
form
system
immunodepress
rare
multipl
excav
pleural
pulmonari
fibrosi
usual
sometim
extens
search
aspergilluswa
often
neg
tissular
invas
easili
seen
locoregion
extens
relaps
usual
frequent
bilateralis
surgeri
often
difficult
follow
frequent
relaps
conclus
den
recent
radiolog
classif
allow
better
understand
complex
diseas
propos
simplifi
use
classif
help
physician
manag
patient
two
form
pulmonari
aspergillosi
also
care
separ
studi
compar
treatment
strategi
sustain
antifung
treatment
might
interest
patient
chronic
form
fals
posit
aspergillu
antigenemia
relat
semisynthet
penicillin
therapi
complex
expect
new
fact
new
hypothesi
bartdelabess
e
souvil
dani
datri
laboratoir
de
parasitologiemycologi
gh
pari
franc
purpos
detect
aspergillu
galactomannan
serum
platelia
aspergillu
enzym
immunoassay
eia
use
tool
earli
diagnosi
invas
aspergillosi
ia
recent
falseposit
test
report
patient
risk
ia
relat
use
piperacillintazobactam
pprtzb
sinc
found
hemisynthet
penicillin
may
crossreact
eia
sought
studi
kinet
antigenemia
patient
receiv
drug
understand
fals
eia
posit
may
circumv
method
review
patient
least
one
posit
serum
cutoff
ngml
detect
absenc
ia
june
juli
antibiot
regimen
prospect
investig
drug
batch
test
aspergillu
eia
result
antibiotherapi
includ
either
amoxicillin
amx
amoxicillinclavulan
acid
amxclv
pprtzb
record
among
patient
followup
antigenemia
patient
reveal
two
type
kinet
observ
either
drug
includ
per
os
amxclv
first
type
valu
ngml
obtain
within
first
h
remain
high
whatev
time
laps
serum
sampl
infus
period
h
upon
last
dose
declin
neg
occur
h
respect
second
type
valu
lower
ngml
shorten
delay
neg
wherea
drug
batch
test
posit
deduc
antigen
concentr
peak
serum
drug
concentr
least
tenfold
lower
obtain
patient
sera
conclus
amx
amxcla
gener
fals
eia
posit
like
pprtzb
whatev
formul
test
everi
batch
demand
costli
indic
possibl
fals
eia
posit
sinc
test
serum
collect
prior
next
antibiot
dose
prevent
data
suggest
eia
posit
presum
due
fungal
galactomannan
present
certain
batch
hemisynthet
penicillin
amplifi
serum
compon
natur
remain
determin
expertis
biologist
import
clinician
avoid
mislead
diagnosi
ia
useless
antifung
therapi
antibiot
switch
brun
dall
f
saulnier
p
c
renier
g
b
bonnin
chabass
bouchara
jp
group
detud
de
interact
franc
b
respiratorydefici
mutant
candida
glabrata
present
reduc
suscept
azol
antifung
easili
induc
vitro
exposur
azol
drug
ethidium
bromid
may
select
vivo
patient
undergo
fluconazol
prophylaxi
therapi
present
studi
therefor
conduct
order
defin
pathogen
petit
mutant
two
wildtyp
isol
c
glabrata
compar
respect
fluconazol
ethidium
bromideinduc
petit
mutant
regard
carbohydr
protein
composit
cell
wall
well
surfac
physic
properti
express
gene
encod
adhesin
also
adher
capabl
virul
mice
thu
flow
cytometr
analysi
cell
wall
carbohydr
use
sever
fluoresc
lectin
show
increas
bind
mutant
cell
concanavalin
compar
parent
isol
suggest
greater
avail
increas
amount
glucosemannos
residu
cell
surfac
petit
mutant
likewis
quantit
differ
shown
sdspage
surfac
protein
blastoconidia
parent
mutant
isol
regard
surfac
physic
properti
signific
differ
seen
electrophoret
mobil
determin
microelectrophoresi
twophas
partit
use
hexadecan
organ
phase
reveal
lower
hydrophob
petit
mutant
compar
parent
isol
moreov
mutant
cell
exhibit
import
overexpress
gene
reveal
realtim
revers
transcriptionpcr
compar
parent
isol
adher
capac
cell
human
enterocyt
cell
line
significantli
differ
final
suggest
slower
growth
petit
mutant
less
virul
parent
isol
experiment
model
system
infect
use
immunocompet
mice
togeth
result
suggest
one
disregard
c
glabrata
petit
mutant
clinic
howev
due
markedli
decreas
virul
mutant
may
constitut
valuabl
tool
character
virul
factor
yeast
proteom
studi
chang
associ
petit
mutat
progress
survey
azoleresist
candida
speci
implement
preemptiv
antifung
strategi
surgic
intens
care
unit
grenouillet
f
b
boisson
k
biot
b
blasco
g
c
millon
l
b
balvay
p
c
boillot
c
piarroux
r
b
franc
b
mycologi
franc
c
soin
intensif
en
chirurgi
franc
universitair
franc
background
earli
target
preemptiv
antifung
therapi
surgic
critic
ill
patient
led
signif
decreas
occurr
acquir
sever
candidiaisi
piarroux
et
al
crit
care
med
press
howev
impact
term
select
resist
candida
strain
especi
c
glabrata
cg
c
krusei
ck
check
patient
method
mycolog
screen
perform
patient
admit
surgic
intens
care
unit
sicu
admitt
weekli
discharg
prospect
survey
patient
correct
colon
index
receiv
preemptiv
therapi
fluconazol
mgday
two
week
studi
focus
cg
ck
epidemiolog
origin
cgck
colon
import
versu
sicuacquir
molecular
type
ck
isol
microsatellit
polymorph
igrpcr
undertaken
identifi
possibl
patienttopati
ck
transmiss
result
cg
ck
repres
respect
yeast
isol
colon
respect
sicu
patient
includ
analysi
one
hundr
twenti
cgck
colon
patient
present
import
colon
wherea
remain
patient
appar
colon
admitt
howev
one
patient
previous
receiv
preemptiv
fluconazol
therapi
molecular
type
show
patient
specif
ckstrain
nock
crosscontamin
could
demonstr
discuss
implement
preemptiv
strategi
sicu
open
acquisit
fluconazol
resist
candida
speci
sicustay
patient
reassur
data
complet
longterm
epidemiolog
survey
molecular
studi
cg
transmiss
posaconazol
treatment
rhinocerebroocular
zygomycosi
bregenz
b
p
podvinec
c
augenklinik
switzerland
b
divis
infecti
diseas
switzerland
c
hnoklinik
katonsspit
aarau
aarau
switzerland
posaconazol
po
investig
triazol
antifung
agent
activ
zygomycet
vitro
shown
activ
anim
model
zygomycosi
case
describ
success
treatment
diabet
patient
zygomycosi
intoler
diseas
refractori
amphotericin
b
amb
man
congenit
deaf
year
histori
type
diabet
mellitu
complic
diabet
retinopathi
right
eye
admit
hospit
august
suspect
facial
erysipela
impair
vision
left
eye
admiss
temperatur
c
empir
therapi
amoxicillinclavulan
acid
start
one
day
later
vision
deterior
occlus
central
retin
vein
arteri
staphylococcu
aureu
isol
nasal
swab
sinus
orbit
cellul
suspect
howev
biopsi
orbit
fat
obtain
decompress
surgeri
show
histolog
evid
zygomycosi
enucl
left
eye
perform
amb
mgkgday
start
baselin
serum
creatinin
umol
despit
four
surgic
revis
week
amb
clinic
improv
erad
fungu
mri
show
infiltr
sinus
develop
ambrel
renal
failur
serum
creatinin
umol
necessit
switch
therapi
liposom
amb
mgkgday
howev
zygomycosi
continu
worsen
patient
sever
impair
vision
deaf
commun
patient
becam
difficult
patient
enrol
openlabel
compassion
treatment
use
protocol
novemb
po
mg
four
time
daili
start
first
week
therapi
involv
cavern
sinu
optic
chiasma
note
week
therapi
zygomycosi
becam
stabl
sign
progress
periorbit
fungal
infiltr
mri
show
progress
diseas
po
treatment
complet
week
one
year
diagnosi
patient
regain
abil
commun
care
success
outcom
observ
patient
indic
po
may
effect
treatment
zygomycosi
talon
wollner
b
bonin
b
bertrand
x
chu
franc
b
cl
bellevaux
franc
wherea
infecti
mrsa
risk
consid
key
qualiti
indic
level
hand
hygien
practic
healthcar
set
longtermcar
facil
ltcf
appear
power
field
inde
surveil
facil
region
incid
mrsa
colonisationsinfect
respect
ltcf
acut
care
facil
object
studi
establish
frequenc
mrsa
acquisit
bedsltcf
discuss
role
screen
mrsa
carrier
type
isol
implement
effici
chemic
decontamin
combin
preval
mrsa
carriag
mrsa
screen
upon
admiss
allow
us
evalu
mrsa
acquisit
risk
accord
characterist
patient
interhospit
transfer
preval
studi
show
patient
mrsa
carrier
admiss
patient
posit
mrsa
among
mrsafre
patient
admiss
without
transfer
becam
posit
mrsa
lost
autonomi
chemic
decolonis
nasal
mupirocin
cutan
chlorexidin
effici
patient
ltcf
frequenc
mrsa
crosstransmiss
could
evalu
basi
clinic
sampl
mrsa
acquisit
occur
exclus
among
total
depend
patient
thu
technic
isol
rule
respect
carri
treatment
efficaci
isol
unaffect
mobil
patient
resocialis
chemic
decolonis
effici
made
possibl
reduc
number
day
technic
isol
given
increas
morbid
associ
mrsa
observ
numer
hospit
emerg
communitybas
diseas
link
strain
emerg
glycopeptideresist
strain
applic
voluntari
strategi
includ
screen
isol
decolon
rccf
appear
urgent
matter
prioriti
lucet
jc
armandlefevr
l
rioux
c
merabet
w
b
andremont
bichatclaud
bernard
pari
franc
background
object
despit
increas
incid
mrsa
littl
known
mrsa
acquisit
outsid
intens
care
unit
prospect
observ
studi
design
assess
preval
factor
associ
mrsa
admiss
four
highrisk
acut
care
ward
acut
geriatr
dermatolog
diabetolog
septic
surgic
ward
ii
incid
risk
factor
mrsa
acquisit
method
month
nasal
swab
obtain
admiss
discharg
unit
togeth
skin
swab
chronic
skin
break
csb
present
admiss
patient
pt
least
one
risk
factor
mrsa
screen
transfer
anoth
healthcar
institut
receiv
home
care
histori
hospit
last
month
hosp
prior
mrsa
carriag
poor
chronic
health
statu
csb
admiss
paramet
obtain
workload
assess
siip
score
durat
unit
stay
du
contact
precaut
use
mrsaposit
pt
result
admit
pt
includ
first
admiss
studi
hospit
stay
h
admiss
studi
unit
day
hospit
admiss
mrsa
preval
previous
known
mrsa
carrier
without
admiss
screen
mrsa
carrier
would
miss
paramet
associ
mrsa
carriag
hospit
admiss
unknown
mrsa
carrier
n
age
year
aor
p
home
care
hosp
csb
target
screen
strategi
use
four
risk
factor
requir
screen
admit
pt
sensit
admit
pt
mrsaneg
admiss
screen
discharg
acquir
mrsa
identifi
screen
specimen
risk
factor
mrsa
acquisit
csb
siip
day
du
popul
averag
day
conclus
highrisk
unit
incid
mrsa
acquisit
half
mrsa
preval
admiss
identifi
mrsa
reservoir
admiss
requir
screen
half
admit
pt
mrsa
spread
far
import
identifi
clinic
sampl
epidemiolog
antimicrobi
resist
pneumococci
greec
preliminari
report
hellen
studi
suscept
purpos
present
preliminari
data
ongo
nationwid
surveil
studi
suscept
streptococcu
pneumonia
strain
nasopharyng
colon
npc
invas
pneumococc
diseas
method
nasopharyng
sampl
healthi
children
year
old
attend
daycent
perform
februari
may
collect
clinic
isol
start
januari
end
decemb
pneumococci
identifi
use
optochin
sensit
bile
solubl
slide
agglutin
pneumolatex
assay
suscept
test
perform
penicillin
pg
cefuroxim
cxm
ceftriaxon
cxt
erythromycin
eri
tetracyclin
tet
cotrimoxazol
cot
levofloxacin
le
moxifloxacin
mx
etest
nccl
methodolog
breakpoint
intermedi
resist
ir
resist
r
use
result
total
npc
pneumococc
strain
isol
children
yield
mean
pneumococc
carriag
sampl
period
twentyeight
clinic
strain
also
collect
nine
npc
pg
resist
strain
total
studi
ie
mic
gml
rang
resist
respiratori
quinolon
observ
pg
em
r
strain
account
total
suscept
pattern
vari
among
differ
geograph
depart
clinic
strain
rate
follow
pg
ir
pg
r
xt
r
em
r
quinolon
resist
observ
well
conclus
data
suggest
increas
trend
resist
rate
penicillin
erythromycin
geograph
variat
resist
may
reflect
climatolog
condit
antibiot
consumpt
behaviour
warrant
investig
despit
increas
trend
resist
low
number
strain
beyond
clinic
resist
cutoff
mic
pg
gml
render
still
potent
agent
pneumococc
diseas
persist
anim
human
glycopeptid
resist
enterococci
norwegian
poultri
farm
formerli
expos
avoparcin
associ
widespread
plasmidmedi
vanael
johnsen
p
b
sletvold
h
b
rosvol
b
ji
b
kruse
h
nielsen
k
b
simonsen
gs
b
sundsfjord
b
norwegian
zoonosi
center
nation
veterinari
institut
oslo
norway
b
microbiolog
virolog
univers
norway
evolutionari
process
respons
longterm
persist
glycopeptid
resist
enterococcu
faecium
gref
nonselect
environ
address
genet
analys
anim
human
e
faecium
popul
two
norwegian
poultri
farm
previous
expos
avoparcin
total
faecal
gref
n
glycopeptid
suscept
n
e
faecium
gsef
isol
obtain
farmer
poultri
three
separ
occas
pulsedfield
gel
electrophoresi
pfge
plasmid
dna
analys
discern
gref
gsef
pfge
type
within
shift
polyclon
anim
human
e
faecium
popul
transfer
plasmid
mediat
vanaresist
exampl
domin
persist
gref
pfge
type
support
notion
environment
welladapt
greftyp
may
counteract
revers
resist
pfge
analys
sequenc
thepurk
housekeep
gene
partial
type
vanacontain
suggest
common
anim
human
reservoir
glycopeptid
resist
invers
pcr
amplif
sequenc
analys
target
right
end
junction
fragment
strongli
indic
presenc
common
singl
mediat
element
gref
pfge
type
observ
strengthen
vanyz
hybrid
analys
plasmid
dna
well
find
physic
linkag
put
postsegreg
kill
system
psk
seven
gref
pfge
type
conclus
observ
suggest
molecular
unit
persist
glycopeptid
resist
common
mobil
plasmid
mediat
vanacontain
element
within
polyclon
grefpopul
chang
time
addit
propos
plasmid
addict
system
may
contribut
persist
gref
nonselect
environ
segond
c
c
clavelbatut
p
c
eydieuxlaport
k
c
le
thomasbori
c
bingen
e
mariani
p
brahimi
n
ravilli
b
chabanon
g
c
servic
de
microbiologi
pari
robert
pari
b
vaincr
la
mucoviscidos
pari
c
laboratoir
de
franc
rangueil
toulous
franc
methicillinresist
aureu
mrsa
major
caus
epidemiolog
concern
due
spread
healthcar
set
increas
preval
commun
emerg
decreas
suscept
glycopeptid
patient
cystic
fibrosi
cf
aureu
sa
usual
first
pathogen
recov
respiratori
tract
rate
mrsa
increas
last
decad
respect
preval
methicillinsuscept
sa
mssa
mrsa
french
cf
popul
establish
observatoir
nation
de
la
mucoviscidos
present
studi
undertaken
assess
characterist
mrsacolonis
cf
popul
analys
antimicrobi
suscept
genet
relationship
isol
one
hundr
eleven
mrsa
colonis
patient
cf
center
region
includ
mean
age
acquisit
year
colonis
chronic
case
document
case
hospit
prior
year
wherea
receiv
antistaphylococc
antibiot
shortli
day
mrsa
diagnosi
mainli
cotrimoxazol
patient
pristinamycin
patient
glycopeptid
use
five
patient
among
nonredund
isol
suscept
gentamicin
resist
tobramycin
amikacin
pristinamycin
cotrimoxazol
fusid
acid
rifampicin
effect
isol
respect
seven
gentamicin
resist
isol
exhibit
reduc
suscept
glycopeptid
one
hundr
fourteen
isol
recov
patient
compar
use
pulsefield
gel
electrophoresi
pfge
classifi
type
type
uniqu
wherea
includ
two
isol
two
type
predomin
involv
patient
eight
six
region
respect
cf
centr
sever
patient
harbour
type
conclus
analysi
within
cf
popul
show
predomin
gentamicinsusceptibletobramycin
resist
phenotyp
occurr
reduc
suscept
glycopeptid
suggest
mrsa
might
communityacquir
andor
patienttopati
transmit
compar
evalu
viuda
hiv
duo
ultra
assay
combin
detect
antigen
antibodi
hiv
lyon
franc
b
depart
microbiolog
nord
chu
de
saintetienn
saintetienn
franc
aim
present
studi
evalu
perform
combin
antigen
antibodi
hiv
screen
assay
vida
hiv
duo
ultra
marci
letoil
franc
comparison
two
combin
test
former
version
test
vida
hiv
duo
axsym
hiv
agab
combo
assay
abbott
laboratori
rungi
franc
prospect
studi
perform
serum
specimen
receiv
routin
basi
hiv
test
blood
sampl
test
three
assay
sensit
three
test
specif
assess
repeat
falseposit
sampl
vida
hiv
duo
ultra
vida
hiv
duo
axsym
hiv
agab
combo
respect
addit
seroconvers
panel
test
vida
duo
ultra
axsym
hiv
agab
combo
assay
four
panel
posit
signal
detect
one
blood
sampl
point
earlier
vida
duo
ultra
assay
result
indic
vida
hiv
duo
ultra
exhibit
improv
specif
comparison
former
version
assay
addit
given
excel
sensit
avail
independ
result
antigen
antibodi
assay
test
appropri
earli
detect
hiv
seroconvers
trakc
new
diagnost
tool
manag
therapeut
followup
hivhcv
coinfect
patient
treat
chronic
hepat
c
pivert
payan
c
lunel
fabiani
f
morand
p
b
laboratoir
de
virologi
chu
anger
anger
franc
b
laboratoir
de
virologi
chu
grenobl
grenobl
franc
background
trakc
develop
orthoclin
diagnost
tm
assay
quantit
total
hepat
c
viru
hcv
core
antigen
serum
evalu
trakc
assay
realis
comparison
viral
kinet
marker
total
hcv
core
antigen
trakc
hcv
viral
load
versant
hcv
rna
bayer
diagnost
evalu
quantit
assay
studi
patient
ribav
protocol
approxim
sampl
assay
method
ribav
therapeut
multicent
randomis
trial
compar
efficaci
two
treatment
chronic
hepat
c
interferon
ifn
mu
week
ribavirin
mgday
versu
pegyl
interferon
pegifn
gkgweek
ribavirin
mgday
week
coinfect
hivhcv
patient
hcv
treatment
patient
test
week
w
sustain
virolog
respond
neg
pcr
month
end
treatment
result
correl
core
antigen
quantit
trakc
rna
quantit
hcv
rna
excel
r
p
found
good
correl
decreas
viral
load
negativ
hcv
core
antigen
treatment
log
iuml
declin
significantli
correl
neg
hcv
core
antigen
sustain
respons
r
p
sustain
respond
rna
decreas
log
iuml
neg
hcv
core
antigen
posit
neg
predict
valu
respons
treatment
respect
viral
load
reduct
log
iuml
neg
hcv
core
antigen
neg
pcr
p
studi
delay
negativ
treatment
appear
respond
delay
week
n
present
neg
pcr
longer
time
relaps
delay
week
n
p
result
must
confirm
relaps
conclus
total
hcv
core
antigen
appear
new
tool
monitor
patient
hcvhiv
coinfect
earli
predictor
respons
treatment
lebarbi
c
william
v
c
garandeau
c
bellaich
g
b
p
c
maisonneuv
l
gordien
e
b
biologi
franc
b
robert
ballang
aulnaysousboi
franc
c
virologi
et
avicenn
bobigni
franc
aim
investig
hbv
pre
cc
mutantchron
infect
pattern
accord
viral
load
vl
level
use
sensit
techniqu
patient
method
fortysix
patient
chronic
infect
hbv
hbsag
antihb
ab
posit
studi
hbv
vl
determin
use
bdna
assay
bayer
healthcar
respect
threshold
copiesml
basal
core
promot
bcp
precor
pc
mutant
assess
affigen
hbv
mutant
vl
assay
sangtec
molecular
diagnost
result
eighteen
patient
detect
vl
rang
copiesml
two
patient
abnorm
alt
valu
n
vl
valu
copiesml
respect
precc
mutant
found
test
patient
three
g
six
tg
mutat
among
patient
vl
copiesml
n
five
normal
alt
valu
pre
cc
mutant
discuss
pre
cc
mutant
chronic
infect
usual
associ
posit
hb
antigen
antihb
ab
elev
serum
alt
vl
copiesml
detect
mutat
wide
rang
copi
ml
viral
replic
pre
cc
mutant
strain
associ
normal
alt
level
rais
hypothesi
pre
cc
mutant
occurr
repres
step
natur
histori
hbv
chronic
infect
interestingli
two
six
patient
hbv
vl
copiesml
bcp
pc
mutant
virus
conclus
studi
highlight
complex
hbv
precc
mutant
chronic
infect
largescal
prospect
studi
need
better
defin
clinic
entiti
gault
e
b
le
gal
f
b
gordien
e
b
affolabi
b
hanslik
c
alloui
c
b
p
b
laboratoir
de
avicenn
assist
de
pari
franc
b
pari
bobigni
franc
c
de
intern
ambrois
boulogn
billancourt
franc
versail
franc
background
aim
hepat
delta
viru
hdv
associ
hepat
b
viru
respons
sever
acut
chronic
hepat
treatment
reli
longterm
administr
highdos
alphainterferon
ifn
effici
follow
detect
antihdv
igm
hdv
genom
serum
chronic
viral
infect
hdv
genom
quantif
serum
use
followup
infect
patient
aim
studi
develop
quantit
assay
detect
hdv
type
serum
evalu
interest
hdvrna
quantif
followup
chronic
infect
patient
receiv
ifn
method
realtim
rtpcr
assay
develop
quantifi
hdvrna
load
serum
assay
efficaci
evalu
serum
sampl
use
sampl
obtain
chronic
infect
patient
treat
pegyl
ifn
result
assay
sensit
enough
detect
copiesml
serum
effici
detect
genom
hdv
type
includ
type
recent
describ
type
viral
load
determin
treat
patient
allow
discrimin
respond
nonrespond
ifn
therapi
accuraci
qualit
approach
conclus
develop
assay
abl
quantifi
hdvrna
type
serum
infect
patient
improv
followup
assay
help
understand
natur
histori
hdv
infect
defin
guidelin
manag
chronic
delta
hepat
human
ubiquit
highli
seropreval
viru
gener
popul
two
variant
b
identifi
basi
genotyp
phenotyp
differ
mani
question
pend
concern
specif
epidemiolog
pathogen
properti
although
variant
may
infect
human
variant
b
account
major
clinic
manifest
primari
infect
reactiv
enceph
hematopoiesi
disord
febril
cutan
rash
wherea
variant
occasion
associ
patholog
fetal
hydrop
enceph
variant
may
detect
lymph
node
lung
tissu
without
clinic
impact
aim
studi
develop
rapid
sensit
specif
method
identifi
variant
differ
type
biolog
sampl
especi
case
mix
infect
evalu
techniqu
adapt
realtim
quantit
method
previous
develop
laboratori
includ
chang
consensu
revers
primer
two
variantspecif
primer
five
differ
strain
variant
gs
sie
tan
variant
b
hst
mar
use
either
separ
mix
variant
b
variou
proport
variant
sensit
genom
copi
regard
specif
human
dna
herpesviru
dna
hsv
vzv
hcmv
ebv
amplifi
case
mix
infect
one
variant
b
could
detect
presenc
fold
copi
one
variou
biolog
sampl
includ
peripher
blood
mononuclear
cell
saliva
cerebrospin
fluid
tissu
biopsi
bone
marrow
oral
mucos
swab
test
sampl
previou
identif
variant
perform
use
refer
method
obtain
total
concord
variant
b
mainli
identifi
variant
mix
infect
could
evidenc
note
variant
infect
observ
case
neurolog
disord
new
method
constitut
use
tool
identifi
variant
variou
biolog
sampl
even
case
mix
infect
also
evidenc
neurolog
tropism
variant
associ
enceph
infant
adult
vrioni
g
gartzonika
c
priavali
christaki
c
levidiot
depart
microbiolog
medic
school
univers
ioannina
ioannina
greec
pcr
becom
new
standard
virolog
diagnosi
infect
central
nervou
system
cn
use
test
shown
impact
patient
manag
measur
shorten
patient
stay
reduct
empir
therapi
administr
studi
aim
report
experi
last
year
detect
manag
herpesvirus
enterovirus
ev
induc
cn
infect
use
pcr
assay
total
consecut
csf
specimen
patient
hospit
april
august
univers
hospit
ioannina
clinic
suspect
viral
cn
infect
test
presenc
herpesviru
ev
genom
use
herp
consensu
enteroviru
consensu
assay
argen
biosoft
franc
herp
consensu
assay
allow
simultan
amplif
six
major
herpesvirus
singl
pcr
herp
simplex
viru
varicellazost
viru
vzv
cytomegaloviru
cmv
epsteinbarr
viru
ebv
human
herpesviru
enteroviru
consensu
assay
allow
revers
transcript
amplif
prototyp
ev
amplifi
product
detect
micropl
hybrid
specif
sensit
assay
evalu
sampl
three
extern
control
profici
panel
overal
csf
sampl
test
posit
pcr
detect
one
adult
enceph
vzv
detect
one
adult
mening
ev
detect
children
mening
andor
enceph
none
specimen
test
posit
cmv
ebv
genom
posit
csf
specimen
none
present
herpesviru
ev
coinfect
cn
precis
diagnosi
viral
cn
infect
avail
within
h
allow
better
clinic
manag
patient
term
durat
hospit
specif
therapeut
intervent
conclus
consensu
pcr
methodolog
enabl
rapid
detect
herpesvirus
ev
csf
provid
reliabl
noninvas
tool
diagnosi
viral
cn
infect
role
mutat
phenotyp
experiment
osteomyel
due
staphylococcu
aureu
antibiot
resist
daurel
c
b
prunier
al
garri
l
c
chau
f
b
leclercq
r
fantin
b
b
microbiologi
centr
hospitali
universitair
caen
franc
b
xavier
bichat
franc
c
inserm
pari
franc
get
insight
role
mutat
phenotyp
osteomyel
physiopatholog
due
staphylococcu
aureu
also
antibiot
resist
studi
behaviour
two
strain
aureusonli
differ
mutat
rate
rat
model
bacteri
osteomyel
tibia
strain
aureu
mutat
counterpart
inactiv
mutl
gene
insert
suicid
plasmid
use
mutat
frequenc
determin
rifampicin
contain
medium
time
higher
mutat
strain
behaviour
two
strain
studi
separ
vitro
rat
model
osteomyel
competit
studi
perform
rat
coinfect
two
strain
ratio
ten
rat
sacrif
five
differ
time
day
sixth
week
postinocul
similar
experi
perform
first
vivo
passag
one
deriv
strain
studi
effect
mutat
phenotyp
emerg
antibiot
resist
rat
infect
strain
separ
treat
rifampicin
sc
mgkg
bid
day
anim
sacrif
h
last
antibiot
inject
differ
observ
separ
growth
two
strain
vitro
vivo
indic
fit
defect
mutat
strain
contrast
competit
studi
indic
mutat
strain
clearli
disadvantag
sinc
found
rat
studi
time
lower
bacteri
titer
rang
log
cfubon
versu
log
cfubon
p
addit
competit
loss
mutat
strain
amplifi
second
passag
vivo
differ
cfu
count
two
strain
p
anim
treat
rifampicin
resist
mutant
appear
one
eight
anim
infect
mutat
strain
rifampicin
resist
mutant
detect
rat
infect
wild
strain
conclud
model
chronic
bone
infect
due
aureu
mutat
phenotyp
associ
decreas
fit
howev
antibiot
select
pressur
initi
disadvantag
could
compens
increas
rate
emerg
antibiot
resist
mutant
may
lead
competit
advantag
bert
f
b
noussair
l
b
lambert
n
b
valla
franc
b
microbiologi
hopit
beaujon
clichi
franc
object
spontan
bacteri
periton
sbp
frequent
complic
cirrhot
patient
ascit
streptococci
increasingli
report
sbp
result
fluoroquinolon
prophylaxi
aim
studi
determin
frequenc
characterist
episod
sbp
caus
streptococci
particular
viridan
group
streptococci
vg
investig
potenti
associ
prophylaxi
emerg
high
level
resist
fluoroquinolon
organ
patient
method
investig
microbiolog
data
episod
sbp
bacterascit
period
medic
record
patient
streptococc
infect
review
mic
agent
fluoroquinolon
determin
muellerhinton
agar
dilut
method
result
eightyfour
episod
caus
streptococci
vg
account
isol
preced
larg
betahaemolyt
streptococci
streptococcu
pneumonia
streptococcu
bovi
preval
speci
belong
oralisgroup
n
salivariusgroup
n
isol
vg
clinic
relev
episod
associ
asymptomat
bacterascit
remain
episod
episod
communityacquir
patient
vg
infect
receiv
norfloxacin
prophylaxi
compar
sbp
caus
nonviridan
streptococci
sbp
caus
vg
less
frequent
associ
fever
posit
blood
cultur
increas
ascit
fluid
polymorphonuclear
neutrophil
count
eleven
streptococc
isol
includ
vg
pneumonia
decreas
suscept
penicillin
four
isol
exhibit
highlevel
resist
mic
mgl
vg
isol
includ
patient
norfloxacin
prophylaxi
remain
suscept
levofloxacin
moxifloxacin
conclus
vg
major
caus
sbp
cirrhot
patient
ascit
longterm
administr
norfloxacin
associ
sbp
caus
vg
express
high
level
resist
fluoroquinolon
outbreak
glycopepetidresist
enterococcu
faecium
french
terciari
care
hospit
end
french
paradox
robin
f
e
introduct
glycopeptidresist
enterococcu
faecium
gref
one
major
caus
nosocomi
infect
usa
still
rare
europ
report
first
outbreak
gref
occur
hospit
clermontferrand
franc
method
casecontrol
studi
perform
infecti
diseas
haematolog
depart
case
inpati
gref
isol
faec
clinic
cultur
januari
juli
control
group
random
sampl
inpati
period
acquir
gref
case
match
three
control
specialti
infecti
diseas
haematolog
result
sixteen
case
gref
carriag
identifi
depart
gref
cultur
stool
patient
addit
urin
three
asciti
one
monthcumul
incid
period
compar
time
p
studi
period
gref
isol
inpati
three
ward
abdomin
surgeri
four
gastroenterolog
four
intens
care
unit
three
gref
cultur
urin
two
redivac
discharg
three
asciti
one
blood
three
two
patient
gref
bacteraemia
die
direct
consequ
infect
two
strain
respons
colon
multivari
analysi
control
time
risk
charlson
index
comorbid
follow
variabl
found
independ
predict
gref
carriag
prior
exposur
third
gener
cephalosporin
ci
p
antimicrobi
regimen
contain
beta
lactamas
inhibitor
ci
p
urinari
cathet
place
period
risk
ci
p
conclus
outbreak
like
result
multiantimicrobi
pressur
patient
patient
transmiss
isol
patient
enhanc
hygien
procedur
implement
report
might
annunci
end
one
could
call
french
european
paradox
mean
low
rate
hospit
colon
despit
high
antibiot
consumpt
commun
reservoir
gref
evalu
strategi
multiplesit
screen
methicillinresist
staphylococcu
aureu
admiss
teach
hospit
eveillard
lancien
e
jolyguil
ml
chu
loui
mourier
colomb
franc
object
carriag
methicillinresist
staphylococcu
aureu
mrsa
longer
confin
patient
known
risk
factor
healthcar
associ
set
make
perform
screen
cultur
increas
amount
admit
patient
limit
number
sampl
site
could
interest
altern
object
determin
sensit
nasal
cultur
alon
compar
multiplesit
screen
undertaken
hospit
method
studi
perform
one
year
teach
hospit
mrsa
carrier
identifi
multiplesit
screen
sampl
nasal
axilla
rectal
admiss
mrsaposit
site
combin
record
follow
nasal
alon
n
axilla
alon
rectal
alon
r
n
n
r
r
n
n
r
concurr
cumul
number
day
hospitalis
repres
number
theoret
isol
day
tid
note
mrsa
carrier
identifi
screen
analysi
carrier
differenti
nasal
carrier
n
n
n
r
n
r
carrier
r
r
intact
skin
rectal
carrier
identifi
way
result
studi
mrsa
carrier
account
tid
identifi
among
patient
underw
multiplesit
screen
admiss
nasal
screen
alon
mrsa
carrier
account
tid
would
miss
without
rectal
screen
carrier
account
tid
would
miss
without
axilla
screen
carrier
account
tid
would
miss
proport
carrier
would
identifi
nasal
screen
alon
nearli
twice
higher
among
male
among
femal
versu
p
conclus
givingup
axilla
cultur
nonicu
ward
carri
rectal
cultur
would
allow
screen
addit
patient
without
extracost
enabl
higher
sensit
screen
polici
inde
addit
sampl
popul
preval
mrsa
carriag
would
suffici
identifi
number
carrier
miss
without
axilla
cultur
background
order
follow
sp
serotyp
antibiot
resist
trend
follow
introduct
prevenar
nation
surveil
network
set
sinc
septemb
recommend
health
author
issu
march
reimburs
grant
decemb
method
nineti
french
pediatrician
recruit
carri
np
swab
per
year
children
month
age
suffer
aom
high
fever
otalgia
receiv
antibiot
treatment
within
day
enrol
result
survey
n
vaccin
children
dose
increas
year
year
year
antibiot
usag
last
month
reduc
p
respect
year
sp
carriag
third
year
lower
p
previou
year
second
year
year
among
children
sp
carriag
n
third
year
result
confirm
decreas
serotyp
includ
first
year
second
year
third
year
p
relev
emerg
nonvaccin
serotyp
identifi
among
vaccin
serotyp
increas
observ
decreas
dramat
rate
highli
penicillin
resist
strain
mic
gml
substanti
decreas
p
respect
year
vaccin
popul
n
sp
carriag
less
import
versu
p
vaccin
serotyp
less
carri
versu
nonvaccin
popul
n
conclus
result
underlin
need
continu
followup
assess
direct
indirect
effect
vaccin
children
sp
colon
papi
e
beaumesnil
v
wolff
lucet
jc
andremont
bouvet
e
certain
farinotti
r
fischel
leport
c
antibiot
studi
group
bichat
claud
bernard
hospitalpari
vii
univers
pari
franc
background
object
data
antimicrobi
prescrib
er
object
studi
describ
antimicrobi
prescrib
time
pattern
modif
subset
patient
admit
hospit
method
prospect
studi
patient
attend
er
period
novemb
prescrib
antibiot
treatment
er
ward
record
inform
use
complet
standard
casereport
characterist
analys
admiss
day
hospit
discharg
result
total
adult
attend
er
prescrib
patient
discharg
home
median
age
year
refer
anoth
hospit
admit
hospit
median
age
year
common
suspect
diagnos
lead
respiratori
tract
infect
n
includ
pneumonia
urinari
tract
infect
uti
n
patient
pneumonia
receiv
frequent
third
gener
cephalosporin
amoxycillinclavulan
alon
associ
fluoroquinolon
fq
amoxicillin
alon
associ
macrolid
uti
treat
fq
n
alon
n
associ
aminoglycosid
n
hospit
stay
mean
modif
day
n
day
n
day
n
broaden
narrow
antimicrobi
spectrum
oral
switch
respect
patient
stop
within
median
delay
day
evid
bacteri
infect
prescrib
consid
inappropri
patient
document
infect
median
durat
day
day
pneumonia
uti
respect
conclus
antibiot
treatment
prescrib
patient
visit
larg
teach
hospit
hospitalis
patient
elderli
patient
nondocu
pneumonia
usual
treat
longcours
broadspectrum
antibiot
necessari
investig
adequaci
regimen
improv
target
use
antibiot
nosocomi
outbreak
acinetobact
baumannii
isol
express
carbapenemhydrolyz
oxacillinas
c
dubouix
b
poirel
l
marti
n
b
nordmann
p
de
assist
de
pari
servic
de
le
kremlinbicetr
franc
b
chu
rangueil
laboratoir
de
toulous
franc
recent
character
carbapenemhydrolyz
oxacillinas
represent
novel
group
oxacillinas
baumanniiclin
isol
isol
burn
unit
rangueil
hospit
toulous
weakli
relat
oxacillinas
share
amino
acid
ident
respect
aim
studi
analyz
spread
oxacillinas
gene
sourc
carbapenemresist
baumannii
hospit
august
march
seven
carbapenemresist
baumannii
isol
collect
six
six
patient
burn
unit
one
environment
isol
collect
surgeri
block
systemat
air
sampl
pcr
experi
use
primer
specif
bla
gene
gave
posit
result
seven
carbapenemresist
baumannii
isol
carbapenemresist
baumannii
isol
bla
posit
plasmid
ca
kb
plasmid
extract
hybrid
bla
probe
genotyp
comparison
perform
evalu
clonal
isol
pulsedfield
gel
electrophoresi
pfge
realiz
digest
wholecel
dna
apai
restrict
enzym
pfge
analysi
show
six
carbapenemresist
isol
patient
correspond
like
singl
clone
wherea
isol
environ
also
bla
posit
differ
genotyp
identif
bla
posit
plasmid
two
differ
clone
baumannii
indic
spread
plasmid
studi
constitut
second
descript
outbreak
carbapenemresist
baumannii
produc
plasmidencod
carbapenemhydrolyz
oxacillinas
baumanniistrain
brazil
observ
carbapenemhydrolyz
oxacillinas
gene
bla
present
form
gene
cassett
class
integron
associ
insert
sequenc
thu
spread
novel
resist
mechan
identifi
underli
emerg
novel
carbapenemhydrolyz
enzym
baumannii
fillaux
j
dubouix
daud
archambaud
segond
c
conil
c
c
laguerr
j
b
marti
n
franc
b
franc
c
chu
rangueil
toulous
franc
introduct
acinetobact
baumannii
essenti
skin
commens
turn
opportunist
pathogen
respons
real
outbreak
particularli
intens
care
unit
recent
past
multiresist
baumannii
strain
describ
summer
baumanni
outbreak
result
colonis
infect
observ
hospit
amongst
isol
strain
none
display
nation
epidem
clone
produc
extend
spectrum
betalactamas
esbl
multiresist
strain
observ
thu
two
characterist
antibiotyp
intens
care
unit
strain
exclus
suscept
imipenem
tobramycin
amikacin
burn
unit
strain
suscept
amikacin
object
aim
work
investig
whether
multiresist
strain
alreadi
present
hospit
previous
outbreak
method
list
clinic
sampl
posit
baumannii
januari
decemb
multiresist
strain
submit
pulsefield
gel
electrophoresi
digest
sma
apa
enzym
clinic
characterist
note
statist
analysi
perform
use
chi
squra
test
fischer
exact
test
result
amongst
clinic
isol
found
correspond
follow
multiresist
criteria
suscept
imipenem
tobramycin
amikacin
exclus
suscept
amikacin
exclus
suscept
imipenem
resist
antibiot
test
resist
strain
like
isol
intens
care
unit
howev
clinic
sampl
variou
origin
non
protect
respiratori
sampl
well
blood
cultur
simultan
analysi
pulsotyp
antibiotyp
abl
highlight
outbreak
observ
intens
care
unit
could
link
initi
endem
clone
isol
respons
four
previous
mention
antibiotyp
manner
second
clone
respons
esbl
phenotyp
sporad
present
institut
howev
strain
isol
burn
unit
also
genet
relat
one
specif
clone
respons
appear
conclus
studi
allow
us
put
evid
exist
sever
multiresist
clone
endem
coexist
sever
year
detect
thank
acut
survey
epidem
sourc
lascol
c
legrand
p
soussi
cj
cambau
e
b
franc
chu
henri
mondor
aphp
franc
b
franc
chu
aphp
de
pari
franc
plasmidmedi
resist
quinolon
recent
describ
klebsiella
pneumonia
escherichia
coli
due
qnr
protein
protect
dna
gyras
quinolon
inhibit
preval
qnr
refer
first
studi
china
spain
usa
unknown
franc
strain
harbour
qnr
gene
usual
produc
plasmidmedi
pcase
extend
spectrum
esbl
screen
nalidix
acid
nal
resist
enterobacteri
strain
isol
henri
mondor
hospit
escherichia
klebsiella
pneumonia
enterobact
spp
citrobact
freundii
marcescen
proteu
providencia
presenc
qnr
gene
pcr
use
specif
primer
amplifi
intragen
bp
fragment
among
phenotyp
concord
esbl
three
pcase
nal
strain
n
test
neg
control
posit
control
origin
strain
k
pneumonia
strain
pcr
posit
test
two
coupl
primer
gener
bp
intragen
fragment
qnr
pcr
product
obtain
sequenc
among
strain
pcr
neg
pcr
posit
first
coupl
primer
three
pcr
posit
two
coupl
primer
one
strain
posit
three
coupl
primer
strain
except
latter
one
pcr
product
expect
size
sequenc
differ
qnr
strain
posit
three
coupl
primer
sequenc
pcr
product
ident
qnr
except
one
base
result
silent
mutat
strain
enterobact
cloaca
high
level
resist
ciprofloxacin
esbl
phenotyp
describ
first
strain
ofenterobact
cloaca
harbour
qnr
gene
known
mediat
plasmidborn
quinolon
resist
strain
among
enterobacteri
strain
test
result
preval
seri
larg
scale
survey
among
hospit
investig
enterobacteri
speci
necessari
confirm
low
preval
rate
qnr
franc
mammeri
h
van
de
loo
poirel
l
martinezmartinez
l
b
nordmann
p
servic
de
de
le
franc
b
depart
microbiolog
univers
hospit
de
valdecilla
santand
spain
object
although
quinolon
resist
result
mostli
chromosom
mutat
recent
survey
indic
resist
may
mediat
plasmidencod
qnr
gene
enterobacteriacea
thu
nalidixicacid
resist
escherichia
coli
clinic
isol
total
e
coli
isol
isol
hospit
franc
screen
qnr
pcr
result
singl
e
coli
isol
identifi
carri
ca
kb
conjug
plasmid
harbor
qnr
determin
confer
lowlevel
resist
quinolon
associ
chromosom
mutat
subunit
topoisomeras
ii
gene
qnr
gene
locat
class
integron
downstream
element
compris
recombinas
promot
sequenc
qnr
express
overlap
extrem
thu
indic
role
express
antibiot
resist
gene
integron
differ
qnrposit
integron
identifi
american
chines
enterobacteri
isol
addit
plasmid
carri
anoth
class
integron
ident
e
coli
possess
seri
gene
cassett
includ
code
extendedspectrum
rifampin
adp
ribosyltransferas
sever
aminoglycosid
resist
marker
conclus
first
report
plasmidmedi
quinolon
resist
europ
associ
unknown
level
plasmidmedi
multiresist
enterobacteriacea
type
ii
topoisomeras
genotyp
quinoloneresist
clinic
isol
escherichia
coli
isol
franc
lascol
c
attalah
l
soussi
cj
cambau
e
b
chu
henri
mondor
aphp
franc
b
chu
aphp
de
pari
franc
aim
studi
seek
mutat
dna
gyras
topoisomeras
iv
gene
involv
quinolon
resist
clinic
strain
escherichia
coli
isol
multicent
studi
strain
studi
clinic
isol
includ
nalidix
acid
nal
resist
r
ciprofloxacin
cip
r
one
nalr
cipintermedi
nalr
cipsuscept
mutat
quinoloneresistancedetermin
region
qrdr
four
topoisomeras
gene
gyra
gyrb
parc
pare
assess
pcr
sequenc
mutat
known
associ
quinolon
resist
shown
strain
one
gyra
mutat
n
n
n
n
n
parc
mutat
n
n
n
n
pare
mutat
found
two
isol
wherea
isol
harbour
mutat
usual
describ
gyrb
among
nalr
cipr
strain
geometr
mean
mic
micg
cip
mgl
strain
three
qrdr
mutat
two
gyra
one
parc
micg
cip
mgl
one
strain
four
mutat
two
gyra
one
parc
one
pare
mic
cip
mgl
one
strain
two
mutat
one
gyra
one
parc
mic
cip
mgl
among
nalr
cip
strain
micg
cip
mgl
strain
micg
cip
mgl
one
mutat
gyra
six
strain
micg
cip
mgl
two
mutat
one
gyra
one
parc
two
strain
micg
cip
mgl
three
mutat
two
gyra
one
parc
mutat
qrdr
observ
one
strain
mic
cip
mgl
unknown
mutat
also
observ
ingyrb
nine
nalr
cipr
three
nalr
cip
strain
parc
two
nalr
cipr
one
nalr
cip
strain
pare
three
nalr
cipr
strain
studi
show
nalr
clinic
isol
e
coli
either
cip
cipr
harbour
least
one
mutat
topoisomeras
gene
gyra
gyrb
parc
pare
nalr
cipr
isol
harbour
associ
mutat
two
three
gene
wherea
find
gyrb
mutant
describ
first
clinic
isol
harbour
pare
mutat
unknown
mutat
observ
gyrb
parc
pare
investig
involv
quinolon
resist
travel
tropic
countri
import
franc
p
falciparum
pf
isol
annual
sent
us
type
isol
symptomat
patient
without
previou
drug
intak
hplc
measur
select
drug
suscept
test
vitro
test
n
molecular
marker
n
characterist
correspond
patient
similar
year
includ
african
nativ
live
franc
travel
africa
return
either
cameroon
cote
divoir
seneg
mali
comoro
mean
age
year
children
year
age
sex
ratio
f
among
preval
pf
chloroquin
resist
vitro
ic
nm
preval
pf
cycloguanil
resist
vitro
ic
nm
dhfr
mutat
footstep
increas
pf
resist
observ
two
antimalari
result
use
annual
basi
adjust
prophylact
recommend
travel
endem
countri
invssantefrbeh
follow
guidelin
use
antimalari
consid
preval
resist
chloroquin
plu
cycloguanil
pf
endem
countri
upper
limit
recommend
prophylact
use
associ
countri
pf
resist
group
togo
benin
exceed
limit
seneg
preval
pf
resist
mefloquin
atovaquoneproguanil
doxycyclin
still
endem
countri
recommend
prophylaxi
countri
chloroquin
plu
cycloguanil
pf
resist
countri
group
three
indirect
evid
effici
recommend
gain
figur
travel
among
pf
attack
analys
cnrcp
correctli
follow
sinc
french
consensu
chloroquin
sulphadoxinepyrimethamin
longer
use
pf
treatment
quinin
resist
detect
period
pf
isol
asia
chloroquin
failur
suspect
import
plasmodium
vivax
oval
malaria
musset
l
massia
l
matheron
bouchaud
le
bra
j
correspond
group
bichatclaud
bernard
cnr
du
paludism
laboratoir
de
parasitologi
pari
franc
market
atovaquoneproguanil
malaron
expand
limit
rang
antimalari
drug
low
falciparum
resist
combin
indic
malaria
prophylaxi
area
chloroquin
resist
treatment
uncompl
p
falciparum
malaria
sinc
indic
gain
increas
favour
french
physician
travel
owe
good
toler
begin
prescript
europ
north
america
six
therapeut
failur
publish
yet
one
earli
therapeut
failur
etf
five
late
one
ltf
three
case
failur
confirm
blood
drug
dosag
uniqu
mutat
codon
parasit
target
atovaquon
cytochrom
b
present
associ
therapeut
failur
cytochrom
b
mutat
need
confirm
last
two
year
inform
atovaquoneproguanil
treatment
travel
contamin
mostli
west
africa
comoro
case
clinic
follow
file
five
failur
record
three
etf
two
ltf
isol
analys
dose
residu
drug
plasma
measur
vitro
atovaquon
suscept
sequenc
fail
cytochrom
b
gene
two
case
bad
observ
andor
poor
absorpt
like
failur
explan
two
three
isol
true
therapeut
failur
present
singl
mutat
caus
amino
acid
chang
respect
compar
seri
isol
without
known
failur
one
mutat
codon
identifi
result
confirm
high
conserv
plasmodium
cytochrom
b
hous
keep
gene
three
failur
case
requir
analysi
conclud
spite
fast
resist
emerg
atovaquon
use
alon
combin
proguanil
exhibit
satisfactori
efficaci
toler
safeti
drug
resist
associ
mutat
cytochrom
b
gene
lead
therapeut
failur
p
falciparum
yet
rare
encount
atovaquoneproguanil
ill
travel
return
tropic
prospect
studi
patient
object
year
million
peopl
travel
industrialis
countri
develop
countri
although
travel
consult
doctor
return
tropic
full
spectrum
health
complaint
unknown
method
analys
rel
frequenc
travelassoci
health
complaint
travel
immigr
expatri
busi
travel
tourist
consult
depart
novemb
may
result
total
patient
studi
women
men
median
age
year
tourist
immigr
expatri
busi
travel
median
durat
travel
day
main
destin
africa
asia
total
diseas
diagnos
distribut
follow
skin
diseas
gastrointestin
infect
respiratori
tract
infect
malaria
viral
hepat
urinari
tract
infect
sexual
transmit
infect
dengu
fever
tuberculosi
other
travel
consult
fever
malaria
intestin
tract
infect
account
diagnos
patient
respect
malaria
associ
travel
africa
p
immigr
statu
p
respiratori
urinari
tract
infect
associ
tourist
statu
p
respect
dengu
fever
travel
asia
p
overal
diagnos
correspond
import
tropic
diseas
main
import
diseas
malaria
schistosomiasi
amebiasi
gastrointestin
disord
caus
intestin
nematod
dengu
fever
conclus
tropic
diseas
lead
caus
consult
travel
return
tropic
noteworthi
except
dengu
fever
invas
schistosomiasi
immigr
visit
home
countri
travel
risk
common
tropic
diseas
postmarket
studi
pm
confirm
cardiac
safeti
profil
izilox
veyssier
p
b
voiriot
p
c
b
brentano
cf
de
victor
segalen
bordeaux
franc
b
servic
de
intern
centr
hospitali
franc
c
de
vandoeuvr
le
nanci
nanci
franc
servic
de
pharmacologi
cliniqu
saint
antoin
pari
franc
background
mention
summari
product
characterist
spc
ecg
analysi
done
clinic
trial
show
po
moxifloxacin
izilox
result
qt
prolong
subject
mean
ms
rel
initi
valu
confirm
izilox
cardiac
safeti
profil
carri
pm
studi
method
prospect
observ
studi
infect
adult
treat
izilox
usual
medic
practic
subject
observ
period
includ
treatment
durat
izilox
followup
end
therapi
eot
assess
izilox
cardiac
safeti
profil
type
incid
critic
advers
event
ae
analyz
independ
expert
committe
ec
event
defin
clinic
event
potenti
surrog
ventricular
rhythm
disord
consequ
qt
prolong
assess
event
document
cardiac
origin
confirm
addit
examsecg
document
cardiac
origin
strong
clinic
presumpt
addit
exam
ecg
extracardiac
origin
initi
visit
subject
subj
follow
ae
occurr
day
eot
result
itt
subject
mean
age
femal
treat
acut
sinus
acut
exacerb
chronic
bronchiti
commun
acquir
pneumonia
respect
total
ae
subj
mainli
gastrointestin
disord
report
ae
subj
assess
drugrel
ae
consid
critic
event
subj
ec
extra
cardiac
origin
assess
ae
document
cardiac
origin
assess
ae
drugrel
document
cardiac
origin
assess
ae
subj
ae
subj
consid
drugrel
palpit
n
tachycardia
n
malais
n
vertigo
n
pallor
n
nineteen
subj
ae
led
izilox
discontinu
ae
resolv
conclus
pm
studi
indic
izilox
clinic
safeti
profil
similar
previous
known
unexpect
advers
effect
identifi
consist
current
spc
clinic
sever
drugrel
advers
event
cardiac
origin
observ
method
consumpt
antibacteri
use
atcddd
classif
version
express
inhabit
per
day
number
packag
antibiot
provid
institut
public
health
republ
slovenia
publish
articl
includ
key
word
antibiot
drug
bacteri
resist
proceed
annual
nation
scientif
meet
five
nation
medic
journal
four
nation
newspap
magazin
six
one
tv
station
slovenian
websit
includ
analysi
health
insur
institut
slovenia
cover
healthcar
cost
popul
introduc
restrict
measur
prescript
amoxicillinclavulan
acid
fluoroquinolon
result
total
outpati
consumpt
antibacteri
increas
fall
increas
consumpt
nonrestrict
antibiot
increas
fall
increas
consumpt
restrict
antibiot
decreas
continu
total
number
publish
articl
profession
journal
newspap
respect
tv
commun
websit
found
yeartoyear
basi
strong
correl
number
newspap
articl
total
antibiot
consumpt
r
conclus
restrict
antibiot
prescript
follow
decreas
consumpt
restrict
antibiot
nonrestrict
antibiot
consumpt
also
decreas
year
increas
fourth
year
correl
paper
media
coverag
total
antibiot
consumpt
target
surveil
antibiot
prescriptiona
clinic
govern
design
northwick
park
hospit
harrow
middlesex
uk
b
pharmaci
microbiolog
peterborough
district
hospit
peterborough
uk
introduct
contribut
busi
district
gener
hospit
nation
fight
misus
broad
spectrum
antibiot
realis
target
key
intraven
broad
spectrum
antibioticsviz
meropenem
ceftazidim
ciprofloxacin
amikacin
piperacillin
vancomycin
teicoplaninwould
produc
signific
impact
clinic
prescript
cost
without
result
excess
workload
programm
clinic
driven
guarante
anticip
reduct
antibiot
would
harm
patient
method
studi
action
research
intend
chang
prescript
cultur
time
seven
select
antibiot
count
hospit
intraven
antibiot
expenditur
principl
clinic
govern
use
measur
programm
outcom
profession
perform
complianc
programm
reduc
empir
antibiot
therapi
resourc
use
reduct
antibiot
expenditur
risk
manag
preval
resist
microorgan
patient
satisfact
increas
mortal
concept
programm
introduc
formal
programm
launch
result
due
excel
complianc
prescript
cultur
chang
toward
antibiogram
guid
prescriptionsth
cost
reduct
beyond
optimist
predict
actual
cost
reduc
level
estim
save
million
preval
resist
organismsstaphylococcu
aureu
enterococci
pseudomona
enterobacteria
yeastwer
remark
unchang
contrast
increas
trend
seen
regard
specif
antibiot
resist
gentamicin
ciprofloxacin
piperacillin
ceftazidim
teicoplanin
vancomycin
increas
mortal
detect
except
neutropen
patient
may
relat
chang
prophylact
antibiot
protocol
conclus
simpl
antibiot
programm
target
seven
select
broad
spectrum
antibiot
chang
prescript
cultur
provid
signific
financi
save
hospit
flora
unchang
harm
patient
seen
neutropen
patient
show
increas
mortal
may
unrel
programm
besnier
jm
e
rodon
p
bastid
f
e
prazuck
b
de
jong
w
e
michelet
c
raffi
f
c
autretleca
e
e
paintaud
g
e
choutet
p
e
le
guellec
c
e
bloi
franc
b
universitair
nant
franc
c
franc
renn
franc
e
universitair
tour
franc
background
adequ
nfv
plasma
level
requir
maintain
maxim
hiv
suppress
howev
variabl
foodeffect
even
trough
concentr
c
lower
morn
c
develop
pharmacokinet
pk
model
predict
even
trough
concentr
morn
one
method
fiftytwo
pt
receiv
nfv
bid
tid
month
prospect
studi
composit
meal
last
drug
intak
breakfast
day
studi
grade
accord
natur
amount
food
two
blood
sampl
taken
morn
dose
morn
c
second
randomli
select
time
drug
intak
h
postdos
serum
nfv
concentr
measur
hplc
individu
concentr
posthoc
nonmem
first
fit
use
popul
pk
paramet
publish
studi
without
covari
test
wether
meal
composit
morningeven
intak
could
explain
differ
observ
predict
concentr
evalu
addit
model
bioavail
drug
intak
set
differ
valu
base
publish
descript
impact
factor
nfv
pk
result
median
morn
c
mgl
concentr
measur
variou
time
morn
dose
rang
mgl
model
includ
combin
impact
meal
diurnal
factor
bioavail
set
eveningrich
meal
eveninglight
meal
morningrich
breakfast
morninglight
breakfast
provid
best
descript
individu
pk
thu
enabl
estim
concentrationtim
cours
dose
interv
use
model
median
estim
even
c
mgl
morn
c
pt
whose
morn
c
target
concentr
mgl
still
time
even
dose
conclus
use
model
take
account
composit
meal
even
c
predict
two
blood
sampl
morn
c
thu
provid
basi
medic
advic
optim
nfv
intak
dosag
modif
predict
even
trough
concentr
mgl
despit
adequ
morn
c
singl
intraven
applic
mg
levofloxacin
result
high
liver
tissu
concentr
weinrich
scheingrab
stremovskaia
b
schill
mk
kee
f
c
pistoriu
ga
depart
gener
viscer
vascular
surgeri
germani
b
institut
gener
special
patholog
univers
hospit
saarland
homburgsaar
germani
c
institut
pharmacolog
univers
regensburg
regensburg
germani
introduct
broad
spectrum
potenc
gramposit
neg
germ
characterist
levofloxacin
high
level
levofloxacin
tissu
bodi
fluid
includ
gallbladd
bile
repeatedli
report
yet
studi
penetr
levofloxacin
human
liver
tissu
patient
may
novemb
patient
given
prophylact
intraven
antibiot
treatment
mg
levofloxacin
tavan
induct
gener
anesthesia
liver
resect
levofloxacin
blood
level
determin
approxim
min
infus
liver
resect
sampl
also
deriv
healthi
liver
tissu
resect
specimen
addit
tissu
examin
histopatholog
determin
grade
cirrhosi
ishak
score
steatosi
result
levofloxacin
level
liver
tissu
gg
mean
standard
deviat
correspond
serum
level
gml
min
infus
gml
resect
min
infus
tissueserum
ratio
time
resect
prove
good
liver
tissu
penetr
take
place
tissu
concentr
show
signific
correl
serum
level
bmi
well
invers
grade
steatosi
without
except
determin
level
mic
common
germ
found
liver
abcess
bilari
tract
infect
infecti
postop
complic
observ
conclus
levofloxacin
penetr
liver
tissu
except
well
therefor
optim
agent
treatment
hepatobilari
infect
caus
levofloxacin
sensibl
germ
oral
applic
levofloxacin
reduc
cost
drastic
effect
intraven
oral
applic
equal
bioavail
aim
studi
investig
imipenem
distribut
muscl
lung
interstiti
fluid
microdialysi
rat
compar
free
tissu
concentr
free
concentr
blood
microdialysi
probe
insert
jugular
vein
hind
leg
muscl
lung
imipenem
recoveri
three
media
determin
rat
retrodialysi
drug
drug
administr
imipenem
infus
intraven
dose
mgkg
min
microdialysi
sampl
collect
min
whole
studi
conduct
isofluran
anaesthesia
non
hydrat
rat
n
hydrat
rat
n
decay
free
concentr
blood
muscl
lung
time
monoexponenti
concentr
profil
three
media
virtual
superimpos
group
accordingli
auc
tissu
muscl
lung
blood
ratio
alway
virtual
equal
compar
valu
previous
determin
awak
rat
clearanc
respect
reduc
nonhydr
hydrat
rat
volum
distribut
unchang
imipenem
distribut
rat
investig
success
use
microdialysi
tissu
associ
intravascular
microdialysi
free
concentr
tissu
equival
could
predict
free
blood
concentr
boisson
k
hocquet
patri
plesiat
p
gespa
group
bacteriologi
chu
besancon
franc
background
combin
therapi
recommend
seriou
pseudomona
aeruginosa
infect
order
rapidli
clear
bacteri
inoculum
prevent
emerg
resist
howev
assess
drug
interact
standard
method
checkerboard
kill
curv
time
consum
operatordepend
report
simpl
etest
method
studi
drug
combin
bacterem
p
aeruginosa
method
synerg
piperacillintazobactam
tzp
ceftazidim
caz
ii
amikacin
ciprofloxacin
cip
test
genotyp
distinct
bacterem
p
aeruginosa
isol
six
french
univers
hospit
gespa
particip
etest
strip
set
side
side
tzpan
tzpcip
cazan
cazcip
mic
mic
onto
mueller
hinton
agar
plate
inocul
standard
incoculum
h
room
temperatur
cip
strip
remov
plate
incub
h
c
synerg
defin
decreas
mic
dilut
presenc
mic
cip
drug
combin
found
strongli
synergist
etest
method
reevalu
checkerboard
techniqu
result
drug
interact
synergist
indifferentaddit
antagonist
strain
respect
overal
combin
often
synergist
combin
synergist
rate
tzpan
cazan
tzpcip
cazcip
synerg
occur
essenti
strain
resist
pair
antibiot
compar
fulli
suscept
strain
versu
cazan
versu
tzpan
versu
cazcip
versu
tzpcip
result
etest
method
detect
synerg
appear
agre
fairli
well
checkerboard
techniqu
strain
conclus
sidebysid
etest
method
offer
mani
advantag
routin
determin
drug
interact
p
aeruginsoa
easi
perform
provid
reliabl
reproduc
result
within
h
studi
confirm
interact
synergist
mostli
strain
resist
combin
drug
chang
suscept
rate
time
locat
impact
predict
valu
disk
diffus
suscept
test
report
introduct
antimicrobi
disk
diffus
suscept
test
devot
clinic
context
predict
whether
antibiot
regimen
effect
test
perform
evalu
predict
valu
report
ie
test
abil
predict
true
truei
truer
isol
approach
impli
variat
suscept
preval
frequenc
suscept
intermedi
resist
isol
affect
predict
valu
result
simpli
level
discrep
vari
preval
r
categori
preval
effect
tradit
taken
account
posit
neg
predict
valu
never
evalu
threeclass
result
test
agar
diffus
base
suscept
test
aim
studi
present
two
simul
exampl
coamoxiclav
lomefloxacin
illustr
impact
suscept
preval
variat
may
perform
disk
diffus
method
method
develop
tool
evalu
qualiti
predict
result
quantifi
influenc
suscept
preval
variat
disk
diffus
method
perform
model
approach
antimicrobi
agent
simul
base
resampl
procedur
perform
minimum
inhibitori
concentrationdiamet
experiment
dataset
experiment
variabl
minimum
inhibitori
concentr
diamet
taken
account
simul
result
result
show
preval
impact
disk
diffus
method
perform
may
quantit
noteworthi
antimicrobi
agent
consid
preval
variat
record
time
locat
type
speci
conclus
consequ
result
zone
diamet
breakpoint
determin
polici
rais
impli
follow
consid
take
account
rigor
suscept
preval
studi
deal
zone
diamet
breakpoint
determin
perform
evalu
ii
reevalu
disk
diffus
breakpoint
consist
weight
preval
variat
noteworthi
iii
estim
consequ
breakpoint
intern
consensu
predict
qualiti
appropri
patient
manag
giannitsioti
e
vorou
r
galani
german
v
koratzani
e
souli
orland
k
greka
g
giamarel
h
univers
gener
hospit
depart
intern
medicin
univers
athen
athen
greec
object
evalu
sensit
disk
diffus
test
cefoxitin
mcg
detect
methicillin
resist
cn
compar
minim
inhibitori
concentr
test
mic
sinc
last
decad
cn
emerg
signific
clinic
pathogen
seriou
infect
method
suscept
test
perform
determin
mic
test
accord
nccl
guidelin
cefoxitin
disc
gr
kirbi
bauer
bd
sensidisc
becton
dickinson
c
inhibit
zone
diamet
mm
indic
methicillin
resist
wherea
mm
indic
methicillin
sensit
accord
nccl
guidelin
strain
mic
gml
investig
presenc
meca
gene
pcr
use
mec
mec
primer
result
total
cn
isol
methicillin
sensit
mic
gml
methicillin
resist
mic
gml
present
rang
gml
mic
gml
isol
mic
mic
cefoxitin
disc
g
inhibit
zone
diamet
mic
correl
follow
nocardiosi
infect
associ
sever
morbid
condit
especi
immunocompromis
patient
diagnosi
present
base
direct
examin
convent
cultur
difficult
time
consum
often
delay
prevent
due
rel
slow
growth
bacteria
empir
therapeut
decis
sampl
object
studi
develop
pcrbase
assay
rapid
detect
nocardia
directli
human
clinic
sampl
techniqu
consist
amplif
combin
chemiluminesc
hybrid
probe
obtain
pcr
dna
type
strain
nocardia
asteroidesatcc
dna
extract
amplif
specimen
bronchoalveolar
liquid
skin
biopsi
cerebr
abscess
seed
serial
dilut
nocardia
asteroid
atcc
allow
evalu
analyt
sensit
assay
reach
cfureact
agaros
gel
electrophoresi
cfureact
transfer
hybrid
applic
pcr
assay
diagnos
human
nocardiosi
evalu
investig
eighteen
clinic
human
sampl
patient
nocardiosi
confirm
convent
cultur
clinic
specimen
posit
sharp
chemiluminesc
signal
hybrid
amplif
observ
clinic
sampl
patient
confirm
tuberculosi
use
neg
control
result
highlight
high
specif
sensibl
pcr
protocol
present
studi
appear
use
rapid
diagnosi
nocardiosi
directli
clinic
sampl
without
cultur
result
time
appropri
clinic
manag
amount
signific
save
patient
techniqu
becam
current
routin
test
hybrid
protect
arnr
hpa
genprob
compar
standard
techniqu
direct
immunofluoresc
direct
ifd
c
trachomati
examin
cultur
n
gonorrhoa
doubt
conflict
test
confirm
techniqu
competit
pca
studi
patient
endocerv
sampl
urethr
sampl
result
analys
statist
woman
case
c
trachomati
diagnos
two
case
n
gonorrhoa
man
case
c
trachomati
diagnos
five
case
n
gonorrhoa
conclus
techniqu
hpa
enabl
us
improv
diagnosi
two
type
bacteria
could
underestim
standard
method
object
rapid
appropri
antibacteri
treatment
import
improv
prognosi
methicillinresist
staphylococccu
aureu
mrsa
bacteremia
rtpcr
identifi
aureu
sa
detect
methicillin
resist
use
directli
posit
blood
cultur
bc
bottl
gram
posit
cocci
gpc
upon
direct
smear
examin
dse
provid
clinician
fast
accur
result
evalu
impact
result
treatment
chang
appropri
method
march
august
analys
first
posit
bc
bottl
patient
staphylococci
bacteremia
dna
extract
posit
gpc
detect
upon
dse
use
quick
cheap
min
procedur
extract
use
templat
new
triplex
rtpcr
target
fem
meca
rrna
gene
pcr
inhibitor
charcoal
elimin
overal
turnout
assay
min
result
pcr
transmit
clinician
result
obtain
parallel
standard
bacteriolog
techniqu
transmit
follow
usual
procedur
antibiot
treatment
chang
time
bc
posit
h
thereaft
record
result
bc
posit
mrsa
methicillinsuscept
sa
mssa
mrsa
mssa
mr
coagulas
neg
staphylococci
cn
mscn
mrcn
mscn
micrococcu
sp
sensit
specif
rtpcr
diagnosi
mrsa
mssa
detect
gpc
bc
upon
dse
patient
induc
immedi
treatment
chang
alreadi
treat
initi
therapi
treat
upon
result
cultur
h
later
treatment
chang
patient
among
patient
sa
posit
bc
treat
time
dse
ineffici
treat
oxacillin
mrsa
inappropri
glycopeptid
mssa
conclus
earli
avail
rtpcr
result
may
dramat
increas
treatment
adequaci
fair
proport
patient
bc
posit
gpc
upon
dse
fluoroquinolon
use
subsequ
multidrugresist
bacteria
emerg
intens
care
unit
background
staphylococcu
aureu
main
caus
earlyonset
infect
liver
transplant
lt
risk
infect
strongli
associ
preoper
nasal
carriag
particularli
methicillinresist
aureu
mrsa
howev
sinc
mrsa
carrier
often
advanc
liver
diseas
noncarri
multivari
analysi
requir
investig
whether
nasal
carriag
independ
risk
factor
infect
aim
studi
identifi
independ
predictor
earli
aureu
infect
liver
transplant
recipi
use
multipl
logist
regress
model
method
conduct
retrospect
cohort
studi
consecut
lt
recipi
patient
screen
aureu
nasal
carriag
surgeri
medic
record
review
preoper
periop
variabl
strain
type
pulsedfield
gel
electrophoresi
pfge
univari
statist
analysi
follow
stepwis
logist
regress
perform
result
case
common
outpati
specialti
inpati
receiv
intens
care
wherea
picu
account
hospit
bed
case
mrsa
outpati
sinc
previous
attend
bch
preced
year
episod
mrsa
bacteraemia
occur
children
inpati
mrsa
colonis
first
document
overal
risk
bacteraemia
inpati
colonis
mrsa
risk
highest
year
year
age
group
lowest
children
age
year
mean
interv
first
isol
mrsa
onset
bacteraemia
median
rang
intravascular
devic
account
bacteraemia
overal
mrsa
account
staphylococcu
aureu
bacteraemia
aureu
bacteraemia
picu
mortal
rate
mrsa
bacteraemia
compar
mssa
bacteraemia
p
fisher
exact
test
conclus
contrari
report
centr
found
evid
mrsa
becom
common
case
seen
children
without
histori
recent
hospit
attend
suggest
mrsa
endem
commun
around
one
seven
children
acquir
mrsa
hospit
subsequ
develop
bacteraemia
recognit
hospit
acquisit
mrsa
common
certain
specialti
facilit
target
control
measur
emerg
new
highli
epidem
methicillinresist
staphylococcu
aureu
clone
produc
toxic
shock
syndrom
toxin
respons
either
hospitalacquir
communityacquir
infect
franc
two
categori
methicillinresist
staphylococcu
aureu
mrsa
clone
harbour
meca
gene
detect
commun
consid
healthcar
associ
correspond
hospit
clone
mrsa
strain
detect
patient
risk
factor
recent
hospitalis
contact
healthcar
worker
ii
truli
emerg
commun
mrsa
strain
infect
unusu
younger
patient
without
establish
risk
factor
mrsa
share
usual
pantonvalentin
leukocidin
character
emerg
mrsa
clone
respons
either
hospitalacquir
infect
communityacquir
infect
contain
tst
gene
encod
toxic
shock
syndrom
toxin
one
hundr
three
strain
tst
aureu
collect
citi
french
refer
center
staphylococci
character
phenotyp
genotyp
method
meca
tst
strain
n
harbour
accessori
gene
regul
agr
two
allel
two
strain
agr
allel
contrario
meca
tst
strain
n
agr
allel
five
strain
agr
allel
clonal
origin
meca
tst
agr
strain
demonstr
determin
pulsotyp
sequenc
type
antibiot
resist
profil
type
staphylococc
chromosom
cassett
mec
sccmec
iv
toxin
profil
strain
respons
infect
occur
predominantli
among
children
median
age
year
either
hospit
commun
clone
may
arisen
de
novo
insert
meca
gene
meca
tst
agr
clone
demonstr
compar
pulsedfield
gel
electrophoresi
type
differ
singl
band
shift
due
insert
sccmec
iv
find
suggest
mrsa
clone
probabl
emerg
other
pandem
mrsa
clone
new
york
japan
clone
conclus
new
highli
epidem
mrsa
clone
produc
respons
nosocomi
communityacquir
infect
emerg
horizont
transfer
sccmec
type
iv
methicillinsuscept
clone
spread
franc
halwani
mh
slack
rs
grundmann
hg
divis
microbiolog
infecti
diseas
univers
hospit
nottingham
nottingham
uk
object
determin
incid
risk
factor
endem
nonoutbreak
situat
respiratori
tract
infect
rti
adult
intens
care
unit
aicu
design
prospect
longitudin
studi
use
daili
surveil
identif
bacteri
isol
set
bed
aicu
tertiari
teach
hospit
patient
patient
stay
h
aicu
januari
april
rti
defin
use
centr
diseas
control
criteria
cdc
result
total
patient
elig
studi
follow
patient
day
median
length
stay
day
fortyseven
episod
rti
identifi
patient
overal
rate
incid
first
incid
per
patientday
respect
median
length
stay
acquir
first
episod
day
rang
staphylococcu
aureu
methicillin
resist
mrsa
ecoli
predomin
pathogen
involv
logist
regress
analysi
identifi
four
independ
risk
factor
endem
rti
exposur
ventil
p
ci
arteri
line
p
ci
throughout
patient
stay
bronchoscopi
p
ci
ciprofloxacin
p
ci
conclus
prevent
rti
aicu
may
depend
effort
minimis
risk
factor
especi
regard
quinolon
use
bronchoscopi
b
rm
de
ayala
e
microbiolog
hu
de
la
princesa
madrid
spain
object
evalu
preval
infect
andor
air
way
colonis
mrsa
cystic
fibrosi
cf
diagnos
patient
determin
suscept
respiratori
isol
method
patient
cystic
fibrosi
male
femal
media
age
year
pancreat
insuffici
patient
came
monograph
unit
adult
cf
sputum
sampl
cultur
follow
standard
microbiolog
procedur
coloni
quantif
ofpbl
agar
saboureaud
chloranphenicol
agar
blood
agar
chocol
agar
chocol
agar
bacitracin
macconkey
agar
mannitol
salt
agar
gram
stain
perform
isol
identifi
convent
test
autom
system
microscan
dadebehr
antimicrobi
suscept
determin
automat
system
microscan
disk
diffus
method
accord
nccl
recommend
result
preval
infect
mrsa
isol
nine
patient
five
femal
four
male
media
age
year
pancreat
insuffici
number
mrsa
isol
nine
patient
studi
period
patient
also
coloniz
p
aeruginosa
aureu
methicillin
sensit
xilosoxidan
antimicrobi
suscept
obtain
shown
conclus
high
frequenc
mrsa
colonis
found
patient
cystic
fibrosi
mrsa
strain
suscept
glycopeptid
linezolid
vitro
highest
resist
rate
show
ciprofloxacin
macrolid
object
epidemiolog
studi
done
unit
state
demonstr
high
hospitalis
outpati
rate
attribut
influenza
children
age
month
rate
compar
seen
children
high
risk
condit
led
recommend
immun
age
group
due
pauciti
epidemiolog
studi
influenza
children
europ
prospect
studi
seek
determin
hospitalis
outpati
influenza
incid
rate
children
year
old
present
royal
london
hospit
uk
two
winter
season
designmethod
recruit
children
age
year
old
hospit
present
acut
influenzalik
ill
structur
electron
questionnair
administ
nasopharyng
aspir
perform
sent
viral
immunofluoresc
pcr
influenza
rate
stratifi
age
clinic
diagnos
influenza
incid
also
estim
predict
clinic
diagnos
model
gener
data
collect
first
season
ie
result
two
season
children
recruit
influenza
attack
rate
two
season
averag
influenza
hospitalis
incid
rate
per
personmonth
wherea
influenza
accid
emerg
outpati
rate
per
personmonth
highest
age
specif
influenza
hospitalis
incid
rate
children
age
month
old
per
personmonth
wherea
month
old
age
specif
influenza
hospitalis
incid
rate
per
personmonth
highest
age
specif
influenza
ae
outpati
incid
rate
children
age
month
old
per
personmonth
wherea
month
age
specif
influenza
ae
outpati
incid
rate
per
personmonth
influenza
predict
model
base
clinic
diagnos
paramet
gener
first
season
data
consist
five
variabl
upper
respiratori
infect
tonsil
pneumonia
incid
otiti
media
non
specif
febril
ill
graph
estim
influenza
incid
rate
elig
children
year
old
recruit
first
season
studi
per
personmonth
influenza
rate
highest
children
present
pharyngotonsil
febril
seizur
otiti
media
conclus
influenza
infect
children
gener
hospitalis
ae
gp
outpati
visit
uk
even
low
intens
influenza
transmiss
season
children
age
month
highest
rate
influenza
infect
highest
rate
influenza
seen
children
present
pharyngotonsil
predict
clinic
diagnos
model
good
fit
season
use
estim
influenza
incid
find
use
inform
influenza
immun
polici
uk
use
respiratori
synciti
viru
rapid
diagnost
test
rsvrdt
predict
occurr
bronchiol
children
month
age
suffer
acut
viral
rhiniti
background
first
week
life
particularli
among
preterm
infant
infect
rsv
could
lead
sever
symptom
lethargi
apneic
episod
respiratori
failur
rhiniti
cough
preced
day
lower
respiratori
sign
symptom
acut
viral
rhiniti
due
respiratori
virus
frequent
situat
set
aim
studi
evalu
interest
rsvrdt
nasopharyng
specimen
children
month
age
suffer
rhiniti
cough
predict
occurr
bronchiol
hospitalis
method
pediatrician
perform
rsvrdt
children
birth
month
suffer
acut
viral
rhiniti
cough
without
wheez
respiratori
distress
inform
collect
includ
durat
breastfeed
presenc
gastrooesophag
reflux
type
cough
respiratori
frequenc
prematur
birth
risk
factor
tobacco
result
test
initi
decis
shortterm
evolut
bronchiol
hospitalis
treatment
result
human
metapneumoviru
recent
discov
viru
caus
respiratori
diseas
children
adult
hmpv
infect
clinic
characterist
similar
respiratori
syncyti
viru
rsv
infect
rang
mild
upper
respiratori
tract
infect
bronchiol
pneumonia
hmpv
genet
relat
avian
pneumoviru
c
replic
turkey
chicken
shown
replic
primat
small
anim
guinea
pig
mice
syrian
golden
hamster
studi
undertaken
evalu
suitabl
balbc
mice
model
hmpv
infect
hmpv
natur
pathogen
mice
howev
show
intranas
inocul
balbc
mice
hmpv
led
product
infect
signific
morbid
inde
hmpv
induc
overt
clinic
diseas
mice
signific
weight
loss
day
lung
viral
replic
occur
day
hmpv
elicit
high
level
iggspecif
antibodi
respons
sera
strong
increas
level
suggest
hmpv
induc
system
respons
mix
profil
accord
fact
ifngamma
produc
bronchoalveolar
lavag
bal
acut
infect
hmpv
elicit
rapid
sustain
pulmonari
inflammatori
respons
without
eosinophilia
airway
obstruct
measur
plethysmographi
airway
hyperrespons
metacholin
challeng
significantli
increas
hmpvinfect
mice
compar
control
summari
present
anim
model
enabl
investig
immunodetermin
protect
recoveri
hmpv
infect
caus
agent
fulmin
hepat
failur
young
children
among
young
children
rise
number
case
fulmin
hepat
failur
fhf
remain
undetermin
caus
human
herpesviru
betaherpesviru
abl
infect
hepatocyt
vitro
associ
fhf
acut
liver
injuri
aim
studi
evalu
incid
infect
group
pediatr
patient
harbour
variou
acut
liver
diseas
comparison
control
group
children
stabl
chronic
liver
diseas
twentythre
children
median
age
month
rang
differ
type
liver
injuri
underw
liver
transplant
fhf
undetermin
caus
three
fhf
etiolog
caus
hepat
viru
hav
infect
wilson
diseas
autoimmun
hepat
three
acut
decompens
chronic
liver
diseas
adcld
stabl
chronic
liver
diseas
biliari
cirrhosi
dna
detect
quantifi
explant
liver
peripher
blood
mononuclear
cell
pbmc
time
tranplant
among
children
fhf
undetermin
caus
adcld
dna
detect
liver
specimen
pbmc
specimen
median
load
higher
liver
biopsi
cell
pbmc
cell
result
favour
viral
replic
hepat
tissu
convers
among
children
stabl
chronic
liver
diseas
one
posit
detect
liver
pbmc
low
load
cell
respect
detect
patient
hav
hepat
load
quit
low
liver
biopsi
pbmc
cell
respect
one
wilson
diseas
note
load
high
patient
autoimuun
hepat
cell
liver
pbmc
respect
identifi
variant
b
result
suggest
may
play
signific
role
occurr
fhf
adcld
moreov
may
act
trigger
factor
develop
autoimmun
fulmin
hepat
nevertheless
viral
mechan
liver
injuri
remain
elucid
result
studi
period
case
varicella
hospit
cr
select
depart
infecti
diseas
hospit
patient
seventi
nine
percent
patient
children
year
age
adult
averag
durat
hospitalis
day
median
durat
day
children
regist
risk
factor
patient
immunosuppress
treatment
complic
observ
patient
patient
local
system
system
complic
observ
children
adult
rr
p
signific
differ
occurr
complic
group
without
risk
factor
occurr
local
complic
group
risk
factor
compar
nonrisk
group
rr
p
incid
system
complic
risk
group
significantli
higher
incid
system
among
adult
patient
rr
p
altogeth
primari
complic
case
enceph
case
liver
involv
patient
diagnos
atyp
pneumonia
averag
age
year
one
hundr
forti
one
patient
treat
intens
care
unit
three
patient
requir
reanim
care
averag
durat
stay
intens
care
unit
day
median
day
patient
histori
risk
factor
five
hundr
twenti
seven
patient
treat
aciclovir
conclus
signific
differ
occurr
complic
immunocompromis
immunocompet
patient
higher
incid
complic
observ
adult
frequent
complic
liver
involv
enceph
adult
atyp
pneumonia
cours
diseas
significantli
influenc
administr
aciclovir
vaccin
varicella
recommend
immunosuppress
children
adult
immunocompet
nonimmun
adult
high
protect
rate
bacteri
viral
diseas
children
teenag
need
constant
awar
parent
pediatrician
germani
mandatori
health
check
usual
take
place
age
six
enrol
primari
school
perform
public
children
youth
health
servic
centr
pcyh
visit
parent
receiv
addit
inform
vaccin
children
yet
obtain
order
increas
vaccin
rate
vaccin
regist
citi
essengermani
establish
first
check
vaccin
card
grader
n
student
complet
vaccin
set
need
age
low
rate
led
implement
activ
vaccin
counsel
program
throughout
citi
essen
student
follow
check
vaccin
card
student
receiv
vaccin
inform
brochur
also
ask
paediatrician
complet
miss
vaccin
follow
year
previou
collect
vaccin
card
collect
increas
protect
rate
investig
overal
protect
rate
increas
measl
mump
rubella
hepat
b
addit
project
video
hepat
bmmr
shown
individu
counsel
extend
inform
increas
protect
rate
anoth
mmr
hepat
b
similar
vaccin
counsel
programm
establish
kindergarten
children
year
old
children
investig
n
complet
vaccin
statu
counsel
children
show
complet
vaccin
statu
month
later
result
indic
vaccin
counsel
children
pcyh
may
help
dramat
increas
coverag
rate
vaccin
achiev
set
vaccin
regist
onetim
individu
vaccin
counsel
addit
inform
video
increas
possibl
close
cooper
kindergarten
school
pcyh
model
counsel
may
help
increas
coverag
vaccin
german
popul
low
cost
almuneef
memish
z
balkhi
h
alotaibi
b
helmi
depart
infect
prevent
control
pediatr
intern
medicin
king
abdulaziz
medic
cityk
fahad
nation
guard
hospit
riyadh
saudi
arabia
introduct
varicella
zoster
infect
chickenpox
common
benign
diseas
childhood
predomin
uncompl
case
children
tend
shadow
morbid
associ
sever
case
result
hospitalis
object
establish
complic
rate
chickenpox
saudi
nation
guard
popul
year
month
period
method
report
case
chickenpox
king
abdulaziz
medic
citi
riyadh
kamcr
prospect
follow
develop
complic
period
june
decemb
result
total
case
chickenpox
report
follow
acut
ill
major
case
occur
children
year
age
among
chickenpox
case
requir
hospitalis
patient
develop
complic
skin
soft
tissu
infect
common
complic
follow
pneumonia
bacteremia
enceph
necrot
fasciti
complic
less
common
children
compar
adult
p
pneumonia
p
hospitalis
p
common
adult
compar
children
overal
fatal
rate
two
patient
die
age
month
year
rate
conclus
data
provid
baselin
morbid
mortal
chickenpox
support
inclus
varicella
vaccin
routin
childhood
immun
program
saudi
arabia
result
patient
pediatr
case
note
mean
age
year
male
femal
ratio
diseas
acut
subacut
chronic
main
present
symptom
fever
sweat
easi
fatig
diffus
ach
fever
vomit
adenopathi
significantli
frequent
acut
form
versu
fever
p
versu
vomit
p
eighteen
percent
versu
adenopathi
p
spenomegali
frequent
children
adult
versu
chez
le
adult
p
osteoarticular
involv
preval
complic
spondyl
seen
case
meningoenceph
frequent
neurolog
manifest
among
haematolog
test
rel
lymphocytosi
significantli
frequent
children
adult
versu
p
acut
form
subacut
versu
p
wherea
leucocytosi
frequent
subacut
form
versu
p
sixti
patient
treat
doxycyclinerifampicin
cotrimoxazolerifampicin
week
month
good
result
case
surgic
treatment
need
case
conclus
brucellosi
still
endem
diseas
lebanon
routin
consid
case
prolong
fever
articular
neurolog
manifest
purpos
prospect
studi
greek
popul
investig
incid
elev
antibodi
titer
chlamydia
cp
patient
restenosi
without
within
first
semest
ptca
seri
patient
igg
iga
igm
antibodi
chlamydia
pneumonia
measur
time
ptca
month
later
patient
examin
restenosi
patient
divid
two
group
group
n
restenosi
group
b
n
without
restenosi
method
microimmunofluoresc
method
use
elementari
bodi
chlamydia
pneumonia
serv
antigen
titer
igg
iga
consid
posit
indic
igg
past
infect
iga
chronic
infect
igm
found
test
neg
igg
consequ
none
patient
suffer
acut
chlamydi
infect
presenc
angina
posit
treadmil
test
patient
underw
angiogram
absenc
mention
exercis
test
myocardium
perfus
imag
tl
perform
result
univari
analysi
chisquar
sex
age
diabet
mellitu
hypertens
hyperlipidaemia
stent
implant
smoke
univari
ttest
age
show
statist
signific
correl
restenosi
multipl
logist
regress
analysi
patient
restenosi
time
frequent
igg
p
time
frequent
iga
p
patient
without
restenosi
conclus
patient
restenosi
time
frequent
igg
time
frequent
iga
patient
without
restenosi
find
indic
elev
igg
iga
antibodi
cp
could
prognost
factor
restenosi
also
support
need
studi
clarifi
real
role
cp
chronic
infect
restenosi
coronari
arteri
post
ptca
bk
viru
infect
prospect
studi
first
year
post
renal
transplant
infect
assess
detect
quantif
viral
dna
urin
plasma
determin
frequenc
risk
factor
bkv
activ
infect
diseas
one
hundr
four
unselect
consecut
patient
underw
renal
allograft
transplant
nant
hospit
enrol
urin
plasma
sampl
collect
month
post
transplant
evalu
viral
dna
homemad
real
time
pcr
posit
sampl
quantifi
use
plasmid
standard
curv
nccr
region
bkv
urin
strain
sequenc
virolog
data
analys
accord
demograph
clinic
biolog
paramet
total
blood
urin
sampl
collect
median
four
urin
four
plasma
per
patient
posit
dnauria
andor
dnaemia
observ
patient
respect
defin
three
group
patient
infect
pt
posit
urin
pt
posit
plasma
pt
dnauria
becam
posit
within
first
month
patient
urin
viral
load
rang
log
copml
median
higher
p
posit
dnauria
significantli
associ
use
mainten
therapi
p
cold
ischemia
durat
h
p
viral
load
significantli
higher
patient
receiv
fk
p
comparison
nccr
sequenc
archetyp
ww
nccr
sequenc
found
ponctual
mutat
associ
paramet
analys
viral
load
plasma
rang
log
copml
median
posit
dnaemia
close
associ
posit
dnauria
rr
p
prospect
data
highlight
high
frequenc
activ
bkv
infect
renal
transplant
favour
fk
therapi
local
ischemia
despit
observ
high
viral
load
patient
none
develop
bkv
nephropathi
systemat
followup
bkv
infect
thu
requir
renal
transplant
seaton
ra
bell
e
gourlay
sempl
l
gartnavel
gener
hospit
glasgow
uk
purpos
studi
evalu
protocol
commun
manag
moder
sever
cellul
method
protocol
detail
indic
iv
therapi
ivor
switch
hospit
admiss
indic
medic
review
develop
approv
nurs
specialist
work
outpati
home
parenter
antibiot
therapi
servic
clinic
outcom
postintervent
compar
data
collect
prior
intervent
result
patient
refer
outpati
manag
suitabl
protocol
prior
introduct
patient
seen
prospect
suitabl
protocol
median
age
year
male
thiri
nine
percent
refer
emerg
depart
median
durat
outpati
iv
therapi
reduc
day
p
readmiss
rate
cureimprov
rate
twenti
patient
postintervent
requir
medic
review
prior
intervent
conclus
moder
sever
cellul
may
effect
effici
manag
commun
train
nurs
staff
use
suitabl
manag
protocol
approach
may
associ
reduc
durat
iv
therapi
background
syndrom
gb
common
caus
acut
flaccid
paralysi
develop
countri
campylobact
jejuni
cj
cytomegaloviru
cmv
two
main
infecti
agent
incrimin
trigger
role
gb
occur
franc
remain
poorli
document
method
studi
patient
gb
greater
pari
admit
januari
decemb
medic
intens
care
unit
raymond
hospit
serum
antibodi
cj
test
complement
fixat
test
institut
virion
germani
igm
igg
serum
antibodi
cmv
test
minivida
system
marci
letoil
franc
igg
avid
measur
sampl
posit
igm
result
conclus
serolog
evid
recent
infect
cj
present
cmv
patient
one
patient
evid
infect
cj
cmv
gb
case
involv
cj
develop
mean
day
infecti
event
mostli
gastrointestin
ill
occur
majoritarili
male
year
mean
sd
age
year
sex
ratio
associ
sever
mechan
ventil
pure
motor
form
serum
igg
antibodi
gangliosid
gb
case
involv
cmv
also
sever
mechan
ventil
develop
mean
day
infecti
event
mostli
upper
respiratori
tract
infect
influenzalik
syndrom
occur
younger
patient
mean
sd
age
year
predominantli
femal
sex
ratio
associ
sever
sensori
loss
igm
antibodi
gangliosid
karpov
kachanka
b
kishkurno
e
infecti
diseas
hospit
medic
univers
belaru
b
infecti
diseas
presid
hospit
minsk
belaru
bacteri
mening
seriou
problem
republ
belaru
consider
mortal
although
morbid
compar
low
accord
offici
statist
infecti
diseas
hospit
chang
etiolog
purul
mening
among
adult
republ
belaru
common
agent
str
pneumonia
caus
approxim
purul
mening
n
mening
caus
approxim
bacteri
mening
l
monocytogen
common
agent
mening
patient
year
chronic
diseas
exampl
diabet
alcohol
rule
drug
user
bacteri
mening
caus
aureu
case
mening
first
manifest
bacteri
endocard
rare
case
bacteri
mening
caus
h
influenza
particular
interest
nowaday
take
consider
consider
increas
resist
str
pneumonia
penicillin
countri
eastern
europ
use
cephalosporin
third
gener
first
line
therapi
ideal
antibiot
patient
ceftriaxon
high
dose
cefotaxim
rule
immunosuppress
patient
old
patient
receiv
combin
ceftriaxonecefotaxim
plu
ampicillin
gday
etiolog
therapi
bacteri
mening
caus
aureu
includ
cephalosporin
third
gener
meropenem
meropenem
use
patient
neutropenia
immunosuppress
state
add
vancomycin
first
line
therapi
suspect
hospitalacquir
mening
prescrib
antibacteri
therapi
pay
attent
basic
patholog
age
patient
initi
local
infect
aim
studi
preval
determin
factor
could
associ
hepat
steatosi
hcvhiv
coinfect
patient
method
hcvhiv
coinfect
patient
aquitain
cohort
male
median
age
year
median
count
includ
patient
elig
hcv
antivir
therapi
alcohol
intak
gday
data
collect
time
liver
biopsi
includ
type
haart
proteas
inhibitor
non
nucleosid
revers
transcriptas
inhibitor
nnrti
nucleosid
revers
transcriptas
inhibitor
cdc
stage
hiv
infect
hiv
plasma
viral
load
bmi
glycemia
total
cholesterol
triglycerid
transaminas
hcv
genotyp
histolog
activ
fibrosi
grade
accord
metavir
score
system
steatosi
classifi
none
minim
hepatocyt
mildtomoder
sever
result
overal
steatosi
present
patient
minim
n
mildtomoder
n
sever
n
consid
microvesicular
macrovesicular
mix
statist
analys
steatosi
defin
outcom
degre
least
mildtomoder
univari
analys
steatosi
significantli
associ
bmi
p
hcv
genotyp
p
use
nnrti
p
aspart
aminotransferas
p
sever
histolog
activ
p
associ
sever
fibrosi
close
signific
p
multivari
analysi
factor
remain
significantli
associ
steatosi
histolog
activ
p
bmi
close
signific
p
examin
magnitud
coeffici
chang
make
histolog
activ
appear
confound
intermedi
factor
occurr
steatosi
inde
histolog
activ
includ
regress
model
bmi
associ
steatosi
p
associ
steatosi
hcv
genotyp
close
statist
signific
p
conclus
steatosi
common
histolog
find
hcvhiv
coinfect
patient
factor
associ
steatosi
patient
appear
similar
report
hcvinfect
patient
howev
associ
steatosi
histolog
activ
investig
persist
hcvrna
mononuclear
cell
hcv
elimin
serum
interferon
therapi
identif
hcvrna
blood
serum
crucial
hepat
c
diagnosi
appropri
treatment
detect
hcvrna
blood
serum
use
therapi
monitor
patient
hepat
c
despit
hcvrna
elimin
blood
serum
treatment
patient
hcv
viremia
appear
complet
therapi
aim
studi
assess
hcvrna
peripher
blood
leukocyt
hepat
c
patient
relat
hcvrna
antibodi
hcv
serum
studi
involv
patient
undergo
antivir
therapi
interferon
ribavirin
rna
isol
serum
peripher
blood
leukocyt
qiagen
kit
genom
viral
rna
examin
presenc
hcvrna
rtpcr
techniqu
use
specif
oligonucleotid
primer
comerci
avail
kit
amplicor
roch
order
show
possibl
presenc
hcv
sequenc
peripher
blood
leukocyt
molecular
dna
probe
construct
pcr
amplicon
biotin
label
nick
translat
hcv
sequenc
detect
fish
also
chromatin
fiber
extend
chromatin
fiber
situ
hybrid
ecfsfish
twenti
two
patient
elimin
hcvrna
serum
remain
hcvposit
serum
neg
group
hcvrna
detect
mononuclear
cell
patient
presenc
hcvrna
mononuclear
cell
confirm
fish
techniqu
ecfsfish
procedur
signal
found
examin
patient
data
suggest
leukocyt
infect
hcv
serv
viru
reservuar
hcvrna
serum
neg
patient
complet
antivir
therapi
hcvrna
leukocyt
would
greater
risk
hepat
c
recurr
hcvrna
serum
neg
leukocyt
posit
patient
would
potenti
sourc
spread
hcv
infect
work
support
kbn
grant
nr
implic
lamivudin
therapi
acut
viral
hepat
havb
object
assess
effici
lamivudin
acut
viral
hepat
b
havb
prolong
high
alt
level
implic
immun
respons
method
patient
havb
prolong
high
alt
level
alt
n
week
onset
admit
hospit
januari
septemb
receiv
lam
mgday
month
patient
month
patient
follow
everi
month
biochem
alt
serolog
hbe
hb
seroconvers
test
follow
dinam
hbsab
month
result
alt
level
rapidli
normal
median
level
iuml
within
month
patient
month
patient
month
last
patient
hbeag
seroconvers
observ
patient
week
patient
week
patient
one
patient
becam
vhb
carrier
loss
hbsag
observ
patient
patient
week
patient
week
patient
hbsab
found
case
month
patient
month
patient
hbsab
never
appear
patient
end
therapi
case
hbsab
titer
protect
month
arrest
lamivudin
hbsab
titer
decreas
patient
hbsab
undetectabil
conclus
lamivudin
may
solut
prevent
chronic
hepat
b
howev
observ
hbsab
level
decreas
probabl
due
influenc
immun
respons
maillard
b
chapplain
jm
arvieux
c
tattevin
p
souala
f
dupont
neveu
c
b
guisthau
b
michelet
c
ruffault
b
maladi
infectieus
franc
b
virologi
chu
pontchail
renn
franc
object
clinic
practic
hivinfect
patient
discord
immunologicalvirolog
outcom
maintain
proteas
inhibitor
pi
base
regimen
despit
persist
viral
replic
investig
kinet
resist
mutat
emerg
select
pressur
patient
impact
futur
drug
regimen
method
enrol
nine
patient
remain
initi
pibas
therapi
least
year
despit
detect
plasma
viremia
genotyp
resist
test
perform
populationbas
sequenc
prepitreat
plasma
first
avail
sampl
virolog
failur
vf
viral
load
copiesml
yearli
treatment
modif
discontinu
follow
proteas
gene
codon
analys
accord
key
mutat
result
pitreat
initi
may
juli
consist
indinavir
n
nelfinavir
n
saquinavir
n
saquinavir
ritonavir
n
median
followup
month
rang
baselin
median
vl
cell
count
log
ml
cellsl
respect
vf
observ
median
month
rang
vl
valu
respect
median
vl
chang
baselin
last
genotyp
vf
last
genotyp
baselin
six
patient
one
three
mutat
proteas
gene
key
mutat
three
six
nrti
mutat
found
nrti
experienc
patient
n
zero
two
key
proteas
mutat
detect
vf
one
three
genotyp
median
total
number
proteas
resist
mutat
rang
vf
rang
genotyp
rang
n
genotyp
n
six
patient
acquir
resist
lopinavir
amprenavir
evolut
observ
rt
gene
except
nrtinaiv
patient
conclus
accumul
pimut
slow
emerg
key
mutat
howev
mutat
led
acquisit
whole
class
resist
six
nine
discord
patient
longterm
vf
thu
could
compromis
futur
treatment
option
costeburel
c
bess
b
c
papi
k
c
lope
p
b
laboiss
c
imbertmarcil
bm
c
anatomi
pathologiqu
franc
b
c
virologi
chu
nant
nant
franc
cervic
cancer
associ
highrisk
type
human
genit
papillomaviru
hrhpv
notabl
genotyp
common
countri
oncogen
potenti
hrhpv
mainli
depend
express
viral
oncoprotein
data
suggest
particular
viral
variant
gene
may
oncogen
evalu
particular
point
local
popul
analys
retrospect
posit
cervic
sampl
obtain
women
consult
gynaecolog
unit
nant
univers
hospit
sampl
normal
cytolog
wherea
other
show
cervic
intraneoplasia
grade
grade
gene
gene
success
amplifi
specif
pcr
variant
analys
direct
nucleotid
sequenc
multipl
sequenc
align
full
length
gene
perform
mega
program
phylogenet
tree
construct
insert
delet
sequenc
fragment
observ
gene
ident
prototyp
sequenc
previous
describ
mutat
gene
present
total
nonpublish
nonsynonym
mutat
nonpublish
nonsynonym
identifi
gene
respect
four
sampl
contain
multipl
nucleotid
chang
typic
noneuropean
variant
signific
associ
observ
variant
differ
cytolog
class
interestingli
four
multipl
variant
sampl
associ
cervic
intraepitheli
neoplasia
highgrad
low
grade
sinc
risk
high
grade
cervic
neoplasia
seem
increas
patient
infect
certain
variant
knowledg
local
preval
interest
furthermor
determin
variant
may
use
perspect
hpv
antivir
treatment
vaccin
background
neonat
bm
poor
prognosi
mortal
rate
signific
sequela
incidenceand
bacteri
epidemiolog
known
franc
method
allcas
bm
birth
year
franc
record
prospect
pediatr
wardsand
microbiolog
network
cover
pediatr
depart
specif
neonat
result
januari
januari
present
result
sex
ratio
mf
case
report
depart
group
b
streptococcu
gb
repres
case
e
n
meningitidi
pneumonia
miscellan
earli
onset
bm
day
n
gb
larg
predomin
versu
e
coli
late
onset
bm
day
n
gb
e
coli
rate
similar
respect
among
preterm
gestat
age
week
n
gb
lower
e
coli
fullterm
n
gb
higher
e
coli
serotyp
iii
gb
isol
e
coli
k
e
coli
ampicillin
resist
rate
third
gener
cephalosporin
use
case
gb
e
coli
case
fatal
rate
higher
preterm
versu
p
conclus
prognosi
bm
newborn
poor
high
mortal
rate
gb
remain
common
pathogen
e
coli
increas
especi
lo
mening
method
sinc
januari
french
pediatr
ward
pediatr
depart
work
microbiolog
depart
enrol
children
bacteri
mening
inform
collect
includ
risk
factor
sign
symptom
cerebrospin
fluid
csf
analysi
treatment
shortterm
evolut
spm
result
center
report
spm
sex
ratio
mf
children
less
year
old
median
age
year
peak
incid
month
year
age
day
care
attend
modal
home
day
care
center
child
minder
underli
condit
report
case
csf
control
day
steril
percent
penicillin
nonsuscept
strain
intermedi
resist
antibiot
combin
vancomycin
plu
thirdgener
cephalosporin
prescrib
case
steroid
case
case
fatal
rate
relat
neither
age
antibiot
suscept
steroid
use
children
less
year
vaccin
serotyp
account
case
addit
serotyp
serotyp
pneumococc
conjug
vaccin
coverag
reach
older
patient
vaccin
serotyp
account
serotyp
among
five
children
vaccin
one
month
old
dose
serotyp
csf
cultur
four
other
nonvaccin
serotyp
conclus
result
repres
baselin
monitor
spm
chang
futur
serotyp
resist
evolut
extend
use
recommend
franc
routin
use
infant
sinc
januari
joram
n
b
loubersac
v
winer
n
c
roze
jc
b
grasl
guen
c
b
laboratoir
de
biochimi
chu
nant
franc
b
et
franc
c
servic
de
hopit
enfant
chu
nant
nant
franc
background
bacteri
maternofoet
infect
one
frequent
caus
neonat
morbid
mortal
prognosi
close
relat
earli
diagnosi
treatment
context
paediatrician
frequent
initi
earli
antibiotherapi
newborn
infecti
risk
factor
expos
non
infect
unnecessari
treatment
aim
work
evalu
valu
procalcitonin
pct
dosag
umbil
cord
earli
specif
marker
perinat
bacteri
sepsi
method
prospect
studi
conduct
neonat
suspect
maternofoetal
infect
thirti
neonat
without
risk
factor
constitut
control
group
serum
procalcitonin
creactiv
protein
concentr
measur
simultan
umbil
cord
blood
matern
blood
accord
clinic
bacteriolog
cours
three
group
defin
group
infect
n
group
colon
n
group
noninfect
noncolon
neonat
ninc
n
result
statist
higher
serum
procalcitonin
concentr
found
infect
group
versu
control
colon
p
pct
valu
greater
equal
ngml
observ
infect
newborn
non
infect
newborn
crp
dosag
mgl
infect
newborn
sensit
specif
neg
posit
predict
valu
respect
pct
crp
matern
pct
serum
level
neg
case
conclus
although
matern
pct
dosag
seem
inform
serum
procalcitonin
cord
blood
seem
use
earli
marker
antenat
infect
infecti
complic
paediatr
acut
myeloid
leukaemia
low
incid
bacteraemia
due
viridan
streptococci
retrospect
studi
brunet
b
c
ploton
c
galambrun
c
b
c
pondarr
c
b
c
page
mp
c
bleyzac
n
c
c
g
c
bertrand
b
c
franc
b
et
transplant
de
moell
osseus
franc
c
hopit
debrouss
lyon
franc
object
infect
remain
import
caus
morbid
mortal
children
acut
myeloid
leukemia
aml
viridan
streptococci
vs
main
caus
sever
sepsi
profound
neutropenia
high
dose
cytarabin
predispos
factor
aim
studi
evalu
children
aml
frequenc
characterist
infecti
complic
ic
incid
vs
sepsi
interest
prevent
decontamin
valu
cytarabin
dosag
occurr
ic
gm
first
intensif
patient
method
medic
chart
children
treat
accord
eortc
clinic
trial
retrospect
analys
includ
chemotherapi
cours
prevent
infect
patient
isol
laminar
air
flow
room
receiv
gut
decontamin
per
os
aminoglycosid
amphotericin
b
gum
decontamin
vancomycin
mouth
wash
trimethoprimsulfamethoxazol
effici
decontamin
evalu
weekli
ic
categor
microbiolog
document
infect
mdi
clinic
document
infect
cdi
fever
unknown
origin
fuo
result
overal
ic
occur
fuo
cdi
mdi
bloodstream
infect
pathogen
tabl
five
patient
die
infectiousassoci
complic
child
die
bacteri
infect
patient
vs
sepsi
requir
manag
intens
care
unit
invas
fungal
infect
proven
four
patient
accord
condit
gum
ant
gut
decontamin
number
ic
per
patient
significantli
differ
accord
dose
cytarabin
first
intensif
preval
ic
significantli
differ
resist
strain
detect
spite
use
local
antibiot
streptococcu
pneumonia
common
caus
bacteri
pneumonia
young
children
pleural
empyema
rare
complic
bacteri
pneumonia
associ
sever
morbid
recent
observ
increas
incid
pneumococc
pleural
empyema
children
admit
necker
hospit
diagnosi
pneumococc
empyema
infect
base
cultur
blood
pleural
fluid
frequent
neg
due
previou
administr
antibiot
rapid
pneumococc
capsular
antigen
pac
detect
latex
agglutin
use
sever
year
diagnost
valu
clearli
establish
work
evalu
retrospect
accuraci
pac
diagnosi
pneumonia
empyema
compar
cultur
blood
pleural
fluid
molecular
biolog
pleural
fluid
test
pac
pleural
empyema
case
collect
period
accord
criteria
light
microbiolog
document
causal
pathogen
cultur
pcr
sequenc
found
case
includ
case
pneumonia
bacteria
aureu
pyogen
found
neg
pac
pleural
fluid
among
pneumococc
empyema
pac
posit
case
provid
sensit
pac
posit
seven
case
bacteri
cultur
pleural
empyema
steril
five
seven
case
diagnosi
pneumococc
empyema
confirm
pcr
perform
posit
cultur
clinic
sampl
two
case
posit
pac
confirm
despit
posit
microscop
examin
one
case
discrep
cultur
pac
could
explain
accord
clinic
histori
patient
previou
administr
antibiot
pac
detect
pleural
fluid
use
test
diagnosi
strategi
pneumococc
empyema
children
high
predict
posit
valu
low
predict
neg
valu
make
imposs
rule
diagnosi
pneumococc
empyema
therefor
detect
pac
provid
addit
rapid
respons
children
pneumococc
empyema
includ
receiv
previou
antibiot
therapi
secret
signific
amount
staphylococc
bicompon
leukotoxin
lukelukd
associ
antibioticassoci
diarrhoea
enterotoxin
bullou
impetigo
epidermolysin
secret
toxin
observ
routin
isol
wherea
correspond
gene
present
isol
analys
independ
isol
presenc
lukelukd
operon
toxin
product
tent
develop
pcr
test
detect
deleteri
mutat
given
isol
furthermor
gene
express
assess
use
competit
rtpcr
test
verifi
role
insert
sequenc
promot
sequenc
correspond
secret
toxin
clone
express
e
coli
assess
biolog
function
compar
control
toxin
isol
carri
lukelukd
operon
secret
leucotoxin
operon
sequenc
four
isol
reveal
numer
mutat
may
affect
protein
structur
three
expressiondefici
strain
show
delet
one
basi
initi
codon
delet
made
imposs
function
translat
despit
correspond
mrna
synthes
level
compar
control
four
isol
estim
carri
delet
among
studi
protein
express
e
coli
mutat
identifi
abl
inactiv
leucotoxin
taken
togeth
studi
evid
extrem
variabl
lukelukd
operon
lack
toxin
expressionfunct
toxin
half
isol
even
gene
present
illustr
discrep
gene
presenc
might
detect
genotyp
test
effect
product
function
toxin
thu
phenotyp
method
remain
indic
detect
leucotoxin
avoid
falseposit
data
previou
clinic
associ
remain
signific
work
cosupport
stawar
project
cnrprovincia
autonoma
trentino
loulergu
p
lina
g
tristan
be
etienn
j
vandenesch
f
staphylococc
infect
frequent
repres
major
public
health
issu
although
resist
methicillin
use
exclus
restrain
hospit
year
worldwid
emerg
communityacquir
methicillinresist
aureu
camrsa
clone
notic
interhuman
skintoskin
transmiss
postul
caus
rapid
epidem
spread
clone
camrsa
strain
three
common
characterist
type
iv
sccmec
cassett
staphylococc
cassett
chromosom
type
agrallel
accessori
gene
regul
phage
phislt
carri
panton
valentin
leukocidin
pvl
gene
combin
element
appear
provid
strain
select
advantag
increas
epidem
potenti
hypothes
insert
phage
phislt
determin
dysregul
staphylococc
proteom
modul
express
protein
one
major
surfac
protein
aureu
analys
express
protein
eleven
isogen
coupl
aureu
strain
transduct
phislt
phage
strain
inactiv
major
regul
system
virul
aureu
two
upregul
system
rot
sar
three
downregul
system
sara
agr
arlr
express
protein
analys
northern
western
blot
observ
acquisit
phage
phislt
induc
overexpress
protein
sever
isogen
strain
notabl
rot
arlinsert
mutant
upregul
protein
promin
protein
level
rather
transcript
level
result
confirm
presenc
phislt
bring
major
cytolyt
toxin
ie
pvl
also
induc
overexpress
protein
potenti
virul
factor
may
enhanc
colon
andor
invas
capac
aureu
twelv
isol
cutan
sampl
other
taken
urinari
site
n
pulmonari
site
n
blood
cultur
n
patient
hospitalis
differ
depart
medicin
surgeri
intens
care
long
term
care
unit
emerg
unit
three
patient
transfer
anoth
hospit
come
home
n
long
term
care
unit
n
mean
age
year
year
sex
ratio
half
histori
previou
hospitalis
last
month
patient
receiv
broadspectrum
antiobiot
lactam
lactamas
combin
lactam
antibiot
mrsa
isol
mrsa
hospitalacquir
colonis
infect
mean
time
acquisit
other
communityacquir
eight
patient
infect
colon
two
patient
statu
unknown
strain
perform
pcr
multiplex
analysi
nuca
meca
rrna
gene
pfge
analysi
genom
dna
strain
reveal
differ
pulsotyp
conclus
result
show
emerg
mrsa
strain
relat
epidem
spread
therefor
ration
isol
patient
discuss
groh
p
b
veil
kac
g
c
montpelli
franc
b
microbiologi
franc
c
unit
hopit
georg
pompid
pari
franc
object
monitor
methicillinresist
staphylococcu
aureu
mrsa
rate
crucial
hospit
set
calcul
hamper
variat
accord
duplic
isol
aim
studi
assess
impact
appli
differ
method
duplic
isol
remov
mrsa
rate
use
specif
design
softwar
materi
method
trend
aureu
resist
analys
use
sirscan
comput
system
isol
collect
univers
hospit
hopit
georg
pompid
period
refer
duplic
rd
criteria
defin
one
major
three
minor
differ
antibiot
pattern
time
period
two
isol
variat
antibiot
pattern
time
period
two
isol
number
antibiot
test
studi
compar
rd
criteria
nccl
recommend
base
upon
result
first
isol
speci
per
patient
per
analysi
period
irrespect
bodi
site
antimicrobi
suscept
profil
phenotyp
characterist
evalu
addit
exclus
outpati
screen
specimen
also
studi
result
juli
june
mrsa
rate
use
rd
antibiot
test
duplic
elimin
mrsa
rate
significantli
increas
p
use
nccl
recommend
mrsa
rate
significantli
decreas
p
differ
toler
antibiot
pattern
time
period
set
five
day
mrsa
rate
significantli
increas
respect
p
trend
observ
test
antibiot
consid
exclus
outpati
screen
specimen
mrsa
rate
vari
slightli
significantli
conclus
assess
accur
mrsa
trend
result
suggest
criteria
use
remov
duplic
care
select
describ
scientif
report
allow
meaning
comparison
hospit
direct
screen
mrsa
swab
specimen
use
duplex
realtim
pcr
assay
implic
antibiot
prophylaxi
desbouchag
l
serazin
v
b
leneveu
rast
g
giudicelli
b
merrer
j
c
uf
b
uf
biologi
c
aim
methicillinresist
staphylococcu
aureu
mrsa
nasal
carriag
potenti
sourc
infect
orthopaed
surgeri
rapid
identif
mrsa
clinic
specimen
import
antibiot
prophylaxi
isol
colon
patient
current
screen
patient
mrsa
use
cultur
method
requir
day
detect
identif
develop
duplex
realtim
pcr
target
meca
specif
methicillin
resist
nuc
specif
aureu
gene
without
previou
isol
enrich
compar
result
method
convent
cultur
group
surgic
patient
high
risk
mrsa
carriag
vancomycin
prophylaxi
usual
recommend
materi
method
nasal
swab
collect
admiss
month
elderli
patient
admit
femor
neck
fractur
sampl
process
parallel
select
plate
method
mueller
hinton
ofloxacin
gml
duplex
realtim
pcr
sybr
green
use
amplicon
detect
result
result
pcr
screen
obtain
within
h
swab
sampl
neg
method
patient
posit
method
posit
cultur
posit
duplex
realtim
pcr
latter
group
sampl
mixtur
methicillinsensit
staphylococcu
aureu
methicillinresist
coagulas
neg
staphylococcu
conclus
duplex
realtim
pcr
rapid
costeffect
valuabl
method
rule
mrsa
nasal
carriag
therefor
vancomycin
prophylaxi
could
safe
avoid
patient
free
mrsa
nasal
carriag
hill
r
levey
r
pharmaceutica
worcest
uk
evolut
bacteri
cell
wall
resist
action
betalactam
antibiot
continu
pose
uniqu
challeng
treatment
infect
emerg
technolog
bacteri
transform
agent
bta
identifi
molecul
revers
cell
wall
resist
primarili
betalactam
relat
agent
therapeut
target
moieti
involv
bind
muropeptid
tail
cell
wall
crosslink
moieti
mimic
pentaglycin
crosslink
aureu
includ
methicillinsensit
mssa
methicillinresist
mrsa
strain
result
peptidoglycan
muropeptid
termin
dalax
instead
daladala
bta
similarli
interact
muropeptid
tailcrosslink
assembl
hypersensitis
cell
wall
transform
mrsa
mssa
without
elimin
basic
test
technolog
vitro
glycin
benzyl
ester
wwv
reduc
mic
mrsa
includ
uk
epidem
mgl
mgl
bta
increas
potenc
time
coformul
betalactamaseresist
antistaphylococc
betalactam
relat
antimicrobi
topic
treatment
becom
immedi
possibl
addit
mic
vancomycin
mrsa
reduc
glycopeptidesensit
reduc
mgl
also
activ
vancomycinresist
enterococcu
faecium
none
substanc
antimicrobi
activ
right
mrsa
transform
mssa
presenc
bta
specif
agent
establish
pharmacokinet
toxic
data
reduc
mic
methicillin
mgl
presenc
serum
benchmark
coformul
antimicrobi
flucloxacillin
cloxacillin
vivo
studi
coformul
bta
could
restor
activ
well
known
antistaphylococc
antimicrobi
activ
mssa
produc
new
therapeut
entiti
radiographi
bacteriolog
investig
furthermor
januari
septemb
systemat
comparison
mycobacterium
tuberculosi
strain
isol
hospit
conduc
molecular
type
method
order
access
eventu
transmiss
sixti
two
strain
compar
spoligotyp
accord
kamerbeek
et
al
spoligotyp
type
method
base
dna
polymorph
present
one
particular
chromosom
locu
direct
repeat
dr
present
mtuberculosi
complex
bacteria
number
dr
element
cluster
vari
strain
speci
bp
dr
interspers
nonrepetit
dna
spacer
bp
forti
three
spacer
repres
tuberculosi
complex
strain
synthes
oligonucleotid
immobil
nylon
membran
isol
straintyp
basi
detect
presenc
absenc
specif
spacer
use
pcr
reverselin
hybrid
techniqu
nurs
auxiliarystrain
clearli
show
distinct
spoligotyp
other
investig
strain
interestingli
spoligotyp
uniqu
spoligotyp
databas
centr
de
de
de
linstitut
pasteur
larg
epidemiolog
survey
suspect
nosocomi
case
tuberculosi
spoligotyp
appear
interest
easi
perform
rapid
method
molecular
type
allow
demonstr
nurs
auxiliari
tuberculosi
unrel
other
case
tuberculosi
diagnos
hospit
period
howev
investig
actual
prolong
recommend
period
month
introduct
despit
widespread
percept
epidemiolog
pulmonari
tuberculosi
tb
athen
chang
recent
part
due
influx
immigr
past
year
investig
properli
aim
therefor
conduct
epidemiolog
survey
collect
relev
data
patient
diagnos
two
largest
pulmonari
hospit
citi
method
tb
patient
diagnos
sotiria
sismanoglion
hospit
period
prospect
enrol
strain
isol
identif
perform
accord
standard
procedur
agar
proport
method
mgit
becton
dickinson
usa
use
suscept
test
isoniazid
inh
rifampin
rif
ethambutol
emb
streptomycin
sm
pyrazinamid
pza
demograph
clinic
laboratori
data
collect
review
medic
record
interview
patient
result
total
tb
case
confirm
major
men
live
athen
patient
nativ
greek
foreign
emigr
eastern
europ
mean
age
year
compar
year
among
greek
pulmonari
tb
diagnos
dissemin
diseas
patient
immunodefici
recogn
patient
patient
report
chronic
diseas
intraven
drug
user
commun
exposur
report
person
institut
transmiss
involv
five
inpati
psychiatr
clinic
strongli
suspect
twentytwo
individu
immigr
document
prior
tb
treatment
acid
fast
stain
posit
case
resist
preval
inh
rif
emb
pza
sm
resist
two
three
four
five
drug
respect
eleven
strain
resist
inh
rif
three
origin
immigr
conclus
pulmonari
tb
athen
affect
primarili
male
immigr
repres
third
popul
preval
multidrugresist
object
outlin
clinic
epidemiolog
featur
tuberculosi
tb
central
nervou
system
cn
parenchyma
along
optim
durat
antitb
therapi
method
retrospect
case
survey
patient
admit
hospit
diagnosi
cn
parenchym
tb
demograph
clinic
laboratori
radiolog
data
along
durat
respons
antitb
therapi
collect
diagnost
criteria
either
proven
presenc
mycobacteria
cn
parenchyma
bacteriolog
proven
tb
elswher
radiolog
imag
cn
tb
along
clinic
radiolog
improv
antitubercul
therapi
result
patient
fulfil
aforement
diagnost
criteria
age
male
sex
fifti
two
african
indian
subcontin
other
asian
european
caribbean
nativ
hiv
infect
main
clinic
symptom
headach
weight
loss
fever
cerebrospin
fluid
csf
patholog
patient
acidfast
bacilli
seen
direct
examin
one
patient
cultur
patient
cn
mycobacteria
identifi
direct
examin
cultur
pcr
patient
ct
scan
show
parenchym
mass
lesion
mri
patient
underw
examin
patient
underw
complet
cours
antitb
therapi
induct
phase
use
regimen
isoniazid
rifampin
pyrazinamid
ethambutol
patient
regimen
consolid
therapi
use
mostli
isoniazid
rifampin
patient
patient
total
durat
treatment
least
month
none
need
addit
therapi
conclus
cn
parenchym
tb
frequent
middleag
adult
diagnosi
base
associ
clinic
laboratori
radiolog
argument
well
respons
antitb
therapi
opinion
treatment
form
tb
requir
cours
regimen
follow
bitherapi
total
durat
least
month
key
word
tuberculosi
cn
parenchyma
tuberculoma
demographi
antitubercul
therapi
diagnosi
lymph
node
tuberculosi
tunisia
lymph
node
tuberculosi
lntb
common
form
extra
pulmonari
tuberculosi
clinic
practic
histolog
cytolog
studi
lymph
node
materi
mostli
permit
diagnosi
object
descript
diagnost
approach
lntb
method
retrospect
studi
case
lntb
hospit
depart
infecti
diseas
rabta
hospit
tuni
ten
year
result
case
lntb
studi
men
women
mean
age
year
twenti
four
patient
immunocompromis
co
infect
hiv
diagnosi
suggest
percept
peripher
lymphadenopathi
first
clinic
examin
patient
tuberculin
skin
test
posit
case
twenti
nine
patient
abdomin
thorac
tubercul
lymph
node
visualis
doppler
sonographi
tomodensitometri
patient
diagnosi
lymph
node
tuberculosi
confirm
cytolog
histolog
exam
lymph
node
patient
seven
patient
treat
basi
clinic
observ
conclus
confirm
lntb
easi
clinic
observ
histolog
cytolog
radiolog
must
combin
establish
diagnosi
magira
e
gounari
th
tsopra
gounari
p
arsenogl
th
sioula
e
present
patient
ethiopia
admit
hospit
high
fever
malais
clinic
examin
reveal
enlarg
lymph
node
upperclavicular
space
axillari
high
bodi
temperatur
loss
weight
liver
palpabl
medic
record
unremark
mention
healthi
life
get
sick
laboratori
valu
consist
anemia
hypoalbuminaemia
abdomin
ultrasound
reveal
enlarg
lymph
node
excis
lymph
node
upperclavicular
space
perform
massiv
white
materi
produc
microscop
examin
show
mycobacterium
tuberculosi
infect
chest
xray
consist
miliari
tb
h
admiss
hospit
patient
condit
deterior
blood
pressur
decreas
puls
rate
temperatur
c
hiv
antibodi
test
turn
posit
coinfect
tuberculosi
recogn
patient
place
anti
hiv
antitb
therapi
well
h
later
succumb
fulmin
tb
sepsi
case
set
human
immunodefici
viru
infect
patient
previous
remain
free
symptom
tuberculosi
treatment
franc
guidelin
practic
tattevin
p
f
chapplain
jm
f
lesprit
ph
b
billi
ch
c
roblot
f
e
alfandari
g
rouveix
e
bouvet
e
ambrois
boulogn
franc
b
henri
mondor
franc
c
quesnay
manteslajoli
franc
bichatclaud
bernard
pari
franc
e
la
poitier
franc
f
pontchail
renn
franc
g
gustav
dron
tourco
franc
background
guidelin
treatment
tuberculosi
tb
updat
usa
center
diseas
control
prevent
american
thorac
societi
infecti
diseas
societi
america
franc
conseil
publiqu
mainli
evid
base
agre
point
recommend
treatment
durat
month
pulmonari
tb
whether
patient
hivinfect
extrapulmonari
tb
except
case
neuromening
involv
month
cours
may
prefer
corticosteroid
recommend
initi
tb
treatment
case
pericard
neuromening
tb
object
assess
whether
practic
franc
agreement
guidelin
method
use
french
infecti
diseas
socitey
net
perform
anonym
audit
practic
focus
tb
treatment
durat
corticosteroid
use
accord
tb
present
may
member
de
pathologi
infectieus
de
langu
spilf
ask
complet
short
form
consid
arestandard
carefor
treatment
tb
depart
data
analys
use
epi
info
cdc
atlanta
result
complet
form
analys
frequent
report
standard
treatment
durat
month
pulmonari
tb
non
hivinfect
patient
report
usual
durat
respond
miliari
tb
respond
month
pulmonari
tb
hivinfect
patient
tb
lymphaden
month
mening
tb
osteoarticular
tb
corticosteroid
mainli
prescrib
treatment
tb
mening
systemat
use
respond
pericard
pleurisi
lymphaden
miliari
clinic
signific
effluxmedi
resist
fq
pseudomona
aeruginosa
evalu
montecarlo
simul
dupont
p
hocquet
patri
chavanet
p
b
p
laboratoir
de
chu
jean
minjoz
franc
b
servic
de
maladi
infectieus
chu
du
bocag
dijon
franc
object
eight
fluoroquinolon
fq
pefloxacin
norfloxacin
ofloxacin
moxifloxacin
levofloxacin
ciprofloxacin
trovafloxacin
grepafloxacin
assess
bacteriostat
bactericid
activ
fqresist
mutant
p
aeruginosa
overproduc
activ
efflux
system
mexaboprm
mexxi
gain
insight
clinic
signific
resist
confer
mechan
mont
carlo
simul
conduct
variou
fq
regimen
method
seven
eleven
clinic
strain
found
overproduc
mexaboprm
mexxi
efflux
system
respect
immunoblot
qrtpcr
experi
gene
sequenc
reveal
mutat
qrdr
gyra
gyrb
parc
pare
isol
mic
determin
microbroth
dilut
assay
mbc
assess
kill
curv
method
pkpd
paramet
calcul
use
montecarlo
simul
conduct
variou
fq
regimen
patient
chose
auc
mic
cmaxmic
pharmacodynam
target
predict
clinic
outcom
result
overexpress
mexaboprm
mexxi
increas
mic
fq
twoto
eightfold
exampl
ciprofloxacin
mic
reach
gml
pump
overexpress
addit
mbc
twoto
fourfold
higher
mic
fq
test
montecarlo
simul
show
pkpd
paramet
attain
rate
decreas
dramat
result
effluxmedi
resist
success
rate
low
even
simul
aggress
treatment
iv
ciprofloxacin
mg
tid
ciprofloxacin
mic
reach
gml
conclus
fq
exhibit
decreas
bacteriostat
activ
remain
bactericid
effluxoverexpress
mutant
low
resist
level
confer
efflux
mechan
howev
predict
result
poor
clinic
outcom
overal
data
strongli
suggest
modest
activ
efflux
provid
p
aeruginosa
resist
may
suffici
impair
efficaci
singl
therapi
fq
object
studi
role
multidrug
efflux
system
acrabtolc
resist
multidrugresist
salmonella
typhimurium
strain
deterg
bile
salt
also
evalu
role
compon
acrb
tolc
colonis
strain
chick
acrb
tolc
mutant
strain
construct
insert
inactiv
delet
gene
respect
mic
deterg
sd
bile
salt
determin
wildtyp
strain
acrb
tolc
mutant
effect
sodium
choleat
chol
vitro
growth
strain
also
evalu
strain
measur
day
old
chicken
model
inocul
sever
dose
log
cfu
per
os
day
postinocul
colonis
level
assess
subleth
dose
day
postinocul
determin
number
cfu
salmonella
faec
caeca
spleen
liver
case
acrb
mutant
mic
valu
sd
sodium
deoxychol
doc
chol
decreas
significantli
respect
rel
wild
type
strain
tolc
mutant
mic
sd
doc
chol
decreas
respect
thu
decreas
resist
level
sd
bile
salt
much
import
tolc
acrb
mutant
chol
affect
vitro
growth
wildtyp
strain
acrb
mutant
inhibit
tolc
mutant
log
log
cfu
one
wild
type
strain
acrb
mutant
respect
calcul
tolc
mutant
strain
small
number
dead
chick
contrast
acrb
mutant
tolc
mutant
unabl
colonis
organ
detect
faec
chick
colonis
level
acrb
mutant
wildtyp
strain
thu
tolc
acrb
appear
essenti
multidrugresist
typhimurium
colonis
chick
correl
well
respect
role
resist
deterg
bile
salt
tolc
could
therefor
better
target
acrb
develop
efflux
system
inhibitor
cagliero
c
cloix
l
payot
cloeckaert
bioagresseur
environn
institut
nation
de
la
recherch
agronomiqu
toursnouzilli
franc
campylobact
one
lead
caus
human
gastroenter
report
worldwid
increasingli
resist
antibiot
apart
target
mutat
efflux
mechan
cmeabc
efflux
system
describ
sequenc
whole
operon
resist
strain
found
contrast
cmea
cmec
cmeb
sequenc
greatli
differ
nctc
strain
object
work
design
pcrrflp
method
studi
divers
multidrug
transport
sever
repres
strain
campylobact
jejuni
campylobact
coli
isol
human
poultri
pig
examin
util
type
method
twentythre
strain
includ
analysi
entir
cmeb
gene
amplifi
pcr
digest
eight
restrict
enzym
comparison
restrict
pattern
made
determin
divers
transport
sequenc
nucleotid
protein
level
eighteen
differ
overal
pattern
obtain
discrimin
could
obtain
associ
half
enzym
singl
hinfihaeii
digest
suffici
discrimin
twothird
strain
three
pair
ident
pattern
includ
one
human
one
poultri
group
togeth
observ
overal
strain
show
homolog
except
one
poultri
strain
less
homolog
differ
local
sequenc
also
concern
characterist
function
motif
transport
twentyeight
potenti
restrict
site
two
five
respect
conserv
except
one
strain
conclus
contrast
salmonella
escherichia
coli
acrb
homolog
high
divers
observ
cmeb
multidrug
transport
gene
campylobact
jejuni
campylobact
coli
could
import
target
pump
combat
resist
furthermor
pcrrflp
design
work
could
cheap
easytoperform
method
compar
isol
bacteri
speci
addit
protein
modif
could
function
signific
characterist
motif
involv
substrat
recognit
energ
also
observ
vidaillac
c
b
guillon
j
arpin
c
b
grellet
j
c
jarri
c
quentin
c
b
ea
laboratoir
de
pharmacochimi
de
bordeaux
bordeaux
franc
b
ea
laboratoir
de
microbiologi
de
bordeaux
bordeaux
franc
c
ea
laboratoir
de
de
pharmaci
de
bordeaux
bordeaux
franc
discoveri
efflux
pump
inhibitor
epi
capabl
restor
antibiot
suscept
bacteri
mutant
overexpress
efflux
particular
multidrug
resist
mdr
system
would
major
interest
provid
devoid
toxic
therapeut
level
among
current
avail
epi
benzimidazol
deriv
omeprazol
safe
use
sinc
year
inhibitor
eukaryot
proton
pump
treatment
gastric
ulcer
exhibit
moder
activ
bacteria
studi
seri
new
potenti
inhibitor
synthes
base
common
featur
share
differ
epi
seri
five
molecul
show
structur
analog
benzimidazol
proton
pump
inhibitor
examin
publish
method
investig
bacteri
efflux
system
inhibit
test
order
delin
strategi
epi
evalu
use
follow
model
staphylococcu
aureu
strain
sa
overexpress
mdr
efflux
pump
nora
germtest
norfloxacin
preferenti
substrat
omeprazol
refer
epi
antibiogram
diffus
method
agar
supplement
epi
subsequ
checkerboard
assay
combin
antibiot
epi
final
hplc
measur
antibiot
intracellular
accumul
without
epi
found
use
approach
product
appear
effici
diffus
test
checkerboard
techniqu
fic
optim
concentr
mgl
norfloxacin
mgl
epi
concentr
promis
molecul
increas
intracellular
level
norfloxacin
cell
compound
gave
poorer
result
comparison
omeprazol
yied
fic
increas
norfloxacin
intracellular
accumul
cell
thu
product
actual
act
epi
mdr
efflux
pump
nora
research
need
obtain
drug
effect
omeprazol
howev
data
allow
structureact
relationship
analysi
help
us
modifi
design
synthesi
throw
light
mechan
action
inhibitor
bacteri
efflux
pump
de
mouy
fabr
r
b
cavallo
jd
b
arzouni
jp
baynat
bicartse
doeschler
gavinet
galini
jl
e
b
gontier
p
grillet
n
larribet
g
lepargneur
jp
naepel
payro
g
aforcopibio
pari
franc
b
hia
franc
aim
studi
determin
distribut
antibiot
suscept
pattern
strain
isol
year
old
femal
communityacquir
urinari
tract
infect
octob
decemb
french
privat
laboratori
consecut
collect
clinic
strain
medic
inform
interview
patient
fever
pregnanc
associ
diseas
histori
urinarytract
abnorm
reinfect
month
previou
antibiot
treatment
hospit
month
escherichia
coli
preval
pathogen
follow
proteu
mirabili
klebsiella
spp
enterobacteriacea
enterococcu
spp
staphylococcu
aureu
staphylococcu
saprophyticu
streptococcu
agalactia
aureu
often
isol
diabet
patient
suscept
antibiot
studi
e
coli
use
determin
minim
inhibitori
concentr
agar
dilut
method
coordin
center
result
interpret
accord
recommend
de
lantibiogramm
de
la
de
microbiologi
susceptibl
amoxicillin
amx
nalidix
acid
nal
norfloxacin
ciprofloxacin
cip
cotrimoxazol
sxt
fosfomycin
gentamicin
cefotaxim
suscept
e
coli
lower
case
previou
treatment
antibiot
amx
versu
p
et
sxt
versu
p
way
previou
treatment
quinolon
associ
decreas
suscept
nal
versu
p
sxt
versu
p
treatment
urinari
tract
infect
fluoroquinolon
repres
prescrib
antibiot
follow
antibiot
fosfomycin
cotrimoxazol
furan
nalidix
acid
singledos
treatment
three
day
seven
day
treatment
respect
prescrib
case
urinari
tract
infect
uti
acquir
commun
seldom
complic
frequent
requir
empir
treatment
protocol
base
antimicrobi
suscept
pattern
etiolog
agent
uropathogen
escherichia
coli
frequent
bacteria
caus
uti
marker
predict
evolut
resist
commun
studi
isol
e
coli
antimicrobi
suscept
pattern
area
last
year
identifi
strain
urin
sampl
signific
count
use
convent
method
broth
dilut
establish
mic
sever
antimicrobi
microscan
dade
behr
evalu
sensit
ampicillin
amoxicillinclavulan
acid
ac
nalidix
acid
strain
decreas
sensit
cip
frequent
versu
also
relev
proport
strain
mic
one
thousand
ten
strain
resist
fluoroquinolon
group
percentag
sensit
antimicrobi
substanti
lesser
ac
tmpsxt
fo
fd
gm
present
crossresist
sever
strain
conclus
remark
recoveri
suscept
antimicrobi
recommend
ambulatori
therapi
perhap
due
antimicrobi
polici
establish
year
commun
healthcar
nevertheless
disturb
constant
increas
resist
quinolon
group
accord
uncontrol
inappropri
use
due
good
imag
activ
toler
ronco
e
deni
p
c
laffont
c
c
martel
p
guillemot
salomon
j
b
dizien
c
bussel
b
c
perronn
c
b
gaillard
jl
background
urinari
tract
infect
uti
common
medic
complic
patient
spinal
cord
injuri
sci
howev
relev
biolog
criteria
remain
unclear
repeat
catheter
common
asymptomat
bacteriuria
andor
pyuria
method
measur
coloni
form
unit
cfu
white
blood
cell
wbc
count
two
group
urin
sampl
collect
prospect
sci
male
patient
intermitt
catheter
ic
urin
sampl
patient
clinic
evid
uti
sampl
asymptomat
control
result
urin
sampl
symptomat
patient
control
sampl
consid
posit
accord
follow
classic
criteria
cfuml
ii
cfuml
iii
cfuml
wbcml
evalu
variou
cfu
wbc
treshold
alon
combin
abil
discrimin
two
group
overal
combin
criteria
bacteriuria
pyuria
discrimin
best
treshold
combin
cfuml
wbcml
versu
around
classic
criteria
combin
provid
sensit
specif
classic
criteria
sensit
much
less
specif
sensitivityspecif
cfuml
cfuml
cfuml
wbcml
conclus
summari
biolog
criteria
overal
weakli
discrimin
sci
patient
ic
ii
combin
criteria
bacteriuria
pyuria
provid
better
sensitivityspecif
ratio
iii
optim
treshold
cfuml
wbcml
data
publish
microbiolog
acut
prostat
microbiolog
studi
urinari
tract
infect
uti
either
specifi
site
infect
focu
cystiti
pyelonephr
prostat
data
avail
mainli
chronic
form
object
describ
compar
microbiolog
data
speci
antibioticresist
profil
communityacquir
nosocomi
acut
prostat
method
retrospect
studi
acut
prostat
case
avail
urocultur
hospit
two
french
univers
teach
hospit
either
urolog
medicin
infecti
diseas
section
result
microbiolog
data
acquisit
mode
bacteri
strain
respons
acut
prostat
appear
similar
uti
site
nosocomi
prostat
includ
patient
indwel
cathet
major
concern
regard
specif
bacteriolog
includ
overrepresent
pseudomona
aeruginosa
major
differ
antibiot
resist
profil
restrict
number
antibiot
diffus
prostat
condit
may
lead
treatment
failur
chronic
evolut
aetiolog
chronic
prostat
syndrom
skerk
v
krhen
b
schonwald
cajic
v
markovinov
l
roglic
zekan
skerk
v
c
tambic
total
patient
symptom
chronic
prostat
examin
period
outpati
depart
urogenit
infect
univers
hospit
infecti
diseas
dr
fran
mihaljev
zagreb
croatia
infecti
aetiolog
determin
patient
patient
inflammatori
find
wbcshpf
found
ep
vb
normal
wbcshpf
found
patient
symptom
chronic
prostat
c
trachomati
detect
ep
vb
patient
isol
trichomona
vaginali
patient
isol
ureaplasma
urealyticum
escherichia
coli
caus
pathogen
enterococcu
proteu
mirabili
klebsiella
pneumonia
streptococcu
agalactia
pseudomona
aeruginosa
three
patient
chronic
prostat
patient
mix
infect
patient
chronic
bacteri
prostat
caus
e
coli
p
mirabili
kl
pneumonia
enterococcu
streptococcu
agalactia
inflammatori
find
regularli
found
ep
vb
bonnal
c
mion
baun
b
armandlefevr
l
lucet
jc
wolmark
purpos
manag
uti
patient
pt
extendedcar
facil
challeng
high
preval
bacteriuria
difficulti
diagnos
symptomat
uti
evid
antibiot
treatment
asymptomat
bacteriuria
ab
rare
benefici
studi
aim
identifi
uti
ab
ii
evalu
impact
antibiot
manag
program
method
juli
june
posit
urin
cultur
puc
obtain
patient
hospit
geriatr
hospit
bed
includ
ab
uti
diagnos
accord
mcgeer
criteria
j
infect
control
institut
uti
ab
prospect
assess
suggest
altern
made
need
accord
standard
recommend
result
patient
puc
includ
mean
age
puc
clinic
sign
uti
present
fever
pain
urin
sign
puc
consid
ab
initi
pt
uti
ab
p
white
blood
count
significantli
higher
pt
receiv
versu
gl
p
criteria
differ
two
group
pt
initi
receiv
fluoroquinolon
ceftriaxon
amoxicillin
cotrimoxazol
drug
intervent
correctli
given
accord
suscept
result
pt
order
durat
correspond
recommend
uti
pyelonephr
order
durat
less
often
appropri
first
month
studi
versu
p
intervent
actual
number
atday
lower
initi
order
higher
reduct
first
month
versu
p
conclus
bacteriuria
institution
pt
alway
correl
presenc
sign
uti
underlin
difficulti
diagnos
uti
pt
time
intervent
improv
appropri
global
reduct
observ
possibl
improv
prescript
clinician
time
purpos
assess
pharmacodynam
activ
azithromycin
simul
clinic
achiev
serum
epitheli
line
fluid
elf
concentr
mg
intraven
dose
macrolideresist
suscept
pneumonia
method
full
comput
control
devic
deriv
origin
twocompart
kinet
model
propos
blaser
et
al
antimicrob
agent
chemoth
use
pharmacokinet
profil
azithromycin
obtain
human
serum
elf
intraven
administr
mg
dose
evalu
four
pneumonia
clinic
isol
use
one
macrolidesuscept
strain
mic
mgl
lowlevel
resist
strain
mic
mgl
intermedi
mic
mgl
highlevel
macrolideresist
strain
mic
mgl
initi
inocula
rang
cfuml
coloni
count
sampl
peripher
compart
determin
h
result
macrolidesuscept
strain
differ
found
concentr
log
reduct
h
low
level
macrolideresist
strain
elf
concentr
achiev
bactericid
activ
time
period
high
elf
concentr
obtain
clinic
azithromycin
show
high
bactericid
activ
lowlevel
macrolideresist
pneumonia
cmi
mgl
bacteriostat
activ
macrolideresist
pneumonia
fact
may
explain
lack
clinic
failur
pneumonia
mic
mg
purpos
explor
pharmacodynam
need
continu
versu
intermitt
tid
administr
ceftazidim
base
vitro
suscept
pseudomona
aeruginosa
isol
method
full
comput
control
devic
deriv
origin
twocompart
kinet
model
propos
blaser
et
al
antimicrob
agent
chemoth
use
pharmacokinet
profil
ceftazidim
obtain
human
serum
intermitt
administr
g
daili
dose
g
tid
gday
continu
infus
produc
similar
auc
h
approxim
g
hml
regimen
simul
four
p
aeruginosa
clinic
isol
use
one
suscept
mic
gml
two
intermedi
mic
gml
one
resist
strain
mic
gml
initi
inocula
rang
cfuml
c
max
mic
continu
infus
intermitt
administr
mic
continu
infus
intermitt
administr
suscept
intermedi
resist
strain
respect
coloni
count
sampl
peripher
compart
determin
h
reduct
initi
inocula
time
calcul
result
suscept
intermedi
strain
differ
found
regimen
log
reduct
h
resist
strain
continu
infus
achiev
bactericid
activ
time
period
minimis
differ
resist
suscept
strain
found
intermitt
administr
conclus
local
preval
p
aeruginosa
resist
strain
mic
gml
ceftazidim
justifi
pharmacodynam
point
view
need
continu
versu
intermitt
administr
cousson
j
c
hoizey
g
b
floch
c
raclot
p
c
petit
js
c
vernetgarni
v
lamiabl
b
leon
c
laboratoir
de
b
laboratoir
de
pharmacologi
c
polyvalent
chu
reim
reim
franc
background
well
known
today
main
determin
betalactam
antibiot
efficaci
durat
time
concentr
remain
excess
minimum
inhibitori
concentr
mic
suscept
organ
cours
therapi
prospect
studi
aim
evalu
efficaci
term
pharmacodynam
profil
continu
infus
versu
intermitt
administr
ceftazidim
intens
care
unit
patient
sever
nosocomi
pneumonia
method
patient
mechan
ventil
nosocomi
pneumonia
randomis
receiv
either
mgkgday
ceftazidim
constant
rate
infus
follow
mgkg
load
dose
group
mgkg
everi
h
intraven
bolu
inject
group
b
patient
renal
dysfunct
elig
group
serial
blood
sampl
collect
h
sampl
group
b
respect
start
drug
administr
plasma
concentr
ceftazidim
measur
high
perform
liquid
chromatographi
base
local
bacteriolog
condit
pharmacodynam
profil
ceftazidim
assess
durat
time
plasma
concentr
remain
desir
target
concentr
mgl
regimen
result
mean
time
plasma
ceftazidim
concentr
decreas
mgl
min
continu
infus
group
group
h
per
day
bolu
group
group
b
conclus
find
show
ceftazidim
administ
continu
infus
critic
ill
patient
mechan
ventil
nosocomi
pneumonia
appear
substanti
improv
pharmacodynam
profil
betalactam
compar
intermitt
regimen
firsov
aa
lubenko
vostrov
sv
alferova
iv
smirnova
zinner
sh
b
depart
pharmacokinet
pharmacodynam
gaus
institut
new
antibiot
moscow
russia
b
harvard
medic
school
mount
auburn
hospit
cambridg
unit
state
object
compar
pharmacodynam
daptomycin
dap
vancomycin
van
kill
kinet
differenti
suscept
aureu
studi
wide
rang
aucmic
ratio
method
two
clinic
isol
aureu
mic
dap
mgl
mic
van
mgl
aureu
mic
dap
mgl
mic
van
mgl
expos
dap
singl
dose
van
two
h
dose
monoexponenti
concentr
decay
simul
halfliv
h
dap
h
van
aucmic
ratio
vari
h
result
antistaphylococc
effect
dap
van
depend
simul
aucmic
higher
aucmic
lower
number
surviv
organ
later
regrowth
despit
pronounc
variabl
timekil
curv
aucmic
relationship
intens
antimicrobi
effect
e
specif
dap
van
independ
bacteri
strain
e
max
model
fit
relationship
r
dap
van
base
e
aucmic
relationship
effect
dap
mgkgpropos
therapeut
dose
aureu
aucmic
h
aucmic
h
may
time
greater
respect
two
dose
van
given
h
interv
aucmic
h
respect
conclus
find
predict
greater
antistaphylococc
effect
clinic
achiev
aucmic
dap
rel
van
meynard
jl
c
lacomb
k
c
poirier
jm
massot
c
lefebvr
b
c
bouchaud
guiardschmidt
jb
e
vertsuyft
c
benlian
p
b
girard
pm
c
maladi
infectieus
avicenn
franc
b
biochimi
saintantoin
franc
c
maladi
infectieus
saintantoin
franc
pharmacologi
saintantoin
franc
e
maladi
infectieus
tenon
pari
franc
background
lpvr
use
frequent
associ
signific
increas
lipid
paramet
impact
lpvc
concentr
lipid
chang
remain
discuss
object
assess
incid
lipid
chang
treatment
lpvr
correl
total
cholesterol
tc
hdlc
ldlc
triglycerid
tg
drug
plasma
concentr
c
min
c
max
lpv
method
prospect
studi
naiv
pi
pretreat
picontain
regimen
patient
measur
tc
ldlc
hdlc
tg
lpv
c
min
c
max
chang
lipid
level
analys
pairedsampl
ttest
correl
paramet
studi
pearson
spearman
correl
test
result
fiftyeight
patient
naiv
pretreat
includ
mean
age
year
femal
baselin
characterist
median
cell
count
hiv
viral
load
vl
log
copiesml
mean
valu
mmoll
ct
ldlc
hdl
c
tg
cell
count
hdl
c
significantli
lower
naiv
patient
pretreat
p
signific
increas
p
ct
versu
ldlc
versu
hdlc
versu
tg
versu
correl
found
lipid
level
chang
lpv
c
min
c
max
mgl
drug
intervent
correct
ldlc
valu
mmolel
accord
guidelin
dyslipidemia
hiv
infect
patient
idsa
indic
patient
ns
conclus
treatment
lpvr
associ
signific
increas
lipid
level
chang
lipid
paramet
influenc
lpv
plasma
level
indic
drug
intervent
correct
lipid
abnorm
remain
low
conclus
tm
cip
show
lowest
valu
mpc
pa
howev
whatev
antibiot
test
mpc
high
compar
mic
ii
none
c
max
mpc
ratio
iii
msw
high
test
regimen
although
antipseudomon
treatment
associ
improv
clinic
outcom
mortal
whole
result
explain
high
frequenc
resist
mutant
vivo
suggest
higher
dose
andor
combin
therapi
may
necessari
achiev
optim
pharmacodynam
indic
use
aminoglycosid
fluoroquinolon
hepat
b
viru
genotyp
c
respons
sever
hepat
diseas
genotyp
b
e
chronic
infectedpati
gordien
e
gann
n
b
william
v
thar
b
kaddouri
h
alloui
c
dziri
mendil
hawajri
trinchet
jc
b
deni
p
beaugrand
b
laboratoir
de
bacteriologi
virologi
hopit
avicenn
bobigni
franc
b
hopit
jean
verdier
bondi
franc
aim
analyz
hepat
b
viru
hbv
genotyp
distribut
clinic
signific
patient
pari
suburban
area
patient
method
hbv
genotyp
basal
core
promot
cp
precor
pc
mutant
determin
chronic
infect
patient
respect
restrict
length
fragment
polymorph
method
andor
direct
sequenc
trugen
tm
hbv
genotyp
kit
bayer
health
care
affigen
kit
sangtec
molecular
diagnost
result
genotyp
b
c
e
found
patient
origin
asia
europ
subsaharan
africa
caribbean
north
africa
genotyp
hbva
infect
subgroup
except
asian
patient
wherea
hbvb
c
found
asian
patient
hbve
infect
subsaharan
african
caribbean
patient
baselin
serum
hbvdna
level
lower
hbvb
andd
p
antihb
seroconvers
occur
patient
mainli
hbvd
infect
patient
p
hbva
infectedpati
higher
serum
alanin
aminotransferas
level
p
cp
pc
mutant
found
antihb
posit
patient
associ
genotyp
p
sever
liver
fibrosi
metavir
classif
p
sever
liver
fibrosi
also
relat
hbva
c
p
howev
differ
occurr
hepatocellular
carcinoma
failur
treatment
observ
conclus
hbv
genotyp
b
c
e
circul
area
reflect
geograph
origin
patient
hbva
c
might
respons
sever
hepat
diseas
lada
benham
poynard
thibault
v
pari
franc
object
chronic
hepat
b
chb
persist
hb
ag
sometim
associ
antibodi
ab
hepat
b
surfac
antigen
antihb
reason
presenc
ag
ab
might
select
hb
ag
immun
escap
variant
assess
hypothesi
variabl
hbv
gene
protein
chb
patient
compar
patient
carri
hb
ag
antihb
antibodi
patient
sole
posit
hbsag
among
chb
patient
carri
hb
ag
ab
sampl
select
patient
present
marker
group
sever
consecut
sampl
four
control
patient
posit
hb
ag
group
ii
method
whole
hbv
genom
patient
serum
pcramplifi
clone
region
clone
per
patient
sequenc
analys
group
mean
antihb
titr
uil
rang
overal
rate
coinfect
differ
hbv
genotyp
assess
clonal
analysi
clone
reach
coinfect
g
n
c
n
result
compar
analysi
adetermin
region
show
increas
variabl
nucleotid
p
mannwhitney
test
protein
p
sequenc
group
patient
compar
control
patient
inde
patient
group
present
least
two
clone
carri
residu
chang
within
adetermin
among
eight
patient
carri
one
substitut
comparison
one
patient
group
ii
present
uniqu
substitut
region
interestingli
frequent
chang
observ
group
patient
locat
posit
describ
mutat
immun
escap
variant
conclus
persist
hbsag
despit
product
detect
amount
hb
ab
associ
increas
adetermin
variabl
progress
select
hbv
immun
escap
mutant
chronic
carriag
may
explain
coexist
hb
ag
antibodi
object
greec
countri
intermedi
low
endem
hepat
b
hbv
hepat
c
viru
hcv
infect
respect
downward
trend
hbv
infect
note
last
year
contrast
high
infect
rate
among
immigr
howev
recent
epidemiolog
data
infect
lack
attikon
new
univers
hospit
locat
western
attica
area
low
socioeconom
statu
inhabit
mani
immigr
purpos
determin
epidemiolog
hbv
hcv
infect
among
patient
present
hospit
present
preliminari
find
method
hbv
hcv
serolog
result
obtain
consecut
patient
examin
period
analyz
retrospect
detect
hbsag
antihb
antihbc
antihb
antihcv
serum
perform
microparticl
enzym
immunoassay
axsym
abbott
greec
result
conclus
popul
preval
seroneg
hbv
infect
marker
low
rate
antihbc
antihb
detect
possibl
indic
low
incid
vaccin
howev
data
need
correl
patient
age
hcv
infect
rate
appear
low
similarli
previou
studi
area
analysi
result
correl
patient
demograph
data
defin
epidemiolog
hepat
viru
infect
among
popul
c
mahot
b
muller
b
le
faou
venard
v
laboratoir
de
virologi
de
chu
de
nanci
vandoeuvr
nanci
franc
b
dimmunologi
laboratoir
nation
de
luxembourg
luxembourg
c
laboratoir
de
biologi
du
point
g
bamako
mali
subsaharan
africa
region
high
endem
hepat
b
viru
survey
medic
student
mali
shown
previou
contact
hbv
aghb
andor
adn
two
patient
aghb
adn
high
preval
two
time
one
estim
gener
popul
puzzl
deserv
investig
popul
clinic
epidemiolog
data
obtain
relat
observ
region
mali
patient
come
hbv
infect
preval
student
gave
written
agreement
hiv
serolog
select
cohort
hiv
seroposit
overal
preval
mali
high
preval
two
infect
popul
student
live
promiscu
campu
faculti
medicin
point
g
bamako
isol
citi
suggest
sexual
transmiss
determin
genotyp
hbv
strain
patient
circul
dna
genotyp
e
four
strain
classifi
genotyp
differ
wide
refer
strain
order
character
strain
sequenc
precc
region
undertaken
strong
analog
sequenc
one
classic
strain
suggest
coinfect
patient
explain
appar
skew
hypothesi
confirm
restrict
fragment
length
polymorph
studi
confirm
high
preval
genotyp
e
subsaharan
western
africa
mulder
et
al
j
inf
di
point
also
high
preval
sexual
transmit
infect
select
popul
howev
result
confirm
prevent
measur
taken
noel
v
c
emmanuelli
j
b
breton
g
longuet
p
macrez
rigolli
b
b
vild
jl
leport
c
maladi
infectieus
et
tropical
chu
bichatclaud
bernard
franc
b
institut
de
veill
sanitair
pari
c
centr
hospitali
reim
franc
march
april
patient
hospit
h
refer
infecti
diseas
depart
suspicion
sar
base
epidemiolog
clinic
data
diagnosi
difficult
owe
nonspecif
present
cough
fever
respiratori
digest
symptom
thirtysix
percent
patient
lymphopenia
thrombopenia
increas
transaminas
level
isol
chest
xray
done
bedsid
patient
show
abnorm
patient
pneumopathi
given
amoxicillin
roxithromycin
absenc
confirm
sar
altern
diagnos
look
order
exclud
suspicion
allow
stop
isol
introduc
appropri
treatment
altern
diagnosi
recogn
patient
varieti
commun
acquir
diseas
identifi
patient
isol
caus
organ
nasopharyngealrespiratori
secret
metapneumoviru
infect
n
influenza
b
n
pneumococc
pneumonia
n
tuberculosi
n
blood
urin
cultur
infect
endocard
n
pyelonephr
n
salmonella
sp
enterocol
n
diagnost
mean
mycoplasma
pneumonia
pneumopathi
n
serolog
maxillari
sinus
n
asian
acquiredinfect
diagnos
one
patient
burkholderia
pseudomallei
n
sar
coronaviru
isol
pt
cure
initi
evalu
patient
perform
concomitantli
clinician
epidemiologist
discord
pt
epidemiolog
data
n
clinicobiolog
data
n
final
evalu
pt
consid
exclud
case
epidemiologist
consid
possibl
doubt
case
clinician
whether
case
minor
form
coronaviru
infect
spontan
heal
remain
hypothet
improv
virolog
method
isol
identifi
coronavirus
potenti
respiratori
infectionsassoci
virus
combin
serolog
test
would
use
assess
hypothesi
retrospect
patient
case
new
outbreak
occurr
influenza
infect
hospit
stay
respons
sever
consequ
immunocompromis
debilit
patient
viru
introduc
medic
set
patient
visitor
health
care
worker
hcw
best
way
prevent
diffus
influenza
viru
hcw
recommend
annual
vaccin
howev
vaccin
coverag
hcw
influenza
weak
aim
studi
evalu
percept
influenza
vaccin
hcw
knowledg
risk
link
influenza
hospit
selfadminist
questionnair
includ
short
item
propos
hcw
two
french
univers
hospit
edouard
herriot
lyon
chu
de
saintetienn
hygien
refer
nurs
ward
depart
occup
medicin
electron
mail
total
questionnair
distribut
respons
obtain
hcw
caregiv
personnel
medic
personnel
personnel
without
contact
patient
mean
age
respond
year
overal
vaccin
coverag
influenza
signific
differ
three
hcw
categori
caregiv
personnel
medic
personnel
personnel
p
main
reason
hcw
get
vaccin
protect
wherea
protect
patient
mention
fact
vaccin
mandatori
first
reason
refus
wherea
fear
vaccin
advers
effect
mention
non
vaccin
hcw
except
medic
personnel
knowledg
regard
influenza
consequ
hospit
prevent
weak
total
respond
mention
influenza
nosocomi
infect
suggest
ignor
nonvaccin
person
risk
transmit
viru
within
hospit
studi
highlight
import
effort
requir
provid
inform
nosocomi
transmiss
influenza
promot
vaccin
among
hcw
especi
nurs
order
reduc
risk
influenza
outbreak
health
care
facil
olivi
c
c
chevalli
b
b
gaudelu
j
reinert
p
jean
verdier
bondi
franc
b
ambrois
boulognebillancourt
franc
c
loui
mourier
colomb
franc
intercommun
franc
purpos
assess
influenza
impact
hospit
pediatr
patient
viral
season
winter
epidem
method
week
year
four
gener
pediatr
ward
belong
parisian
region
includ
hospit
children
age
least
month
less
year
surveil
net
gave
epidem
pike
signal
influenza
occur
rsv
epidem
optim
plateau
week
children
nasopharyng
sampl
within
first
h
hospit
allow
viru
identif
influenza
rsv
refer
center
influenza
franc
nord
result
one
hundr
seventi
children
includ
posit
either
rsv
five
children
coinfect
sexratio
mf
mean
age
rsv
p
among
children
less
age
year
age
among
rsv
children
less
age
year
age
mean
durat
hospit
significantli
differ
rsv
j
comparison
two
respect
group
rsv
show
signific
differ
fever
occurr
versu
p
respiratori
diseasesbronchiol
cough
andor
respiratori
distress
versu
p
nonsignific
digest
symptom
versu
consid
occurr
complic
rsv
group
differ
signific
convuls
versu
p
nonsignific
acut
otiti
media
versu
pulmonari
condens
versu
among
daili
care
criteria
taken
account
two
respect
group
antibiot
prescript
frequent
among
versu
p
rate
oxygenodepend
children
versu
children
need
continu
gastric
feed
andor
infus
versu
nonsignificantli
differ
conclus
pilot
studi
confirm
influenza
impact
hospit
young
children
especi
preval
year
age
clinic
differ
well
consequ
emphas
influenza
rsv
object
respiratori
virus
particularli
influenza
viru
respiratori
syncyti
viru
rsv
often
describ
potenti
trigger
acut
respiratori
cardiac
failur
frail
individu
howev
littl
virolog
evid
support
view
design
set
patient
undertook
virolog
survey
critic
care
unit
two
consecut
winter
patient
admit
unit
acut
respiratori
cardiac
failur
enrol
nasal
swab
taken
pcr
detect
influenza
viru
rsv
metapneumoviru
rhinoviru
coronaviru
result
one
hundr
twentytwo
patient
enrol
mean
age
year
patient
femal
sap
ii
score
admiss
patient
acut
respiratori
failur
report
flulik
ill
admiss
patient
die
unit
nine
patient
test
posit
respiratori
viru
first
winter
second
winter
link
found
virolog
result
clinic
outcom
strong
link
found
rate
influenza
viru
posit
incid
flulik
ill
commun
p
conclus
result
support
view
respiratori
virusesand
particularli
influenza
viru
epidem
periodscan
trigger
acut
respiratori
cardiac
failur
method
retrospect
studi
conduct
januari
decemb
cmit
spilf
member
receiv
questionnair
electron
postal
mail
also
avail
wwwinfectiologiecom
result
obtain
case
defin
clinic
radiolog
posit
legionella
antigen
detect
urin
sampl
thirti
depart
five
intens
care
unit
provid
case
mean
age
men
risk
factor
cigarett
smoke
alcohol
recent
travel
exposur
air
condit
immunosuppress
cancer
diabet
mellitu
steroid
seventeen
percent
identifi
risk
factor
two
risk
factor
three
risk
factor
less
two
risk
factor
mean
bodi
temperatur
c
c
neurolog
digest
myalgia
occur
patient
respect
creatinin
kinas
hepat
transaminas
increas
patient
respect
pao
na
decreas
respect
xray
show
alveolar
infiltr
interstiti
infiltr
alveolar
interstiti
infiltr
patient
respect
mean
hospit
stay
day
medic
ward
icu
nasal
oxygen
mechan
ventil
requir
patient
respect
macrolid
quinolon
rifampicin
use
patient
respect
macrolid
quinolon
combin
use
patient
mean
treatment
durat
macrolid
quinolon
death
occur
patient
patient
icu
conclus
studi
confirm
nonspecif
clinic
radiolog
biolog
sign
legionnair
diseas
case
favor
outcom
medic
ward
patient
wide
use
quinolon
monotherapi
combin
macrolid
strain
sp
isol
blood
cultur
cerebrospin
fluid
ear
adult
respect
mic
penicillin
p
amoxicillin
amx
cefotaxim
ctx
determin
agar
dilut
interpret
accord
casfm
breakpoint
erythromycin
eri
cotrimoxazol
sxt
tetracyclin
tet
chloramphenicol
c
pristinamycin
pri
fosfomycin
fo
rifampicin
ra
test
agar
diffus
atb
pneumo
vitek
galleri
observ
signific
decreas
pdsp
convers
signific
increas
resist
r
amoxicillin
differ
strain
highli
resist
p
mic
versu
two
period
respect
strain
highli
resist
mic
mgl
amx
versu
ctx
versu
remain
rare
stabl
increas
strain
diminish
suscept
amx
mgl
mic
mgl
rate
sp
resist
r
p
amx
ctx
antibiot
shown
follow
tabl
method
dataprocess
screen
use
identifi
new
hivinfect
patient
either
first
diagnosi
initi
manag
previous
known
seroposit
seen
set
period
descript
analysi
sociodemograph
clinic
virolog
characterist
perform
comparison
two
subgroup
ie
french
subsaharan
africa
nativ
patient
done
result
studi
period
new
hivinfect
patient
identifi
characterist
median
age
year
sex
ratio
mw
singl
hiv
known
sexual
partner
ethnic
origin
caucasian
african
maghrebian
asian
nation
french
subsaharan
african
irregular
situat
franc
foreign
employ
hiv
transmiss
group
heterosexu
homobisexu
ivdrug
user
unknown
circumst
hiv
diagnosi
histori
hiv
exposur
primari
infect
symptomsaid
pregnanc
initi
cdc
stage
b
c
median
median
plasma
hivrna
cpml
coinfect
hbv
hcv
outcom
still
follow
st
antoin
hospit
transfer
hospit
lost
follow
dead
date
point
univari
analysi
comparison
french
n
african
n
men
show
signific
differ
heterosexu
transmiss
versu
p
marri
versu
p
work
statu
versu
p
versu
p
outcom
lost
follow
versu
p
comparison
french
n
african
n
women
show
signific
differ
age
year
versu
year
p
work
statu
versu
p
cdc
stage
versu
p
comparison
african
patient
accord
sex
women
show
signific
differ
age
year
versu
year
p
marit
statu
versu
p
work
statu
versu
p
outcom
lost
follow
versu
p
conclus
studi
conduct
larg
hospit
pari
highlight
continu
hiv
epidem
homosexu
french
nativ
men
grow
contribut
african
migrant
diagnos
later
cours
hiv
infect
social
statu
precari
women
repres
drop
follow
high
determin
adher
patient
take
antiretrovir
chemoprophylaxi
sexual
exposur
hiv
lacomb
k
b
lebeau
v
b
daguenelnguyen
girard
pm
b
meyoha
mc
b
pharmaci
central
pari
franc
b
servic
de
maladi
infectieus
saintantoin
pari
franc
context
sinc
highli
activ
antiretrovir
therapi
haart
deliv
franc
day
hiv
neg
patient
face
sexual
exposur
hiv
despit
risk
becom
hivinfect
free
access
treatment
adher
usual
suboptim
object
analys
sociocultur
determin
adher
haart
hivneg
patient
expos
sexual
contamin
hiv
method
data
concern
patient
seen
sexual
exposur
hiv
octob
septemb
saintantoin
hospit
outpati
clinic
retrospect
collect
nonadher
defin
noncomplet
daycours
haart
determin
analys
logist
regress
p
consid
signific
result
one
hundr
fortyon
patient
includ
studi
analys
three
patient
test
hivposit
initi
test
male
predomin
median
age
patient
european
come
africa
haart
initi
patient
receiv
bitherapi
earli
side
effect
haart
estim
adher
end
treatment
univari
analysi
follow
factor
associ
good
rate
adher
european
origin
former
hivneg
test
sexual
exposur
anal
intercours
men
sex
men
trend
poor
adher
note
sex
sex
worker
multivari
analysi
european
origin
sexual
exposur
anal
intercours
remain
associ
optim
adher
conclus
albeit
haart
sexual
exposur
may
prevent
transmiss
hiv
adher
treatment
optim
may
explain
socioeconom
factor
percept
risk
transmiss
associ
type
sexual
intercours
prevent
campaign
thu
target
african
commun
person
vagin
intercours
sex
sex
worker
respect
valid
sae
includ
differ
categori
symptom
complic
sever
event
relat
art
assess
use
procedur
small
group
experienc
physician
guaranti
strong
homogen
valid
process
process
product
good
accept
improv
monitor
specif
event
appropri
detect
unexpect
event
set
larg
multicent
cohort
studi
long
durat
ecv
strict
rule
assess
event
need
provid
data
best
qualiti
possibl
hcvrelat
factor
hivrel
factor
baselin
predict
respons
treatment
peginterferon
kd
pegasi
plu
ribavirin
copegu
patient
hivhcv
coinfect
predictor
analysi
apricot
studi
background
apricot
studi
combin
pegasyscopegu
produc
significantli
higher
sustain
virolog
respons
svr
rate
patient
hivhcv
coinfect
either
pegasi
monotherapi
combin
interferon
plu
ribavirin
object
studi
identifi
baselin
characterist
predict
svr
patient
treat
pegasi
copegu
method
hivhcv
coinfect
patient
receiv
pegasi
gweek
plu
copegu
mgday
week
random
multin
studi
patient
follow
week
end
treatment
svr
defin
singl
undetect
iuml
hcv
rna
end
followup
week
qualit
pcr
coba
amplicor
hcv
test
factor
consid
stepwis
multipl
logist
regress
analysi
prognost
factor
svr
includ
age
gender
race
bodi
surfac
area
hcv
rna
titer
hcv
genotyp
histolog
diagnosi
alt
quotient
cell
count
use
activ
antiretrovir
therapi
haart
result
signific
independ
factor
associ
svr
patient
treat
pegasyscopegu
hcv
rna
versu
iuml
p
hcv
genotyp
versu
p
absenc
cirrhosi
age
alt
quotient
cell
count
use
haart
signific
predictor
svr
week
patient
earli
virolog
respons
defin
undetect
hcv
rna
iuml
log
declin
hcv
rna
achiev
svr
convers
two
patient
without
earli
virolog
respons
week
achiev
svr
conclus
patient
hivhcv
coinfect
treat
combin
pegasyscopegu
infect
hcv
genotyp
hcv
rna
titer
iuml
greatest
impact
achiev
svr
absenc
earli
virolog
respons
week
highli
unlik
patient
achiev
svr
neg
predict
valu
syphili
reveal
uveiti
relationship
hiv
result
patient
men
eleven
eye
patient
exhibit
activ
anterior
nongranulomat
uveiti
vitriti
three
eleven
eye
includ
retin
one
neuroretin
seven
papil
laboratori
test
fluoresc
treponem
antibodi
absorpt
reveal
posit
serolog
activ
syphili
ten
patient
human
immunodefici
viru
antibodi
test
prove
posit
eight
ten
eight
patient
evid
concomit
central
nervou
syndrom
involv
dramat
respons
note
highdos
beta
lactamin
treatment
case
conclus
need
awar
resurg
ocular
syphili
accompani
increas
sexual
transmit
diseas
intern
scale
sinc
syphilit
uveiti
treatabl
infect
ophthalmologist
nt
overlook
phospholipas
cation
peptid
neutral
cryptosporidium
parvum
sporozoit
infect
either
parasiticid
nonparasiticid
mechan
carryn
b
schaefer
da
b
imboden
homan
ej
bremel
rd
rigg
mw
b
iogenet
llc
madison
wi
usa
b
depart
veterinari
scienc
microbiolog
univers
arizona
tucson
az
usa
purpos
c
parvum
common
caus
gastrointestin
infect
present
parasitespecif
cur
therapi
innat
immun
first
line
host
defens
mani
infect
previou
studi
shown
compon
respons
exert
vitro
activ
bacteria
protozoa
therefor
test
cathelicidin
cat
indolicidin
ind
lysozym
lyz
phospholipas
phosphoinositol
specif
phospholipas
c
piplc
direct
vitro
kill
abil
reduc
infect
c
parvum
sporozoit
method
sporozoit
ml
incub
min
gml
compound
c
parvum
neutral
mab
medium
parasiticid
activ
assess
addit
fluorescein
diacet
propidium
iodid
quantit
sporozoit
viabil
fluoresc
microscopi
assess
infect
intracellular
stage
quantifi
h
inocul
treatedsporozoit
onto
cell
use
c
parvumspecif
mab
autom
immunofluoresc
microscop
nonspecif
toxic
compound
cell
assess
ldh
releas
result
none
compound
mab
toxic
cell
cat
ind
highli
parasiticid
sporozoit
viabil
compar
control
respect
p
contrast
piplc
show
significantli
less
activ
viabil
respect
p
lyz
mab
signific
parasiticid
activ
viabil
p
cat
ind
mab
also
significantli
decreas
infect
cell
decreas
respect
p
interestingli
piplc
similar
activ
cation
peptid
reduc
sporozoit
infect
decreas
respect
p
lyz
modifi
infect
conclus
cation
peptid
phospholipas
warrant
investig
potenti
anticryptosporidi
agent
howev
reduct
sporozoit
infect
exert
phospholipas
show
viabil
assess
alon
suffici
identifi
potenti
activ
compound
c
parvum
method
set
abdomin
surgeri
center
includ
intens
care
unit
icu
teach
hospit
systemat
rectal
swab
perform
unit
detect
extendedspectrum
betalactamas
produc
enterobacteriacea
index
case
patient
transfer
greec
liver
transplant
day
admiss
patient
carri
fecal
flora
imipenemresist
k
pneumonia
detect
case
icu
patient
screen
irkp
rectal
swab
upon
admiss
week
b
control
measur
taken
includ
barrier
safeti
measur
result
start
decemb
outbreak
involv
eight
patient
monthperiod
eight
acquir
irkp
four
icu
three
acut
surgic
facil
genotyp
analysi
includ
pulsedfield
gel
electrophoresi
resist
gene
identif
show
strain
close
relat
measur
control
multiresist
strain
dissemin
includ
irkp
carrier
isol
privat
room
b
disinfect
alcoholbasedhand
antisept
c
wear
dispos
gown
glove
enter
room
carrier
daili
staff
train
e
environment
clean
measur
reinforc
end
may
cohort
irkp
carrier
one
separ
section
icu
b
nurs
staff
exclus
dedic
irkp
carrier
c
decreas
admiss
surgic
care
center
strict
control
patient
transfer
care
center
e
antibiot
prescript
control
screen
patient
perform
twice
week
use
imipenem
contain
plate
mgl
irkp
carrier
inform
medic
staff
statu
given
specif
instruct
follow
discharg
hospit
conclus
new
case
cross
contamin
detect
june
august
identif
risk
factor
acquisit
irkp
current
process
resist
carbapenem
emerg
problem
among
gramneg
hospit
pathogen
studi
seven
strain
klebsiella
pneumonia
resist
imipenem
involv
outbreak
french
teach
hospit
method
mic
determin
standard
agar
dilut
synergi
test
use
imipenem
edta
use
detect
metallobetalactamas
class
extendedspectrum
blactamas
detect
synergi
test
third
gener
cephalosporin
clavulan
acid
clonal
relat
isol
studi
use
genotyp
method
ericpcr
reppcr
pfge
transfer
resist
assess
conjug
e
coli
electropor
e
coli
plasmid
content
analyz
alkalin
lysi
method
fingerprint
analysi
perform
plasmid
dna
digest
ecori
gene
encod
tem
shvctxm
cmi
imp
vim
spm
acc
foxtyp
blactamas
screen
pcr
clone
experi
perform
genom
dna
partial
digest
vector
pacyc
insert
dna
fragment
code
imipenem
resist
sequenc
strand
result
isol
highli
resist
betalactam
includ
aztreonam
imipenem
mic
mgl
posit
imipenemedta
disk
synergi
test
strain
also
resist
almost
aminoglycosid
mic
gentamicin
mgl
newer
quinolon
sulfamethoxazol
show
intermedi
level
resist
tetracyclin
mic
mgl
uniqu
profil
observ
reppcr
ericpcr
pfge
identifi
one
major
profil
three
subtyp
pcrbase
screen
variou
blactamas
reveal
presenc
blactamas
strain
transfer
blactam
resist
achiev
electropor
analysi
plasmid
content
e
coli
transform
express
betalactamas
betalactamas
confirm
two
enzym
code
two
differ
plasmid
fingerprint
plasmid
carri
enzym
gener
ident
restrict
pattern
bla
gene
part
class
integron
also
includ
dhfri
aada
similar
report
strain
isol
greec
conclus
report
character
first
strain
k
pneumonia
produc
betalactamas
franc
cc
c
biendo
locher
g
c
lescur
x
b
lauran
g
schmit
jl
b
eb
f
de
cliniqu
laboratoir
de
chu
nord
franc
b
pathologi
infectieus
franc
c
et
de
de
infect
nosocomial
laboratoir
de
chu
nord
amien
franc
object
studi
aim
understand
main
patientrel
risk
factor
acquisit
extendedspectrum
betalactamas
esbl
produc
enterobact
aerogen
ea
resist
imipenem
amien
univers
hospit
franc
ward
decemb
juli
method
studi
incorpor
case
control
match
age
control
imipenem
sensit
strain
esbl
ea
survey
continu
ea
strain
isol
diagnost
three
screen
rectal
sampl
patient
dataag
sex
medic
nurs
act
medic
anteced
past
histori
hospit
antibiot
treatment
record
patient
file
univari
analysisnonparametr
wilcoxontest
ttestar
perform
spss
window
statist
test
signific
assess
pvalu
result
outbreak
esbl
ea
resist
imipenem
incid
rais
per
hospitalstay
day
comparison
year
uninterrupt
surveil
esbl
ea
imipenem
sensit
strain
incid
per
hospitalstay
day
none
imipenem
resist
strain
among
case
seven
previous
colon
imipenem
sensit
esbl
ea
strain
genotyp
studi
identifi
two
differ
clone
implic
epidem
control
case
nt
statist
differ
respect
sex
sampl
natur
medic
anteced
past
histori
hospitalis
control
nt
often
p
longer
time
invas
act
antimicrobi
treatment
howev
case
often
catheteris
p
mostli
central
cathet
p
intub
p
treat
imipenem
p
addit
imipenem
consumpt
increas
healthcar
ward
concern
outbreak
conclus
esbl
ea
strain
resist
imipenem
probabl
select
antimicrobi
treatment
practic
therefor
reason
restrict
control
antimicrobi
treatment
polici
need
hospit
treatment
patient
posit
esbl
produc
enterobacteria
consequ
avoid
imipenem
use
moreov
thorough
grasp
outbreak
need
prior
adjust
adapt
multidrug
resist
bacteria
cross
transmiss
guid
principl
hospit
ward
chromosom
induc
imipenemhydrolyz
class
ralstonia
pickettii
girlich
naa
nordmann
p
parissud
hopit
de
le
franc
chromosomallyencod
oxacillinas
character
ralstonia
pickettii
explain
resist
profil
speci
analysi
genet
background
speci
led
identifi
anoth
oxacillinas
gene
inactiv
induct
studi
bla
bla
gene
r
pickettii
perform
identifi
rel
contribut
oxacillinas
resist
profil
r
pickettii
express
induct
share
amino
acid
ident
narrowspectrum
hydrolysi
profil
includ
imipenem
enzym
identifi
r
pickettii
isol
test
studi
identifi
two
unrel
oxacillinas
may
found
natur
singl
bacteri
speci
underlin
divers
oxacillinas
ii
two
oxacillinas
gene
may
regul
iii
novel
naturallyoccur
oxacillinas
carbapenemhydrolyz
properti
character
lartigu
mf
poirel
l
nordmann
p
de
aphp
de
parissud
le
franc
bordetella
bronchiseptica
bordetella
parapertussi
close
relat
gramneg
rod
may
colon
respiratori
tract
mammal
b
bronchiseptica
caus
chronic
respiratori
infect
wide
rang
anim
rare
implic
human
pathogen
b
parapertussi
may
caus
milder
form
whoop
cough
complet
genom
sequenc
b
bronchiseptica
mb
b
parapertussi
mb
publish
recent
insilico
analysi
sequenc
identifi
open
read
frame
orf
share
nucleotid
ident
ambler
class
gene
stenotrophomona
maltophilia
clone
experi
correspond
gene
bla
b
bronchiseptica
refer
strain
gave
recombin
clone
express
clavulanicacid
inhibit
class
pi
valu
rel
molecular
mass
ca
kda
sequenc
also
gene
bla
two
clinic
strain
b
bronchiseptica
refer
strain
b
parapertussi
cip
case
bla
gene
found
share
amino
acid
ident
close
relat
enzym
chromosom
encod
enzym
rhodopseudomona
palustri
stenotrophomona
maltophilia
b
parapertussi
suscept
except
cefoxitin
wherea
b
bronchiseptica
suscept
amino
carboxi
ureidopenicillin
cephalothin
carbapenem
resist
broadspectrum
cephalosporin
wherea
refer
strain
speci
hydrolyz
nitrocefin
clone
substrat
profil
noninduc
clavulanicacid
inhibit
narrowspectrum
penicillinas
hydrolyz
significantli
benzylpenicillin
ampicillin
ticarcillin
piperacillin
lower
level
cephalothin
wherea
activ
detect
broadspectrum
cephalosporin
carbapenem
studi
indic
b
bronchiseptica
b
parapertussi
harbor
ident
naturallyoccur
ambler
class
penicillinas
may
contribut
significantli
naturallyoccur
resist
phenotyp
least
case
b
parapertussi
emerg
produc
klebsiella
spp
pari
area
genet
organ
acquir
ampc
ampr
gene
morganella
morganii
verdet
c
b
benzerara
b
gautier
v
arlet
g
b
upr
ea
de
saintantoin
pari
vi
franc
b
tenon
pari
franc
sinc
klebsiella
pneumonia
one
klebsiella
oxytoca
clinic
strain
produc
induc
class
c
betalactamas
isol
pari
area
horizont
transfer
one
plasmid
carri
bla
could
shown
seven
strain
aim
studi
compar
genet
organ
bla
eleven
strain
analog
previou
result
obtain
k
pneumonia
salmonella
enteritidi
produc
plasmidmedi
enzym
primer
design
genom
walk
pcr
map
methodolog
fail
either
resist
cefoxitin
clone
pbkcmv
genomewalk
tm
dna
walk
use
find
unknown
dna
sequenc
adjac
bla
strain
klebsiella
spp
region
mobil
morganella
morganii
includ
ampc
ampr
gene
insert
upstream
second
copi
conserv
segment
cs
complex
sulityp
integron
like
three
strain
morganii
region
variabl
length
insert
complex
sulityp
integron
differ
cassett
gene
profil
one
strain
morganii
region
lay
straight
downstream
common
region
cr
like
previous
describ
cr
includ
presum
code
recombinas
involv
mobil
resist
gene
two
strain
cr
morganii
region
insert
addit
kb
fragment
partial
ident
sap
abc
transport
psp
phage
shock
protein
operon
salmonella
typhimurium
genet
organ
bla
dha
ident
eight
strain
seven
harbor
plasmid
surprisingli
despit
presenc
truncat
cs
adjac
ampr
integron
element
found
neither
int
gene
nevertheless
upstream
morganii
region
lay
part
fragment
ident
typhimurium
includ
psp
operon
emerg
acquir
klebsiella
spp
pari
area
partial
due
horizont
spread
one
plasmid
bla
dha
seem
mobil
morganii
sever
independ
recombin
event
often
complex
sulityp
integron
includ
put
recombinas
polymorph
drugselect
mutat
revers
transcriptas
gene
naiv
treat
patient
isol
seinesaintdeni
district
franc
differ
b
nonb
subtyp
comparison
phenotyp
genotyp
result
obtain
isol
allow
defin
antirevers
transcriptas
rt
treatment
algorithm
deduc
aminoacid
sequenc
rt
howev
collect
data
obtain
b
subtyp
isol
public
avail
concern
rt
gene
mutat
nonb
subtyp
collect
analyz
rt
sequenc
naiv
patient
b
nonb
subtyp
treat
patient
b
nonb
subtyp
one
hand
sequenc
interpret
accord
stanford
virtual
phenotyp
algorithm
hand
align
statist
analyz
order
detect
eventu
subtyperel
differ
rt
sequenc
profil
naiv
group
patient
b
subtyp
isol
display
antirt
resist
mutat
two
isol
present
mutat
associ
resist
azt
efv
nvp
three
azt
one
one
isol
display
mutat
anoth
nonb
subtyp
isol
display
antirt
resist
mutat
moreov
signific
differ
aminoacid
substitut
found
b
nonb
subtyp
isol
posit
includ
associ
drugresist
treat
group
stanford
virtual
phenotyp
algorithm
indic
higher
preval
antirt
resist
b
compar
nonb
subtyp
isol
versu
amino
acid
substitut
analysi
rt
sequenc
evidenc
signific
differ
b
nonb
subtyp
isol
posit
includ
six
drugresist
associ
site
even
though
treatment
regimen
similar
b
nonb
infect
patient
result
indic
aminoacid
profil
b
nonb
subtyp
isol
differ
either
natur
polymorph
result
treatment
histori
high
preval
resist
mutat
b
subtyp
isol
encourag
systemat
rt
gene
sequenc
order
adapt
treatment
strategi
viru
result
suggest
treatment
algorithm
base
b
subtyp
cohort
studi
may
need
modif
appli
nonb
subtyp
isol
effort
consid
studi
subtyp
independ
g
leport
c
e
spire
b
b
lewden
c
pierret
j
h
peytavin
g
g
brunvezinet
f
f
le
mo
v
c
salamon
r
raffi
f
aprococopilot
studi
group
e
bordeaux
franc
b
background
vast
major
treat
hivinfect
patient
western
countri
initi
highli
activ
antiretrovir
haart
regimen
longterm
evolut
patient
benefit
regimen
best
describ
larg
prospect
cohort
method
consecut
pinaiv
patient
present
french
hiv
clinic
center
picontain
regimen
initi
except
primari
infect
prospect
includ
aprocoanr
studi
data
record
initi
pi
therapi
baselin
month
everi
month
thereaft
sociodemograph
clinic
data
cell
count
plasma
rna
level
clinic
laboratori
advers
event
prospect
record
result
patient
includ
male
mean
age
year
homosexu
inject
drug
user
heterosexu
baselin
mean
rna
log
copiesml
mean
cell
count
aid
year
patient
still
followedup
still
haart
without
pi
dual
antiretrovir
combin
stop
antiretrovir
estim
surviv
patient
without
prior
aid
prior
aid
progress
new
aidsdefin
event
patient
without
prior
aid
prior
aid
cumul
probabl
seriou
advers
effect
sae
year
rna
log
copiesml
mean
cell
count
gain
cellsmm
sinc
baselin
year
major
patient
still
remain
haart
regimen
although
proport
without
pi
high
clinic
progress
death
still
seen
haart
especi
patient
advanc
diseas
initi
occurr
sae
high
context
recent
use
new
drug
clinician
strategi
optim
use
current
antiretrovir
still
need
improv
achiev
sustain
efficaci
well
better
toler
improv
qualiti
life
set
lifelong
chronic
diseas
background
high
rate
earli
virolog
failur
report
naiv
patient
receiv
tenofovir
tdf
either
lamivudin
lam
didanosin
lam
abacavir
abc
howev
oncedaili
zidovudin
zdv
lam
abc
tdf
regimen
show
high
rate
virolog
success
resist
pattern
less
v
suggest
role
zdv
resist
modul
method
pilot
open
studi
conduct
hiv
outpati
clinic
strasbourg
univers
hospit
treatment
subject
receiv
fix
dose
combin
zdvlam
mg
twice
day
tdf
mg
day
cell
count
flow
cytometri
viral
load
coba
amplicor
hiv
monitor
v
roch
diagnost
system
assess
baselin
month
treatment
everi
month
earli
virolog
respons
week
also
evalu
result
thirti
patient
includ
april
june
male
six
femal
median
age
rang
year
asymptomat
group
cdc
classif
group
b
group
c
baselin
median
rang
count
median
viral
load
log
log
twelv
subject
hiv
rna
log
month
treatment
analysi
median
viral
load
decreas
log
log
viral
load
copiesml
earli
virolog
respons
log
median
hiv
rna
decreas
week
treatment
evalu
subject
median
count
increas
month
month
treatment
interrupt
clinic
side
effect
seen
abdomin
pain
nausea
anemia
probabl
due
zdv
renal
deficit
observ
preexist
tdf
therapi
first
month
treatment
viral
failur
occur
mutat
tam
tam
two
success
chang
arv
treatment
other
remain
zdv
lam
tdf
low
viral
load
conclus
combin
zdv
lam
tdf
arv
hivinfect
subject
induc
rapid
sustain
hiv
rna
decreas
associ
good
immunolog
respons
safe
raffi
fr
c
antoun
z
b
le
camu
c
vertex
pharmaceut
europ
courbevoi
franc
b
glaxosmithklin
marli
le
roy
franc
c
servic
de
maladi
infectieus
chu
hotel
dieu
nant
franc
goal
parallel
assess
efficaci
adher
data
collect
subgroup
pt
studi
compar
treatment
tx
fpv
mg
ritonavir
r
mg
qd
versu
nelfinavir
nfv
mg
bid
associ
abacavir
lamivudin
bid
week
time
point
phase
iii
multicentr
open
studi
random
arm
tx
naiv
hiv
infect
pt
selfreport
patient
medic
adher
questionnair
pmaq
administ
five
englishspeak
countri
everi
week
upon
earli
withdraw
pill
count
either
fpv
nfv
collect
visit
except
week
subanalysi
pt
fail
virolog
complet
pmaq
assess
incid
virolog
failur
accord
level
adher
result
six
hundr
sixti
pt
includ
receiv
fpvr
nfv
bid
baselin
median
plasma
hiv
rna
level
log
cpml
log
cpml
median
count
cmm
cmm
vl
cpml
pt
intent
treat
analysi
itt
f
respect
median
count
rise
cmm
cmm
rate
success
compar
two
arm
howev
rate
virolog
failur
fpvr
qd
versu
nfv
bid
incid
mutat
pt
experienc
tx
failur
statist
differ
fpvr
nfv
zero
versu
ari
ari
proteas
mutat
versu
revers
transcriptas
mutat
p
pmaq
complet
pt
indic
barrier
adher
signific
test
complet
pt
report
perfect
adher
score
fpvr
versu
nfv
week
versu
versu
among
virolog
failur
popul
report
perfect
adher
fpvr
arm
major
failur
occur
adher
versu
nfv
mutat
occur
level
adher
discuss
conclus
dose
conveni
low
pill
count
absenc
food
restrict
relat
better
adher
fpvr
fewer
virolog
failur
fpvr
versu
nfv
appar
absenc
correl
failur
level
adher
suggest
greater
potenc
higher
resist
barrier
boost
regimen
clinic
virolog
followup
cohort
infect
patient
receiv
enfuvirtid
bienvenu
b
b
krivin
spiridon
g
b
pietri
mp
b
lebaut
v
b
sicard
b
lebon
p
salmon
b
launay
b
laboratoir
de
virologi
pari
franc
b
servic
de
intern
group
hospitali
cochinsaint
vincent
de
paul
pari
franc
background
enfuvirtid
enf
antiretrovir
agent
act
inhibit
viruscel
membran
fusion
process
avail
franc
data
regard
clinic
virolog
effici
shown
method
retrospect
studi
cohort
infect
pt
began
enf
therapi
cochin
hospit
pari
result
patient
pt
includ
studi
men
women
advanc
hivdiseas
stage
c
b
median
nadir
previou
exposur
median
antiretrovir
drug
median
durat
year
median
genotyp
sensit
score
baselin
median
cell
count
median
plasma
rna
copiesml
enf
given
optimis
regimen
includ
mean
sd
drug
accord
result
genotyp
resist
test
pt
individu
educ
selfinject
toler
treatment
good
pt
minor
advers
event
occur
mostli
injectionsit
reaction
lead
discontinu
therapi
median
durat
followup
month
pt
respons
therapi
observ
sinc
plasma
rna
decreas
log
baselin
three
pt
experienc
viral
rebound
within
month
virolog
respons
sustain
plasma
rna
undetect
copiesml
reach
seven
pt
sustain
month
five
group
median
cell
count
increas
three
pt
virolog
respons
observ
analysi
resist
mutat
region
three
six
pt
virolog
failur
show
wildtyp
viru
treatment
presenc
describ
enfresist
mutat
non
respond
two
patient
experienc
viral
rebound
conclus
enf
associ
optimis
antiretrovir
therapi
show
sustain
immunovirolog
effici
good
toler
event
virolog
failur
genotyp
chang
observ
region
revers
enf
withdraw
influenc
viral
replic
remain
studi
incid
risk
factor
hepatotox
associ
nevirapin
infect
patient
background
rash
hepatotox
common
limit
toxic
nevirapin
nvp
object
studi
assess
incid
risk
factor
develop
hepatotox
within
week
w
nvp
initi
method
two
hundr
pt
enrol
vizyr
trial
random
doubl
blind
placebocontrol
trial
show
prevent
effect
cetirizin
nvpassoci
rash
physic
examin
studi
entri
week
liver
test
perform
screen
week
trough
nvp
plasma
concentr
determin
w
treatment
hepatotox
defin
increas
least
twofold
serum
alanin
aminotransferas
alt
aspart
aminotransferas
ast
level
compar
baselin
valu
alt
andor
ast
level
time
upper
limit
normal
uln
sever
hepatotox
increas
alt
andor
ast
level
time
uln
statist
analysi
perform
use
logist
regress
test
assess
risk
factor
hepatotox
result
twentysix
pt
develop
hepatotox
median
day
day
includ
pt
sever
hepatotox
find
includ
fever
n
cutan
reaction
n
includ
two
pt
hypersensit
syndrom
eosinophilia
n
five
pt
clinic
symptom
pt
experienc
restor
transaminas
level
resolut
clinic
symptom
mean
nvp
plasma
concentr
w
differ
pt
develop
hepatotox
other
versu
gml
respect
multivari
analysi
identifi
predict
risk
factor
hepatotox
conclus
close
monitor
liver
enzym
level
recommend
pt
start
nvp
contain
regimen
eosinophilia
appear
associ
hepatotox
extendedspectrum
enterobacteria
commun
set
clinic
molecular
analysi
extrahospit
survey
conduct
januari
may
aquitain
network
privat
laboratori
enterobacteria
strain
produc
extendedspectrum
esbl
among
five
respons
urinari
tract
infect
uti
patient
live
home
e
coli
produc
enzym
patient
e
coli
express
patient
k
neumonia
elabor
patient
final
e
aerogen
patient
includ
one
imipenem
resist
strain
e
aerogen
belong
preval
